Compositions and methods for delivering nucleic acids to cells
By using the 3E10 monoclonal antibody to form a complex with nucleic acid cargo, the limitations of existing viral vectors and synthetic liposomes are overcome, enabling efficient, non-viral nucleic acid delivery into cells, suitable for gene therapy and gene editing.
Patent Information
- Application Number
- CN202080076637.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-12-05
- Filing Date
- 2020-08-31
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2040-08-31
AI Technical Summary
Existing viral vectors and synthetic liposomes suffer from production complexity, limited packaging capabilities, and unfavorable immunological characteristics in gene therapy, which restrict the application of nucleic acid transfection technology, especially in in vivo applications, necessitating improved nucleic acid delivery methods.
The 3E10 monoclonal antibody or its cell-penetrating fragment, monovalent, bivalent or multivalent single-chain variable fragment (scFv) or biclonal antibody forms a complex with nucleic acid cargo, and delivers nucleic acid into cells through non-covalent linkage. The binding protein, such as 3E10-scFv, has nucleic acid binding ability and binds to the target cell type, tissue or organ.
It enables efficient and non-viral delivery of nucleic acid cargo to the cytoplasm and nucleus, improving nucleic acid transfection efficiency and functionality, and is suitable for in vitro, ex vivo, and in vivo gene therapy, including gene editing and CAR T cell production.
Smart Images

Figure HDA0003624229810000011 
Figure HDA0003624229810000012 
Figure HDA0003624229810000021
Abstract
Description
[0001] Cross-references to related applications
[0002] This application claims a patent filed with the U.S. Patent and Trademark Office on December 5, 2019, entitled " Used to deliver the nucleus to the cell Compositions and methods of acids U.S. Provisional Application No. 62 / 944,281, filed on August 30, 2019, with the U.S. Patent Cooperation Treaty Receiving Office, entitled " Compositions and methods for enhancing donor oligonucleotide-based gene editing The international application number PCT / US2019 / 048953, and the application filed on August 30, 2019, with the U.S. Patent Cooperation Treaty Office entitled " Compositions and methods for enhancing triplex- and nuclease-based gene editing The rights and priorities of the international application number PCT / US2019 / 048962 are hereby acknowledged. U.S. Provisional Application No. 62 / 944,281, International Application No. PCT / US2019 / 048953, U.S. Provisional Application No. 62 / 725,920, International Application No. PCT / US2019 / 048962, and U.S. Provisional Application No. 62 / 725,852 are each specifically incorporated herein by reference in their entirety.
[0003] Statement regarding federally funded research
[0004] This invention was completed with government support under license CA197574 granted by the National Institutes of Health in the United States. The government owns certain rights to this invention.
[0005] References to sequence lists
[0006] The sequence list submitted by a text file named “YU_7503_3_ST25”, created on August 31, 2020 and of size 154,701 bytes, is hereby incorporated by reference in accordance with 37 CFR § 1.52(e)(5). Technical Field
[0007] This invention generally relates to the field of intracellular delivery of nucleic acids, and its applications include, but are not limited to, in vitro, ex vivo, and in vivo gene therapy and gene editing. Background Technology
[0008] Gene therapy encompasses a range of applications, from gene replacement and knockdown for genetic or acquired diseases such as cancer to vaccination. Viral vectors and synthetic liposomes have become the preferred medium for many applications today, but both have limitations and risks, including manufacturing complexity, limited packaging capabilities, and unfavorable immunological characteristics, which restrict the application of gene therapy and hinder its potential for preventative gene therapy (Seow and Wood, Mol Ther . 17(5): 767–777 (2009)).
[0009] Nucleotide uptake and distribution in cells and tissues have been observed (Huang et al., FEBS Lett ., 558(1-3):69-73 (2004)). Furthermore, although, for example, Nyce et al. have found that antisense oligodeoxynucleotides (ODNs) bind to endogenous surfactants (lipids produced by lung cells) and are absorbed by lung cells upon inhalation without the need for additional carrier lipids (Nyce et al., 558(1-3):69-73 (2004)). Nature , 385:721-725 (1997)), small nucleic acids were taken up into T24 bladder cancer tissue culture cells (Ma et al., , Antisense Nucleic Acid Drug Dev ., 8:415-426 (1998) , but improved nucleic acid transfection techniques are still needed, especially for in vivo applications. AAV9 was discovered in 2003, and it remains the commonly used viral vector for humans (Robbins, “Gene therapy pioneer says the field is behind – and that delivery technology is embarrassing,” Stat (November 2019).
[0010] Therefore, one object of the present invention is to provide compositions and methods of using thereof to improve the delivery of nucleic acids into cells. Summary of the Invention
[0011] Compositions for delivering nucleic acid cargo into cells and methods of using thereof are provided. The composition typically comprises (a) a 3E10 monoclonal antibody or a cell-penetrating fragment thereof; a monovalent, bivalent, or multivalent single-stranded variable fragment (scFv); or a biclonal antibody; or a humanized form or variant thereof; and (b) nucleic acid cargo comprising, for example, nucleic acids encoding polypeptides, functional nucleic acids, nucleic acids encoding functional nucleic acids, or combinations thereof. Elements (a) and (b) are typically non-covalently linked to form a complex. 3E10 is believed to bind to RNA, PNA, and other nucleic acids in addition to DNA.
[0012] The exemplary 3E10 antibody and its fragments and fusion proteins comprise those having: (i) a combination of a CDR of any one of SEQ ID NO: 1-6, 12, 13, 46-48 or 50-52 with a CDR of any one of SEQ ID NO: 7-11, 14 or 53-58; (ii) a combination of a first, second, and third heavy chain CDR selected from SEQ ID NO: 15-23, 42 or 43 with a first, second, and third light chain CDR selected from SEQ ID NO: 24-30, 44 or 45; (iii) the humanized form of (i) or (ii); (iv) a combination of a heavy chain comprising an amino acid sequence containing at least 85% sequence identity with any one of SEQ ID NO: 1 or 2 with a light chain comprising an amino acid sequence containing at least 85% sequence identity with any one of SEQ ID NO: 7 or 8; (v) the humanized form of (iv); or (vi) a combination of a heavy chain comprising an amino acid sequence containing at least 85% sequence identity with any one of SEQ ID NO: 1 or 2; A combination of a heavy chain comprising an amino acid sequence of at least 85% sequence identity, any one of 3-6, 46-48, or 50-52, and a light chain comprising an amino acid sequence of at least 85% sequence identity with SEQ ID NO: 9-11 or 53-58.
[0013] In some embodiments, the antibody, its fragments, and the fusion protein are CDR1 heavy chain variants having amino acid residues corresponding to the 3E10 heavy chain amino acid sequence or its CDR that are substituted with arginine (R) or lysine (L).
[0014] In some embodiments, the antibody, its fragments, and the fusion protein contain a nucleic acid binding pocket of SEQ ID NO: 92 or 93, or a variant thereof with the same or enhanced ability to bind to nucleic acids (such as DNA, RNA, or combinations thereof).
[0015] Also provided is the binding protein itself, comprising a CDR1 heavy chain variant having amino acid residues corresponding to the 3E10 heavy chain amino acid sequence or its CDR1 substituted with arginine (R) or lysine (L), and the binding protein itself having a nucleic acid binding pocket of SEQ ID NO: 92 or 93, or a variant thereof having the same or enhanced ability to bind to nucleic acids (such as DNA, RNA, or combinations thereof).
[0016] In some implementations, the antibody or fragment or fusion protein may be bispecific and may, for example, contain binding sequences that target a specific cell type, tissue, or organ.
[0017] Nucleic acid cargo can consist of DNA, RNA, modified nucleic acids (including but not limited to PNA), or combinations thereof. Nucleic acid cargo is typically functional cargo, such as functional nucleic acids (e.g., repressive RNA), mRNA, or vectors, such as expression vectors. Nucleic acid cargo (including vectors) can contain a nucleic acid sequence encoding a target polypeptide operatively linked to an expression control sequence. Vectors can be, for example, plasmids. For example, the cargo is typically not randomly spliced or fragmented genomic DNA.
[0018] In some embodiments, the cargo comprises or consists of nucleic acids encoding Cas endonucleases, gRNA, or combinations thereof. In some embodiments, the cargo comprises or consists of nucleic acids encoding chimeric antigen receptor polypeptides. In some embodiments, the cargo is a functional nucleic acid, such as an antisense molecule, siRNA, microRNA (miRNA), aptamer, ribozyme, RNAi, or an external guide sequence, or a nucleic acid construct encoding it.
[0019] The cargo may comprise or consist of multiple single nucleic acid molecules, or multiple 2, 3, 4, 5, 6, 7, 8, 9, 10 or more different nucleic acid molecules. In some embodiments, the nucleic acid molecules of the cargo comprise or consist of nucleic acid molecules with a length of about 1 to about 25,000 nucleobases. The cargo may be single-stranded nucleic acid, double-stranded nucleic acid, or a combination thereof.
[0020] Pharmaceutical compositions comprising a complex and pharmaceutically acceptable excipients are also provided. In some embodiments, the complex is encapsulated in polymer nanoparticles. Targeting portions, cell-penetrating peptides, or combinations thereof are bound, linked, conjugated, or otherwise directly or indirectly attached to the nanoparticles.
[0021] Methods for delivering nucleic acid cargo into cells by contacting cells with an effective amount of a complex or a complex encapsulated in nanoparticles are also provided. Contact can occur in vitro, ex vivo, or in vivo. In some embodiments, an effective amount of ex vivo treated cells is administered to a subject in need, for example, an effective amount for treating one or more symptoms of a disease or condition.
[0022] In some embodiments, contact occurs in the body after administration to a subject in need. The subject may have a disease or condition, such as a genetic disorder or cancer. An effective amount of the composition may be administered to the subject, for example by injection or infusion, to alleviate one or more symptoms of the subject's disease or condition.
[0023] Applications of the compositions and methods are also provided, including but not limited to gene therapy and CAR T cell production / formation / therapy. Attached Figure Description
[0024] Figure 1A-1CThe scatter plot shows PNA uptake in the control (1A) and alone (1B) and mixed with 3E10 for 1 hour (1C). Figure 1D It is quantification Figure 1A-1C A bar chart of the data.
[0025] Figure 2A-2C The scatter plot shows PNA uptake in the control (2A) and alone (2B) and mixed with 3E10 for 24 hours (2C). Figure 2D It is quantification Figure 2A-2C A bar chart of the data.
[0026] Figures 3A-3C The scatter plot shows the uptake of siRNA in the control (3A), as well as in the control alone (3B) and in the control mixed with 3E10 for 24 hours (3C). Figure 3D It is quantification Figures 3A-3C A bar chart of the data.
[0027] Figures 4A-4H The scatter plot shows mRNA uptake in the control (4A), as well as in the control alone (4B) and in the control mixed with various concentrations of 3E10 for 24 hours (4C-4H). Figure 4I It is quantification Figures 4A-4H A bar chart of the data.
[0028] Figures 5A-5H The scatter plot shows mRNA uptake in the control (5A), as well as in the control alone (5B) and in the control mixed with various concentrations of 3E10 for 1 hour (5C-5H). Figure 5I It is quantification Figures 5A-5H A bar chart of the data.
[0029] Figure 6 It is a series of images showing cellular expression of GFP reporter plasmid DNA 72 hours after mixing with 3E10 and 24 hours after incubation with cells.
[0030] Figure 7A The bar graph shows the accumulation of fluorescently labeled siRNA in tumors in mice 15 minutes at room temperature prior to systemic injection, when mixed with increasing doses of 3E10 (0.25, 0.5, and 1 mg). Figure 7B This is a bar graph showing the accumulation of fluorescently labeled siRNA in tumors in mice after mixing with 1 mg of 3E10 or 0.1 mg of the D31N variant 3E10 at room temperature for 15 minutes prior to systemic injection. All tumors were analyzed 24 hours post-injection.
[0031] Figure 8 It is a line graph showing 3E10-mediated mRNA delivery (bioluminescence (photons / second)) into mouse muscle (IM) over time (days after IM injection).
[0032] Figure 9A and Figure 9B It displays a comparison ( Figure 9A ) and IV-injected 3E10-D31N are distributed to the muscles ( Figure 9B The image was created by IVIS (Perkin Elmer) 24 hours after injection. Figure 9C It is a bar graph of fluorescence in a quantified IVIS image.
[0033] Figure 10 This is a bar graph of fluorescence in IVIS images quantifying the dose-dependent biodistribution of 3E10-D31N in tissues 24 hours after intravenous injection of 100 µg or 200 µg of VivoTag680 (Perkin Elmer) labeled 3E10-D31N into mice.
[0034] Figure 11A and Figure 11B It displays a comparison ( Figure 11A ) and IV-injected 3E10-D31N were distributed to syngeneic colon tumors (CT26) ( Figure 11B The image was taken by IVIS (Perkin Elmer) 24 hours after injection. Figure 11C It is a bar graph of fluorescence in a quantified IVIS image.
[0035] Figure 12A , 12B and Figure 12C It displays a comparison ( Figure 12A ), and naked single-stranded DNA (ssDNA) injected via IV ( Figure 12B ) and 3E10-D31N+ ssDNA ( Figure 12C Images of the distribution of the syngeneic colon tumor (CT26) by IVIS (PerkinElmer) 24 hours after injection. Figure 12D It is a bar graph of fluorescence in a quantified IVIS image.
[0036] Figure 13 It is a bar graph showing 3E10-mediated RIG-I delivery and stimulation.
[0037] Figure 14A It is 3E10, its putative nucleic acid binding pocket (NAB1), and a molecular modeling illustration of the predicted structural changes induced by amino acid mutations within it. Figure 14B This is a molecular modeling illustration of 3E10-scFv (Pymol), in which the NAB1 amino acid residues are highlighted as dots. Detailed Implementation
[0038] I. Definition
[0039] As used herein, the term "single-chain Fv" or "scFv" refers to a single-chain variable fragment containing a light chain variable region (VL) and a heavy chain variable region (VH) in a single polypeptide chain linked by a linker that enables the scFv to form the desired antigen-binding structure (i.e., the VH and VL regions for the single polypeptide chain associate with each other to form the Fv). The VL and VH regions may be derived from parental antibodies or may be chemically or recombinantly synthesized.
[0040] As used herein, the term "variable region" is intended to distinguish this domain of immunoglobulins from domains widely shared by antibodies (such as the antibody Fc domain). Variable regions contain "hypervariable regions," whose residues are responsible for antigen binding. The hypervariable region contains amino acid residues from the complementarity-determining region (CDR) or CDR (i.e., typically residues 24-34 (L1), 50-56 (L2), and 89-97 (L3) in the light chain variable domain and residues 27-35 (H1), 50-65 (H2), and 95-102 (H3) in the heavy chain variable domain; Kabat et al., Sequences of Proteins of Immunological Interest, Public Health Service, National Institutes of Health, Bethesda, MD. (1991)) and / or residues from the hypervariable ring (i.e., residues 26-32 (L1), 50-52 (L2), and 91-96 (L3) in the light chain variable domain and residues 26-32 (H1), 53-55 (H2), and 96-101 (H3) in the heavy chain variable domain; Chothia and Lesk, 1987, J. Mol. Biol . 196:901-917).
[0041] As used herein and as defined herein, the term “frame region” or “FR” residues are those variable domain residues other than hypervariable region residues.
[0042] As used herein, the term "antibody" refers to a natural or synthetic antibody that binds to a target antigen. The term includes both polyclonal and monoclonal antibodies. In addition to the complete immunoglobulin molecule, the term "antibody" also includes binding proteins, fragments, and polymers of those immunoglobulin molecules, as well as human or humanized forms of immunoglobulin molecules that bind to target antigens.
[0043] As used herein, the term "cell-penetrating antibody" refers to an immunoglobulin, fragment thereof, variant thereof, or fusion protein thereof that is transported into the cytoplasm and / or nucleus of a living mammalian cell. "Cell-penetrating anti-DNA antibody" specifically binds to DNA (e.g., single-stranded and / or double-stranded DNA). In some embodiments, the antibody is transported into the cytoplasm of the cell without the aid of a carrier or conjugate. In other embodiments, the antibody is conjugated to a cell-penetrating portion (such as a cell-penetrating peptide). In some embodiments, the cell-penetrating antibody is transported into the cell nucleus with or without the aid of a carrier or conjugate.
[0044] In addition to complete immunoglobulin molecules, the term "antibody" also includes fragments of immunoglobulin molecules, binding proteins and polymers, chimeric antibodies (such as human or humanized antibodies) containing sequences from more than one species, class, or subclass of immunoglobulins, and recombinant proteins containing at least a unique type of immunoglobulin that specifically binds to DNA. The desired activity of an antibody can be tested using the in vitro assays described herein or by similar methods, followed by testing its in vivo therapeutic activity according to known clinical testing methods.
[0045] As used herein, the term "variant" refers to a polypeptide or polynucleotide that differs from a reference polypeptide or polynucleotide but retains its essential properties. A typical variant of a polypeptide differs from another reference polypeptide in its amino acid sequence. Generally, the differences are limited, making the sequences of the reference polypeptide and the variant very similar overall and identical in many regions. Differences in the amino acid sequence between a variant and a reference polypeptide can occur through one or more modifications (e.g., substitution, addition, and / or deletion). Substituted or inserted amino acid residues may or may not be encoded by the genetic code. Variants of a polypeptide can be naturally occurring, such as allelic variants, or they may be variants that are not known to exist naturally.
[0046] The structure of the polypeptides disclosed herein can be modified and altered, and molecules with similar properties to the polypeptides can still be obtained (e.g., conserved amino acid substitutions). For example, certain amino acids can replace other amino acids in the sequence without significant loss of activity. Because the interaction capabilities and properties of polypeptides define their biological functional activity, certain amino acid sequence substitutions can be made in the polypeptide sequence, but polypeptides with similar properties can still be obtained.
[0047] When making such changes, the hydrophilicity index of the amino acid can be considered. The importance of the hydrophilic amino acid index in conferring interacting biological functions to peptides is generally understood in the art. It is known that certain amino acids can substitute for other amino acids with similar hydrophilicities or scores and still produce peptides with similar biological activities. Based on their hydrophobic and charge properties, a hydrophilicity index has been assigned to each amino acid. These indices are: Isoleucine (+4.5); Valine (+4.2); Leucine (+3.8); Phenylalanine (+2.8); Cysteine / Cysteine (+2.5); Methionine (+1.9); Alanine (+1.8); Glycine (-0.4); Threonine (-0.7); Serine (-0.8); Tryptophan (-0.9); Tyrosine (-1.3); Proline (-1.6); Histidine (-3.2); Glutamic acid (-3.5); Glutamine (-3.5); Aspartic acid (-3.5); Asparagine (-3.5); Lysine (-3.9); and Arginine (-4.5).
[0048] It is believed that the relative hydrophilicity of amino acids determines the secondary structure of the resulting polypeptide, which in turn defines the interaction of the polypeptide with other molecules such as enzymes, substrates, receptors, antibodies, antigens, and cofactors. It is known in the art that amino acids can be substituted with another amino acid having a similar hydrophilicity index and still yield functionally equivalent polypeptides. In such modifications, substitution of amino acids with a hydrophilicity index within ±2 is preferred, particularly preferred is substitution of amino acids with a hydrophilicity index within ±1, and even more particularly preferred is substitution of amino acids with a hydrophilicity index within ±0.5.
[0049] Substitution of similar amino acids on the basis of hydrophilicity is also possible, especially when the resulting biologically equivalent polypeptides or peptides are intended for use in immunological implementations. The following hydrophilicity values have been assigned to the amino acid residues: arginine (+3.0); lysine (+3.0); aspartic acid (+3.0±1); glutamic acid (+3.0±1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); proline (-0.5±1); threonine (-0.4); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4). It should be understood that an amino acid can be substituted for another amino acid with a similar hydrophilicity value and still yield a biologically equivalent, and particularly immunologically equivalent, polypeptide. In such a modification, substitution of amino acids with a hydrophilicity value within ±2 is preferred, substitution of amino acids with a hydrophilicity value within ±1 is particularly preferred, and substitution of amino acids with a hydrophilicity value within ±0.5 is even more particularly preferred.
[0050] As outlined above, amino acid substitutions are typically based on the relative similarity of amino acid side chain substituents, such as their hydrophobicity, hydrophilicity, charge, size, etc. Exemplary substitutions for the various aforementioned characteristics are well known to those skilled in the art and include (original residue: exemplary substitution): (Ala: Gly, Ser), (Arg: Lys), (Asn: Gln, His), (Asp: Glu, Cys, Ser), (Gln: Asn), (Glu: Asp), (Gly: Ala), (His: Asn, Gln), (Ile: Leu, Val), (Leu: Ile, Val), (Lys: Arg), (Met: Leu, Tyr), (Ser: Thr), (Thr: Ser), (Tip: Tyr), (Tyr: Trp, Phe), and (Val: Ile, Leu). Therefore, embodiments of this disclosure contemplate functional or biological equivalence schemes of the peptides described above. Specifically, the implementation of the polypeptide may include variants having about 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the polypeptide of interest.
[0051] As used herein, the term "sequence identity percentage (%)" is defined as the percentage of nucleotides or amino acids in a candidate sequence that are identical to those in a reference nucleic acid sequence after, where necessary, sequence alignment and vacancy introduction to obtain the maximum sequence identity percentage. Alignments for the purpose of determining the sequence identity percentage can be performed in various ways within the art, such as using publicly available computer software like BLAST, BLAST-2, ALIGN, ALIGN-2, or Megalign (DNASTAR) software. Appropriate parameters for measuring alignment can be determined by known methods, encompassing any algorithm required to achieve maximum alignment across the full length of the sequences being compared.
[0052] For the purposes of this paper, the sequence identity % of a given nucleotide or amino acid sequence C with respect to a given nucleic acid sequence D (which can be alternatively expressed as the given sequence C having or containing a certain sequence identity % with respect to the given sequence D) is calculated as follows:
[0053] 100 multiplied by the fraction W / Z,
[0054] Where W is the number of nucleotides or amino acids that are identified as identical matches by the sequence alignment program in the alignment of C and D, and Z is the total number of nucleotides or amino acids in D. It should be understood that when the length of sequence C is not equal to the length of sequence D, the sequence identity percentage of C to D will not be equal to the sequence identity percentage of D to C.
[0055] As used herein, the term "specific binding" refers to an antibody binding to its homologous antigen (e.g., DNA) without significantly binding to other antigens. Specific binding of an antibody to a target under such conditions requires antibody selection based on its target specificity. Various immunoassays can be used to select antibodies that specifically react with a particular protein. For example, solid-phase ELISA is routinely used to select monoclonal antibodies that specifically react with a protein. See, for example, Harlow and Lane (1988) Antibodies, A Laboratory Manual, Cold Spring Harbor Publications, New York, for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity. Preferably, the antibody binds to the second molecule at a concentration greater than about 10... 5 mol -1 (For example, 10) 6 mol -1 10 7 mol -1 10 8 mol -1 10 9 mol -1 10 10 mol -1 10 11 mol -1 and 10 12 mol -1 An affinity constant (Ka) of 100% or greater binds specifically to an antigen.
[0056] As used herein, the term “monoclonal antibody” or “MAb” refers to an antibody obtained from a substantially homogeneous population of antibodies, meaning that individual antibodies in the population are identical except for possible naturally occurring mutations that may exist in a small subset of antibody molecules.
[0057] As used herein, the term "subject" refers to any individual who serves as the target of administration. A subject can be a vertebrate, such as a mammal. Therefore, a subject can be a human. The term does not indicate a specific age or sex.
[0058] As used herein, the term "effective amount" means an amount of composition used that is sufficient to improve one or more causes or symptoms of a disease or condition. Such improvement requires only reduction or alteration, not elimination. The precise dosage will vary depending on a variety of factors, such as subject-related variables (e.g., age, immune system health status, etc.), the disease or condition being treated, and the route of administration and pharmacokinetics of the administered agent.
[0059] As used herein, the term “pharmaceutically acceptable” means a material that is not biologically or otherwise undesirable, i.e., that the material can be administered to a subject without causing any undesirable biological effects or interacting with any other component in a pharmaceutical composition containing the material in any harmful manner.
[0060] As used herein, the terms “carrier” or “excipient” refer to an organic or inorganic component, a natural or synthetic inactive component, or one or more active components in combination thereof in a formulation. As is well known to those skilled in the art, a carrier or excipient will be naturally selected to minimize any degradation of the active component and to minimize any adverse side effects in the subject.
[0061] As used herein, the term "treatment" refers to the medical management of a patient with the intention of curing, improving, stabilizing, or preventing a disease, pathological condition, or symptom. This term includes active treatment, which is treatment specifically aimed at improving a disease, pathological condition, or symptom, and also includes etiological treatment, which is treatment aimed at eliminating the cause of the related disease, pathological condition, or symptom. Furthermore, this term includes palliative treatment, which is treatment designed to alleviate symptoms rather than cure a disease, pathological condition, or symptom; preventive treatment, which is treatment aimed at minimizing or partially or completely inhibiting the development of the related disease, pathological condition, or symptom; and supportive treatment, which is treatment used to complement another specific therapy aimed at improving the related disease, pathological condition, or symptom.
[0062] As used herein, a “targeting portion” is a substance that directs particles or molecules to receptor sites in selected cell or tissue types, and can be used as an attachment molecule or to couple or attach to another molecule. As used herein, “direction” refers to the preferential attachment of molecules to selected cell or tissue types. As described below, this can be used to direct cellular materials, molecules, or drugs.
[0063] As used herein, the terms “inhibition” or “reduction” mean a reduction in activity, response, symptom, disease, or other biological parameters. This can include, but is not limited to, complete ablation of activity, response, symptom, or disease. It can also include, for example, a 10% reduction in activity, response, symptom, or disease compared to native or control levels. Thus, a reduction compared to native or control levels can be 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any reduction in between.
[0064] As used herein, a "fusion protein" is a polypeptide formed by linking two or more polypeptides together via peptide bonds between the amino terminus of one polypeptide and the carboxyl terminus of another. Fusion proteins can be formed by chemical coupling of the constituent polypeptides or by expressing a single polypeptide from a nucleic acid sequence encoding a single, continuous fusion protein. A single-chain fusion protein is a fusion protein having a single, continuous polypeptide backbone. Fusion proteins can be prepared using conventional techniques in molecular biology to link two genes using the same reading frame into a single nucleic acid sequence, and then express the nucleic acid in a suitable host cell under conditions that produce the fusion protein.
[0065] Unless otherwise specified herein, the description of the range of values herein is intended only as a shorthand for individually referring to each individual value falling within that range, and each individual value is incorporated into this specification as if described separately herein.
[0066] The term "about" is used to describe values that are higher or lower than the stated value within a range of about + / - 10%; in other embodiments, these values may be higher or lower than the stated value within a range of about + / - 5%; in other embodiments, these values may be higher or lower than the stated value within a range of about + / - 2%; in other embodiments, these values may be higher or lower than the stated value within a range of about + / - 1%. The above ranges are intended to be determined according to the context and do not imply further limitations.
[0067] Unless otherwise specified or obviously contradicted by the context, all methods described herein may be performed in any suitable order. Unless otherwise required, the use of any and all instances or exemplary language (e.g., "such") provided herein is intended only to better illustrate the embodiments and does not constitute a limitation on the scope of the embodiments. No language in the specification should be construed as indicating that any unclaimed element is necessary for practicing the invention.
[0068] II. Composition
[0069] 3E10 antibodies have been found to facilitate the delivery of nucleic acids across the plasma membrane and into the cytoplasm and nucleus. Therefore, compositions and methods for enhancing the delivery of nucleic acid constructs using 3E10 are provided. Typically, an effective amount of 3E10 antibody is contacted with the nucleic acid to be delivered into the cell. Typically, the contact occurs for a sufficient duration to allow the 3E10 and the nucleic acid cargo to form a complex. The complex is then contacted with the cell for a sufficient duration to allow the nucleic acid cargo to be delivered into the cell. Compared to cases where the cell is contacted with the nucleic acid cargo in the absence of an antibody, the cargo can accumulate in greater quantities, with higher quality (e.g., more complete, higher functionality, etc.), or at a faster rate, or a combination thereof. Because antibodies are used as the means of delivery, the delivery system is typically non-viral.
[0070] A. 3E10 antibody
[0071] Although generally referred to herein as “3E10” or “3E10 antibody”, it should be understood that fragments and binding proteins, including antigen-binding fragments, variants and fusion proteins such as scFv, di-scFv, tr-scFv, and other single-chain variable fragments, as well as other cell-penetrating nucleic acid transport molecules disclosed herein, are all covered by this phrase, which also explicitly provides for the compositions and methods disclosed herein. Therefore, antibodies and other binding proteins are also referred to herein as cell-penetrating.
[0072] In a preferred embodiment, the 3E10 antibody is transported into the cytoplasm and / or nucleus of cells without the assistance of a carrier or conjugate. For example, Richard Weisbart's U.S. Patents 4,812,397 and 7,189,396 disclose a monoclonal antibody 3E10 and its active fragment that can be transported to the nucleus of mammalian cells in vivo without cytotoxicity.
[0073] In some implementations, the antibody may bind to and / or inhibit Rad51. See, for example, Turnick et al. Nucleic Acids Res The antibodies described in ., 45(20): 11782-11799 (2017), WO 2020 / 047344 and WO 2020 / 047353, each of which is specifically incorporated herein by reference.
[0074] Antibodies that can be used in compositions and methods include any class of intact immunoglobulins (i.e., intact antibodies), fragments thereof, and synthetic proteins containing at least an antigen-binding variable domain. The variable domains differ in sequence between antibodies and are used for the binding and specificity of each particular antibody to its specific antigen. However, variability is not typically uniformly distributed within the antibody variable domains. It is usually concentrated in three segments called complementarity-determining regions (CDRs) or hypervariable regions in the light and heavy chain variable domains. The more conserved portions of the variable domains are called frames (FRs). The variable domains of the natural heavy and light chains each contain four FR regions, predominantly in a β-sheet configuration, linked by three CDRs that form loops connecting the β-sheet structure and, in some cases, a portion of the β-sheet structure. The CDRs in each chain are tightly held together by the FR regions and, together with CDRs from the other chain, contribute to the formation of the antibody's antigen-binding site. Therefore, antibodies typically contain at least the CDRs necessary to maintain DNA binding and / or interfere with DNA repair.
[0075] 3E10 antibodies are typically monoclonal 3E10, or its variants, derivatives, fragments, fusions, or humanized forms, which bind to the same or different epitopes as 3E10.
[0076] On September 6, 2000, a hybridoma cell line producing monoclonal antibody 3E10 was received for deposit under the terms of the Budapest Treaty and accepted by the American Center for Type Culture Collection (ATCC) 10801 University Blvd., Manassas, VA 20110-2209, USA, and granted patent accession number PTA-2439.
[0077] Therefore, the antibody can have the same or different epitope specificity as the monoclonal antibody 3E10 produced by hybridoma ATCC No. PTA 2439. The antibody can have a complementary site to the monoclonal antibody 3E10. The antibody can be a single-chain variable fragment or variant of 3E10, for example, a conserved variant thereof. For example, the antibody can be a single-chain variable fragment of 3E10 (3E10 Fv) or a variant thereof.
[0078] 1. 3E10 sequence
[0079] The amino acid sequence of the monoclonal antibody 3E10 is known in the art. For example, the sequences of the heavy and light chains of 3E10 are provided below, wherein a single underscore indicates a CDR region identified according to the Kabat system, while in SEQ ID NO: 12-14, italics indicate variable regions and double underscores indicate signal peptides. The CDR according to the IMGT system is also provided.
[0080] a. 3E10 heavy chain
[0081] In some implementations, the heavy chain variable region of 3E10 is:
[0082] EVQLVESGGGLVKPGGSRKLSCAASGFTFS DYGMH WVRQAPEKGLEWVA YISSGSSTIYYADTVKG RFTISRDNAKNTLFLQMTSLRSEDTAMYYCAR RGLLLDY WGQGTTLTVSS (SEQ ID NO: 1; Zack et al., Immunology and Cell Biology , 72:513-520 (1994); GenBank: L16981.1 – Mouse Ig rearrangement of L chain Genes, some CDS ; and GenBank: AAA65679.1 – Immunoglobulin heavy chains, partially [in house mice] ).
[0083] In some implementations, the 3E10 heavy chain is expressed as
[0084] MGWSCIILFLVATATGVHS EVQLVESGGGLVKPGGSRKLSCAASGFTFS DYGMH WVRQAPEKGLEWVA YISSGSSTIYYADTVKG RFTISRDNAKNTLFLQMTSLRSEDTAMYYCAR RGLLLDY WGQGTTLTVS AASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (3E10 WT heavy chain; SEQ ID NO: 12).
[0085] Variants of the 3E10 antibody that incorporate mutations into the wild-type sequence are also known in the art, for example, by Zack et al. J. ImmunolAs disclosed in ., 157(5):2082-8 (1996). For example, the amino acid position 31 of the heavy chain variable region of 3E10 has been determined to affect the ability of antibodies and their fragments to penetrate the cell nucleus and bind to DNA (in bold in SEQ ID NO:1, 2 and 13). The D31N mutation in CDR1 (in bold in SEQ ID NO:2 and 13) penetrates the cell nucleus and binds to DNA with much greater efficiency than the original antibody (Zack et al., Immunology and Cell Biology , 72:513-520 (1994), Weisbart et al., J. Autoimmun ., 11, 539-546 (1998); Weisbart, Int. J. Oncol ., 25, 1867-1873 (2004). In some embodiments, the antibody has a D31N substitution.
[0086] In some embodiments, the preferred amino acid sequence of the heavy chain variable region of 3E10 is:
[0087] EVQLVESGGGLVKPGGSRKLSCAASGFTFS NYGMH WVRQAPEKGLEWVA YISSGSSTIYYADTVKG RFTISRDNAKNTLFLQMTSLRSEDTAMYYCAR RGLLLDY WGQGTTLTVSS (SEQ ID NO: 2).
[0088] In some implementations, the 3E10 heavy chain is expressed as
[0089] MGWSCIILFLVATATGVHS EVQLVESGGGLVKPGGSRKLSCAASGFTFS NYGMH WVRQAPEKGLEWVA YISSGSSTIYYADTVKG RFTISRDNAKNTLFLQMTSLRSEDTAMYYCAR RGLLLDY WGQGTTLTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (3E10 D31N variant heavy chain; SEQ ID NO: 13).
[0090] In some embodiments, the C-terminal serine of SEQ ID NO: 1 or 2 is absent or replaced, for example, with alanine in the 3E10 heavy chain variable region.
[0091] The complementarity-determining regions (CDRs) identified by Kabat are underlined and include CDR H1.1 (original sequence): DYGMH (SEQ ID NO: 15); CDR H1.2 (with D31N mutation): NYGMH (SEQ ID NO: 16); CDRH2.1: YISSGSSTIYYADTVKG (SEQ ID NO: 17); CDR H3.1: RGLLLDY (SEQ ID NO: 18).
[0092] Variants of Kabat CDR H2.1 include YISSGSSTIYYADSVKG (SEQ ID NO: 19) and YISSSSSTIYYADSVKG (SEQ ID NO: 42).
[0093] Alternatively or concurrently, the heavy chain complementarity-determining region (CDR) can be defined according to the IMGT system. The complementarity-determining regions (CDRs) identified by the IMGT system include CDR H1.3 (original sequence): GFTFSYG (SEQ ID NO: 20); CDR H1.4 (with the D31N mutation): GFTFSNYG (SEQ ID NO: 21); CDR H2.2: ISSGSSTI (SEQ ID NO: 22) and the variant ISSSSSTI (SEQ ID NO: 43); CDR H3.2: ARRGLLLDY (SEQ ID NO: 23).
[0094] b. 3E10 light chain
[0095] In some implementations, the light chain variable region of 3E10 is:
[0096] DIVLTQSPASLAVSLGQRATISC RASKSVSTSSYSYMH WYQQKPGQPPKLLIK YASYLES GVPARFSGSGSGTDFTLNIHPVEEEDAATYYC QHSREFPWT FGGGTKLEIK (SEQ ID NO:7).
[0097] The amino acid sequence of the 3E10 light chain variable region can also be:
[0098] DIVLTQSPASLAVSLGQRATISC RASKSVSTSSYSYMH WYQQKPGQPPKLLIK YASYLES GVPARFSGSGSGTDFHLNIHPVEEEDAATYYC QHSREFPWT FGGGTKLELK (SEQ ID NO:8).
[0099] In some implementations, the 3E10 light chain is expressed as
[0100] MGWSCIILFLVATATGVHS DIVLTQSPASLAVSLGQRATISC RASKSVSTSSYSYMH WYQQKPGQPPK LLIK YASYLES GVPARFSGSGSGTDFTLNIHPVEEEDAATYYC QHSREFPWT FGGGTKLEIKR TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (3E10 WT light chain; SEQ ID NO: 14).
[0101] Other 3E10 light chain sequences are known in the art. See, for example, Zack et al. J. Immunol. , 15;154(4):1987-94 (1995); GenBank: L16981.1 – Mouse Ig rearrangement of L light chain, partial cds GenBank: AAA65681.1 – Immunoglobulin light chains, in some mice. ).
[0102] The complementarity determination regions (CDRs) identified by Kabat are shown underlined, including CDR L1.1: RASKSVSTSSYSYMH (SEQ ID NO: 24); CDR L2.1: YASYLES (SEQ ID NO: 25); CDR L3.1: QHSREFPWT (SEQ ID NO: 26).
[0103] Variants of Kabat CDR L1.1 include RASKSVSTSSYSYLA (SEQ ID NO: 27) and RASKTVSTSSYSYMH (SEQ ID NO: 44).
[0104] A variant of Kabat CDR L2.1 is YASYLQS (SEQ ID NO: 28).
[0105] Alternatively or alternatively, the heavy chain complementarity determination region (CDR) can be defined according to the IMGT system. For example, the complementarity determination regions (CDRs) identified by the IMGT system include CDR L1.2 KSVSTSSYSY (SEQ ID NO: 29) and its variant KTVSTSSYSY (SEQ ID NO: 45); CDR L2.2: YAS (SEQ ID NO: 30); CDR L3.2: QHSREFPWT (SEQ ID NO: 26).
[0106] In some embodiments, the C-terminus of the sequence SEQ ID NO: 7 or 8 further comprises arginine in the 3E10 light chain variable region.
[0107] 2. Humanization 3E10
[0108] In some embodiments, the antibody is a humanized antibody. Methods for humanizing nonhuman antibodies are well known in the art. Typically, humanized antibodies have one or more amino acid residues introduced from a nonhuman source. These nonhuman amino acid residues are often referred to as “import” residues, and these import residues are typically derived from an “import” variable domain. Antibody humanization techniques generally involve using recombinant DNA techniques to manipulate the DNA sequence encoding one or more polypeptide chains of the antibody molecule.
[0109] The exemplary 3E10 humanized sequence is discussed in WO 2015 / 106290, WO 2016 / 033324, WO 2019 / 018426 and WO / 2019 / 018428 and is provided below.
[0110] a. Humanized 3E10 heavy chain variable region
[0111] In some implementations, the humanized 3E10 heavy chain variable structural domain includes
[0112] EVQLVQSGGGLIQPGGSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVSYISSGSSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSS (hVH1, SEQ ID NO: 3), or
[0113] EVQLVESGGGLIQPGGSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVSYISSGSSTIYYADSVKGRFTISRDNSKNTLYLQMTSLRAEDTAVYYCARRGLLLDYWGQGTTLTVSS (hVH2, SEQ ID NO: 4), or
[0114] EVQLQESGGGVVQPGGSLRLSCAASGFTFSNYGMHWIRQAPGKGLEWVSYISSGSSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRSEDTAVYYCARRGLLLDYWGQGTLVTVSS (hVH3, SEQ ID NO: 5), or
[0115] EVQLVESGGGLVQPGGSLRLSCSASGFTFSNYGMHWVRQAPGKGLEYVSYISSGSSTIYYADTVKGRFTISRDNSKNTLYLQMSSLRAEDTAVYYCVKRGLLLDYWGQGTLVTVSS (hVH4, SEQ ID NO: 6), or
[0116] EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSS (Variants 2, 6 and 10, SEQ ID NO: 46), or
[0117] EVQLVESGGGVVQPGGSLRLSCAASGFTFSNYGMHWVRQAPEKGLEWVSYISSSSSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSS (Variants 3, 7 and 11, SEQ ID NO: 47), or
[0118] EVQLVESGGGDVKPGGSLRLSCAASGFTFSNYGMHWVRQAPEKGLEWVSYISSSSSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSS (Variants 4, 8 and 12, SEQ ID NO: 48), or
[0119] EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVSYISSGSSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSS (Variants 13, 16 and 19, SEQ ID NO: 50), or
[0120] EVQLVESGGGVVQPGGSLRLSCAASGFTFSNYGMHWVRQAPEKGLEWVSYISSGSSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSS (Variants 14 and 17, SEQ ID NO: 51), or
[0121] EVQLVESGGGDVKPGGSLRLSCAASGFTFSNYGMHWVRQAPEKGLEWVSYISSGSSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSS (variants 15 and 18, SEQ ID NO: 52).
[0122] b. Humanized 3E10 light chain variable zone
[0123] In some implementations, the humanized 3E10 light chain variable structural domain includes
[0124] or
[0125] OR
[0126] DIVLTQSPASLAVSPGQRATITCRASKSVSTSSYSYMHWYQQKPGQPPKLLIYYASYLESGVPARFSGSGSGTDFTLTINPVEANDTANYYCQHSREFPWTFGQGTKVEIK (hVL3, SEQ ID NO:11)
[0127] DIQMTQSPSSLSASLGDRATITCRASKSVSTSSYSYMHWYQQKPGQPPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDAATYYCQHSREFPWTFGGGTKVEIK (Variant 2, 3 and 4, SEQ ID NO: 53)
[0128] DIQMTQSPSSLSASLGDRATITCRASKSVSTSSYSYMHWYQQKPGQAPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSREFPWTFGQGTKVEIK (Variant 6, 7 and 8, SEQ ID NO: 54)
[0129] DIQMTQSPSSLSSASVGDRVTITCRASKSVSTSSYSYMHWYQQKPGKAPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSREFPWTFGQGTKVEIK (variants 10, 11 and 12, SEQ ID NO: 55)
[0130] DIQMTQSPSSLSASLGDRATITCRASKTVSTSSYSYMHWYQQKPGQPPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDAATYYCQHSREFPWTFGGGTKVEIK (Variant 13, 14 and 15, SEQ ID NO: 56)
[0131] DIQMTQSPSSLSSASVGDRVTITCRASKTVSTSSYSYMHWYQQKPGKAPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSREFPWTFGQGTKVEIK (variants 16, 17 and 18, SEQ ID NO: 57)
[0132] DIQMTQSPSSLSASLGDRATITCRASKTVSTSSYSYMHWYQQKPGQAPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSREFPWTFGQGTKVEIK (Variant 19, SEQ ID NO: 58)
[0133] c. Cell penetration and nuclear localization
[0134] The disclosed compositions and methods typically utilize antibodies that maintain the ability to penetrate cells and, optionally, the cell nucleus.
[0135] The mechanisms of cell internalization via autoantibodies are diverse. Some enter the cell through electrostatic interactions or FcR-mediated endocytosis, while others utilize mechanisms based on binding to cell surface myosin or calreticulin, followed by endocytosis (Ying-Chyi et al., Eur J Immunol 38, 3178-3190 (2008), Yanase et al., J Clin Invest 100, 25-31 (1997)). 3E10 penetrates cells via a Fc-independent mechanism (as demonstrated by the ability of Fc-deficient 3E10 fragments to penetrate cells), but involves the presence of the nucleoside transporter ENT2 (Weisbart et al., Sci Rep 5:12022. doi: 10.1038 / srep12022. (2015), Zack et al. J Immunol 157, 2082-2088(1996), Hansen et al., J Biol Chem 282, 20790-20793 (2007)). Therefore, in some embodiments, the antibodies used in the disclosed compositions and methods are antibodies that penetrate cells via a non-Fc-dependent mechanism but involve the presence of the nucleoside transporter ENT2.
[0136] Mutations in 3E10 that interfere with its DNA-binding ability may prevent the antibody from penetrating the nucleus. Therefore, generally, disclosed antibody variants and humanized forms retain the ability to bind nucleic acids (especially DNA). Furthermore, 3E10 scFv has previously been shown to penetrate living cells and the nucleus in an ENT2-dependent manner, with impaired uptake efficiency in ENT2-deficient cells (Hansen et al., J. Biol. Chem 282, 20790-20793 (2007)). Therefore, in some embodiments, the disclosed antibody variants and humanized forms retain the ability to penetrate the cell nucleus in an ENT-dependent, preferably ENT2-dependent manner.
[0137] As discussed in WO 2019 / 152806 and WO 2019 / 152808, some humanized 3E10 variants were found to penetrate the nucleus more effectively than the original mouse 3E10 (D31N) di-scFv, while others were found to have lost the ability to penetrate the nucleus. In particular, variants 10 and 13 penetrated the nucleus very well compared to the mouse antibody.
[0138] Potential nucleus localization signals (NLS) have been identified in humanized 3E10 VL, which may include some or all of the following sequences:
[0139] RASK S VSTSSYSYMHWYQQKPGQPPKLLIKY (SEQ ID NO: 88);
[0140] RASK TVSTSSYSYMHWYQQKPGQPPKLLIKY (SEQ ID NO: 89); or
[0141] RVTIT CRASKSVSTSSYSYMHWYQQKPGKAPKL (SEQ ID NO: 90).
[0142] An example shared NLS may be or include,
[0143] ( X) RASKTVSTSSYSYMHWYQQKPGQPPKLL( X) KY (where (X) = any residue, but preferably a basic residue (R or K) (SEQ ID NO:91), or a variant thereof, said variant having at least 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99% sequence identity with SEQ ID NO:53.
[0144] Therefore, in some embodiments, particularly where nuclear input is important, the disclosed antibody may comprise any of the sequences of SEQ ID NO: 88-91 that can be translocated to the cell nucleus, or fragments and variants thereof (e.g., having 70, 75, 80, 85, 90, 95, 96, 97, 98, 99, or 100% amino acid sequence identity with any of SEQ ID NO: 88-91).
[0145] The presence of NLS suggests that 3E10 may cross the nuclear envelope via the nuclear input pathway. In some embodiments, NLS enhances input by interacting with one or more members of the input pathway. Thus, in some embodiments, NLS may bind to input protein-β, the input protein-β / input protein-α heterodimer, or a combination thereof.
[0146] 3. Nucleic acid binding
[0147] The disclosed compositions and methods typically utilize antibodies that retain the ability to bind nucleic acids (such as DNA, RNA, or combinations thereof).
[0148] The following examples illustrate molecular modeling of 3E10 and other 3E10 variants. Molecular modeling of 3E10 (Pymol) reveals the putative nucleic acid binding pocket (NAB1) (see, for example, Figure 14A and Figure 14B ), and illustrate with the underlined sequence below.
[0149] WT heavy chain scFv sequence
[0150] E VQ LVESGGG L VKPGGS RKLSC AASGFTFSD Y GMHWVRQ AP E KG L E WVAYISSGSSTI YYADTVKGRFT I S RDNAKNT LFL QMTSLRSEDT AM YYCARRG L LL DYWGQGTT LTVS (SEQ ID NO:92)
[0151] Light chain scFv sequence
[0152] DIVLT QSPASL AVSLGQRATI SC RASKSVS T SSY SYMH W Y Q QKPGQPPKL LI K YASYLESGVPARFSGSGSGTDFTLNIHPVEEEDA ATYYCQHSR EFPW TFGGG TKLEIK RADAAPGGGG SGGGGSGGGGS (SEQ ID NO:93)
[0153] In some embodiments, the disclosed antibody comprises some or all of the underlined NAB1 sequence. In some embodiments, the antibody comprises a variant sequence having altered nucleic acid binding ability. In some embodiments, mutations in NAB1 (e.g., substitution, insertion, and / or deletion) improve antibody binding to nucleic acids such as DNA, RNA, or combinations thereof. In some embodiments, the mutation is a conserved substitution. In some embodiments, the mutation increases the cationic charge in the NAB1 pocket.
[0154] As discussed and illustrated in this paper, mutating aspartic acid at residue 31 of CDR1 to asparagine increases the cationic charge of that residue and enhances nucleic acid binding and delivery in vivo (3E10-D31N).
[0155] Other exemplary variants include a mutation of aspartic acid at residue 31 of CDR1 to arginine (3E10-D31R), which modeling indicates an amplification of the cationic charge, or lysine (3E10-D31K), which modeling indicates a change in charge orientation. Therefore, in some embodiments, the 3E10-binding protein includes either D31R or D31K substitutions.
[0156] All sequences disclosed herein containing residues corresponding to 3E10 D31 or N31 explicitly disclose D31R or D31K or N31R or N31K substitutions.
[0157] Molecular modeling of 3E10 (Pymol) revealed the putative nucleic acid binding pocket (NAB1). Figures 14A-14B Mutating aspartic acid at residue 31 of CDR1 to asparagine increases the cationic charge of that residue and enhances nucleic acid binding and delivery in vivo (3E10-D31N).
[0158] Mutating astaxanthin at residue 31 of CDR1 to arginine (3E10-D31R) further expands the cationic charge, while mutagenesis to lysine (3E10-D31K) alters the charge direction. Figure 14A ).
[0159] The NAB1 amino acids predicted from molecular modeling are underlined in the heavy and light chain sequences above. Figure 14B This is a diagram showing the molecular model (Pymol) of 3E10-scFv, where NAB1 amino acid residues are represented as dots.
[0160] 4. Fragments, variants, and fusion proteins
[0161] Anti-DNA antibodies may consist of antibody fragments or fusion proteins comprising an amino acid sequence of a variable heavy chain and / or a variable light chain, the amino acid sequence being at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to the amino acid sequence of the heavy chain and / or light chain of 3E10 or its humanized form (e.g., any one of SEQ ID NO: 1-11 or 46-58, or the heavy chain and / or light chain of any one of SEQ ID NO: 12-14).
[0162] Anti-DNA antibodies may consist of antibody fragments or fusion proteins containing one or more CDRs whose amino acid sequence is at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to that of 3E10 or its variants or humanized forms of a CDR (e.g., a CDR of any one of SEQ ID NO: 1-11 or 46-58, or a CDR of any one of SEQ ID NO: 12-14, or a CDR of any one of SEQ ID NO: 15-30 or 42-45). The percentage of identity between two amino acid sequences can be determined by BLAST protein comparison. In some embodiments, the antibody contains one, two, three, four, five, or all six CDRs of the aforementioned preferred variable domains.
[0163] Preferably, the antibody comprises a combination of one of each of the heavy chains CDR1, CDR2, and CDR3 and one of each of the light chains CDR1, CDR2, and CDR3.
[0164] The above provides the predicted complementarity-determining regions (CDRs) for the 3E10 light chain variable sequence. See also GenBank:AAA65681.1 - Immunoglobulin light chain, in some mice And GenBank: L34051.1- Mouse Ig rearranged κ chain mRNA V district The above provides the predicted complementarity-determining regions (CDRs) for the heavy-chain variable sequence of 3E10. See, for example, Zack et al. Immunology and Cell Biology , 72:513-520 (1994), GenBank accession number AAA65679.1. Zach et al., J. Immunol . 154 (4), 1987–1994 (1995) and GenBank: L16982.1- Mouse Ig rearranged H chain group Because, some CDS .
[0165] Therefore, in some embodiments, the cell-penetrating antibody contains the CDR of SEQ ID NO: 1 or 2, or the entire heavy and light chain variable region, or the heavy chain region of SEQ ID NO: 12 or 13; or the humanized form thereof in combination with SEQ ID NO: 7 or 8, or the light chain region of SEQ ID NO: 14; or the humanized form thereof. In some embodiments, the cell-penetrating antibody contains the CDR of SEQ ID NO: 3, 4, 5, or 6 in combination with SEQ ID NO: 9, 10, or 11, or the entire heavy and light chain variable region. In some embodiments, the cell-penetrating peptide contains the CDR of any one of SEQ ID NO: 46-48 or 50-52 in combination with any one of SEQ ID NO: 53-58, or the entire heavy and light chain variable region.
[0166] All sequences disclosed herein containing residues corresponding to 3E10 D31 or N31 explicitly disclose the substitution of D31R or D31K or N31R or N31K. Therefore, in some embodiments, the 3E10 binding protein is a variant of any of the foregoing or following sequences, wherein the amino acid residue corresponding to 31 of the 3E10 heavy chain residue is substituted with arginine (R) or lysine (K).
[0167] It also contains biologically active antibody fragments. Whether or not attached to other sequences, the fragments contain insertions, deletions, substitutions, or other selected modifications of specific regions or specific amino acid residues, provided that the activity of the fragment is not significantly altered or impaired compared to unmodified antibodies or antibody fragments.
[0168] Techniques for generating single-chain antibodies specific to the antigen proteins of this disclosure can also be employed. Methods for generating single-chain antibodies are well known to those skilled in the art. Single-chain antibodies can be created by fusing variable domains of the heavy and light chains together using short peptide linkers, thereby reconstructing the antigen-binding site on a single molecule. Single-chain antibody variable fragments (scFvs) have been developed, in which the C-terminus of one variable domain is embolized to the N-terminus of another variable domain via a peptide or linker having 15 to 25 amino acids, without significantly disrupting antigen binding or binding specificity. The linker is selected to allow the heavy and light chains to bind together in their appropriate conformation.
[0169] Anti-DNA antibodies can be modified to enhance their therapeutic potential. For example, in some embodiments, a cell-penetrating anti-DNA antibody is conjugated to another antibody that is specific to a second therapeutic target in the cytoplasm and / or nucleus of the target cells. For example, the cell-penetrating anti-DNA antibody may be a fusion protein containing a single-chain variable fragment of 3E10 Fv and a monoclonal antibody that specifically binds to a second therapeutic target. In other embodiments, the cell-penetrating anti-DNA antibody is a bispecific antibody having a first heavy chain and a first light chain from 3E10 and a second heavy chain and a second light chain from a monoclonal antibody that specifically binds to a second therapeutic target.
[0170] In Weisbart, etc. Mol. Cancer Ther ., 11(10):2169-73 (2012), and Weisbart et al., Int. J. Oncology Bispecific antibodies and other binding proteins having a first heavy chain and a first light chain from 3E10 and a second heavy chain and a second light chain from a monoclonal antibody that specifically binds to a second target are discussed in references to, 25:1113-8 (2004), and U.S. Patent Application No. 2013 / 0266570, the entire contents of which are specifically incorporated herein by reference. In some embodiments, the second target is specific to the target cell type, tissue, organ, etc. Therefore, the second heavy chain and the second light chain can be used as a targeting portion to target the complex to the target cell type, tissue, organ. In some embodiments, the second heavy chain and the second light chain target hematopoietic stem cells, CD34, etc. + Cells, T cells, or any other preferred cell type, for example, by targeting receptors or ligands expressed on the preferred cell type. In some embodiments, the second heavy chain and the second light chain target the thymus, spleen, or cancer cells.
[0171] In some implementations, particularly those for in vivo targeting of T cells, such as for the in vivo production of CAR T cells, the target may be immune cells or T cell markers, such as CD3, CD7, or CD8. For example, anti-CD8 antibodies and anti-CD3 Fab fragments have been used to target T cells in vivo (Pfeiffer et al.). EMBO Mol Med ., 10(11) (2018). pii:e9158. doi: 10.15252 / emmm.201809158., Smith et al., Nat Nanotechnol., 12(8):813-820(2017). doi: 10.1038 / nnano.2017.57). Therefore, in some embodiments, the 3E10 antibody or antigen-binding fragment or fusion protein is a bispecific antibody portion that can specifically bind to CD3, CD7, CD8 or another immune cell (e.g., T cell) marker, or a marker of a specific tissue such as the thymus, spleen or liver.
[0172] Bivalent single-chain variable fragments (bis-scFvs) can be engineered by linking two scFvs together. This can be done by generating a single peptide chain with two VH regions and two VL regions, resulting in a tandem scFv. ScFvs can also be engineered to have a linker peptide that is too short for the two variable regions to fold together (about five amino acids), thus forcing the scFv to dimerize. This type is called a bimeric antibody. Bimeric antibodies have been shown to have dissociation constants that are up to 40 times lower than the corresponding scFvs, meaning they have a much higher affinity for their targets. Even shorter linkers (one or two amino acids) lead to trimer (trimeric or trimeric antibody) formation. Tetrameric antibodies have also been generated. They exhibit even higher affinity for their targets than bimeric antibodies. In some embodiments, anti-DNA antibodies may contain two or more linked single-chain variable fragments of 3E10 (e.g., 3E10 bis-scFv, 3E10 tri-scFv) or conserved variants thereof. In some embodiments, the anti-DNA antibody is a bisomic antibody or a trisomic antibody (e.g., a 3E10 bisomic antibody, a 3E10 trisomic antibody). Sequences of single and two or more linked single-stranded variable fragments of 3E10 are provided in WO 2017 / 218825 and WO2016 / 033321.
[0173] The function of an antibody can be enhanced by conjugating the antibody or a fragment thereof to a therapeutic agent. Such conjugation of an antibody or fragment to a therapeutic agent can be achieved by preparing an immunoconjugate, by preparing a fusion protein, or by linking the antibody or fragment to a nucleic acid such as DNA or RNA (e.g., siRNA), thereby including the antibody or antibody fragment and the therapeutic agent.
[0174] Recombinant fusion proteins are proteins produced through genetic engineering of fusion genes. This typically involves removing the stop codon from the cDNA sequence encoding the first protein and then attaching the cDNA sequence of the second protein in cascade via ligation or overlap extension PCR. The DNA sequence is then expressed by the cell as a single protein. Proteins can be engineered to contain the complete sequences of both original proteins or only a portion of either one. If both entities are proteins, adapter (or “spacer”) peptides are often added, making it more likely that the proteins will fold independently and behave as expected.
[0175] In some embodiments, cell-penetrating antibodies are modified to alter their half-life. In some embodiments, it is desirable to increase the half-life of the antibody, so that the antibody remains in circulation or at the treatment site for a longer period. For example, it may be desirable to maintain an extended antibody titer in circulation or at the treatment site for an extended period. In other embodiments, the half-life of anti-DNA antibodies is reduced to reduce potential side effects. The half-life of an antibody fragment (such as 3E10Fv) may be shorter than that of a full-size antibody. Other methods for altering half-life are known and can be used in the described methods. For example, the antibody can be engineered to have an extended half-life Fc variant, such as using Xtend. TM Antibody half-life extension technology (Xencor, Monrovia, CA).
[0176] a. Connector
[0177] As used herein, the term "linker" includes, but is not limited to, peptide linkers. Peptide linkers can be of any size, as long as they do not interfere with binding to epitopes via the variable region. In some embodiments, the linker comprises one or more glycine and / or serine amino acid residues. In monovalent single-chain antibody variable fragments (scFvs), the C-terminus of one variable domain is typically tethered to the N-terminus of another variable domain by a 15- to 25-amino acid peptide or linker. Linkers are selected to allow the heavy and light chains to bind together in their appropriate conformation. As mentioned above, linkers in bivalent antibodies, trivalent antibodies, etc., typically contain linkers shorter than those in monovalent scFvs. Bivalent, trivalent, and other multivalent scFvs typically contain three or more linkers. The length and / or amino acid composition of the linkers can be the same or different. Therefore, as is known in the art, the number, composition, and length of linkers can be determined based on the desired valence of the scFv. Linkers can allow or drive the formation of bivalent, trivalent, and other multivalent scFvs.
[0178] For example, the linker may contain 4-8 amino acids. In a particular embodiment, the linker contains the amino acid sequence GQSSRSS (SEQ ID NO: 31). In another embodiment, the linker contains 15-20 amino acids, such as 18 amino acids. In a particular embodiment, the linker contains the amino acid sequence GQSSRSSSGGGSSGGGGS (SEQ ID NO: 32). Other flexible linkers include, but are not limited to, the amino acid sequences Gly-Ser, Gly-Ser-Gly-Ser (SEQ ID NO: 33), Ala-Ser, Gly-Gly-Gly-Ser (SEQ ID NO: 34), (Gly4-Ser)2 (SEQ ID NO: 35), (Gly4-Ser)4 (SEQ ID NO: 36), and (Gly-Gly-Gly-Gly-Ser)3 (SEQ ID NO: 37).
[0179] Other exemplary connectors include, for example,
[0180] RADAAPGGGGSGGGGSGGGGS (SEQ ID NO: 59) and ASTKGPSVFPLAPLESSGS (SEQ ID NO: 60).
[0181] b. Exemplary anti-DNA scFv sequence
[0182] Exemplary mouse 3E10 scFv sequences comprising mono-, di-, and tri-scFvs are disclosed and provided hereinafter in WO 2016 / 033321, WO 2017 / 218825, WO 2019 / 018426, and WO / 2019 / 018428. Cell-penetrating antibodies used in the disclosed compositions and methods comprise exemplary scFvs and their fragments and variants.
[0183] The amino acid sequence of scFv 3E10 (D31N) is:
[0184] AGIHDIVLTQSPASLAVSLGQRATISCRASKSVSTSSYSYMHWYQQKPGQPPKLLIKYASYLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSREFPWTFGGGTKLEIKRADAAPGGGGSGGGGSGGGGSE VQLVESGGGLVKPGGSRKLSCAASGFTFSNYGMHWVRQAPEKGLEWVAYISSGSSTIYYADTVKGRFTISRDNAKNTLFLQMTSLRSEDTAMYYCARRGLLLDYWGQGTTLTVSSLEQKLISEEDLNSAVDHHHHHH
[0185] (SEQ ID NO: 38).
[0186] Refer to SEQ ID NO: 38 for annotation of the scFv protein domain.
[0187] • The AGIH sequence increases solubility (amino acids 1-4 of SEQ ID NO: 38)
[0188] • Vk variable region (amino acids 5-115 of SEQ ID NO: 38)
[0189] • Initial (6aa) of the light chain CH1 (amino acids 116-121 of SEQ ID NO: 38)
[0190] • (GGGGS)3 (SEQ ID NO: 37) linker (amino acids 122-136 of SEQ ID NO: 38)
[0191] • VH variable region (amino acids 137-252 of SEQ ID NO: 38)
[0192] • Myc tag (amino acids 253-268 of SEQ ID NO: 38)
[0193] • His 6 tag (amino acids 269-274 of SEQ ID NO: 38)
[0194] The amino acid sequence of 3E10 di-scFv (D31N)
[0195] Di-scFv 3E10 (D31N) is a double single-stranded variable fragment containing 2X 3E10 heavy and light chain variable regions, with the aspartic acid at position 31 of the heavy chain mutated to asparagine. The amino acid sequence of Di-scFv 3E10 (D31N) is as follows:
[0196] AGIHDIVLTQSPASLAVSLGQRATISCRASKSVSTSSYSYMHWYQQKPGQPPKLLIKYASYLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSREFPWTFGGGTKLEIKRADAAPGGGGSGGGGSGGGG SEVQLVESGGGLVKPGGSRKLSCAASGFTFSNYGMHWVRQAPEKGLEWVAYISSGSSTIYYADTVKGRFTISRDNAKNTLFLQMTSLRSEDTAMYYCARRGLLLDYWGQGTTLTVSSASTKGPSVFPLAPLESSG SDIVLTQSPASLAVSLGQRATISCRASKSVSTSSYSYMHWYQQKPGQPPKLLIKYASYLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSREFPWTFGGGTKLEIKRADAAPGGGGSGGGGSGGGGSEV QLVESGGGLVKPGGSRKLSCAASGFTFSNYGMHWVRQAPEKGLEWVAYISSGSSTIYYADTVKGRFTISRDNAKNTLFLQMTSLRSEDTAMYYCARRGLLLDYWGQGTTLTVSSLEQKLISEEDLNSAVDHHHHHH
[0197] (SEQ ID NO: 39).
[0198] Refer to SEQ ID NO: 39 for annotation of the di-scFv protein domain.
[0199] • The AGIH sequence increases solubility (amino acids 1-4 of SEQ ID NO: 39)
[0200] • Vk variable region (amino acids 5-115 of SEQ ID NO: 39)
[0201] • Initial (6aa) of the light chain CH1 (amino acids 116-121 of SEQ ID NO: 39)
[0202] • (GGGGS)3 (SEQ ID NO: 37) linker (amino acids 122-136 of SEQ ID NO: 39)
[0203] • VH variable region (amino acids 137-252 of SEQ ID NO: 39)
[0204] • The linker between the Fv fragments consisting of the initial 13 amino acids of human IgG CH1 (amino acids 253-265 of SEQ ID NO: 39)
[0205] • Rotational sequence (amino acids 266-271 of SEQ ID NO: 39)
[0206] • Vk variable region (amino acids 272-382 of SEQ ID NO: 39)
[0207] • Initial (6aa) of the light chain CH1 (amino acids 383-388 of SEQ ID NO: 39)
[0208] • (GGGGS)3 (SEQ ID NO: 37) linker (amino acid 389-403 of SEQ ID NO: 39)
[0209] • VH variable region (amino acids 404-519 of SEQ ID NO: 39)
[0210] • Myc tag (amino acids 520-535 of SEQ ID NO: 39)
[0211] • His 6 tag (amino acids 536-541 of SEQ ID NO: 39)
[0212] amino acid sequence of tri-scFv
[0213] Tri-scFv 3E10 (D31N) is a triple single-stranded variable fragment containing a 3X 310E heavy chain and light chain variable region, wherein the aspartic acid at position 31 of the heavy chain is mutated to asparagine. The amino acid sequence of Tri-scFv 3E10 (D31N) is as follows:
[0214] AGIHDIVLTQSPASLAVSLGQRATISCRASKSVSTSSYSYMHWYQQKPGQPPKLLIKYASYLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSREFPWTFGGGTKLEIKRADAAPGGGGSGGGGSGGGGSEVQLVESGGGLVKPGGSRKLSCAASGFTFSNYGMHWVRQAPEKGLEWVAYISSGSSTIYYADTVKGRFTISRDNAKNTLFLQMTSLRSEDTAMYYCARRGLLLDYWGQGTTLTVSSASTKGPSVFPLAPLESSGSDIVLTQSPASLAVSLGQRATISCRASKSVSTSSYSYMHWYQQKPGQPPKLLIKYASYLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSREFPWTFGGGTKLEIKRADAAPGGGGSGGGGSGGGGSEVQLVESGGGLVKPGGSRKLSCAASGFTFSNYGMHWVRQAPEKGLEWVAYISSGSSTIYYADTVKGRFTISRDNAKNTLFLQMTSLRSEDTAMYYCARRGLLLDYWGQGTTLTVSSASTKGPSVFPLAPLESSGSDIVLTQSPASLAVSLGQRATISCRASKSVSTSSYSYMHWYQQKPGQPPKLLIKYASYLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSREFPWTFGGGTKLEIKRADAAPGGGGSGGGGSGGGGSEVQLVESGGGLVKPGGSRKLSCAASGFTFSNYGMHWVRQAPEKGLEWVAYISSGSSTIYYADTVKGRFTISRDNAKNTLFLQMTSLRSEDTAMYYCARRGLLLDYWGQGTTLTVSSLEQKLISEEDLNSAVDHHHHHH
[0215] (SEQ ID NO: 40).
[0216] Refer to SEQ ID NO: 40 for annotation of the tri-scFv protein domain.
[0217] The AGIH sequence increases solubility (amino acids 1-4 of SEQ ID NO: 40)
[0218] • Vk variable region (amino acids 5-115 of SEQ ID NO: 40)
[0219] • Initial (6aa) of the light chain CH1 (amino acids 116-121 of SEQ ID NO: 40)
[0220] • (GGGGS)3 (SEQ ID NO: 37) linker (amino acids 122-136 of SEQ ID NO: 40)
[0221] • VH variable region (amino acids 137-252 of SEQ ID NO: 40)
[0222] • The linker between the Fv fragments consisting of the initial 13 amino acids of human IgG CH1 (amino acids 253-265 of SEQ ID NO: 40).
[0223] • Rotational sequence (amino acids 266-271 of SEQ ID NO: 40)
[0224] • Vk variable region (amino acids 272-382 of SEQ ID NO: 40)
[0225] • Initial (6aa) of the light chain CH1 (amino acids 383-388 of SEQ ID NO: 40)
[0226] • (GGGGS)3 (SEQ ID NO: 37) linker (amino acids 389-403 of SEQ ID NO: 40)
[0227] • VH variable region (amino acids 404-519 of SEQ ID NO: 40)
[0228] • From human IgG C H 1. The linker between the initial 13 amino acids of the Fv fragment (amino acids 520-532 of SEQ ID NO: 40).
[0229] • Rotational sequence (amino acids 533-538 of SEQ ID NO: 40)
[0230] • Vk variable region (amino acids 539-649 of SEQ ID NO: 40)
[0231] • Initial (6aa) of the light chain CH1 (amino acids 650-655 of SEQ ID NO: 40)
[0232] • (GGGGS)3 (SEQ ID NO: 37) linker (amino acids 656-670 of SEQ ID NO: 40)
[0233] • VH variable region (amino acids 671-786 of SEQ ID NO: 40)
[0234] • Myc tag (amino acids 787-802 of SEQ ID NO: 40)
[0235] • His 6 tag (amino acids 803-808 of SEQ ID NO: 40)
[0236] WO 2016 / 033321 and Noble, etc. Cancer Research , 75(11):2285-2291 (2015) shows that di-scFv and tri-scFv have some improved and additional activities compared to their monovalent counterparts. Subsequences corresponding to different domains of each exemplary fusion protein in the exemplary fusion proteins are also provided above. Those skilled in the art will understand that the exemplary fusion proteins or their domains can be used to construct the fusion proteins discussed in more detail above. For example, in some embodiments, the di-scFv comprises a first scFv containing a Vk variable region (e.g., amino acids 5-115 of SEQ ID NO: 39 or functional variants or fragments thereof), the Vk variable region being linked to a VH variable domain (e.g., amino acids 137-252 of SEQ ID NO: 39 or functional variants or fragments thereof), which is linked to a second scFv containing a Vk variable region (e.g., amino acids 272-382 of SEQ ID NO: 39 or functional variants or fragments thereof), which is linked to a VH variable domain (e.g., amino acids 404-519 of SEQ ID NO: 39 or functional variants or fragments thereof). In some embodiments, the tri-scFv includes a di-scFv connected to a third scFv domain, which includes a Vk variable region (e.g., amino acids 671-786 of SEQ ID NO: 40 or functional variants or fragments thereof) connected to a VH variable domain (e.g., amino acids 671-786 of SEQ ID NO: 40 or functional variants or fragments thereof).
[0237] The Vk variable region can be linked to the VH variable domain alone or in combination with the (6aa) of the light chain CH1 (amino acids 116-121 of SEQ ID NO: 39) via, for example, a linker (e.g., (GGGGS)3 (SEQ ID NO: 37)). Other suitable linkers have been discussed above and are known in the art. The scFv can be linked alone or in combination with the rotatable sequence (e.g., amino acids 266-271 of SEQ ID NO: 39) via a linker (e.g., the initial 13 amino acids (253-265) of human IgG CH1 in SEQ ID NO: 39). Other suitable linkers have been discussed above and are known in the art.
[0238] Therefore, the di-scFv may contain amino acids 5-519 of SEQ ID NO: 39. The tri-scFv may contain amino acids 5-786 of SEQ ID NO: 40. In some embodiments, the fusion protein contains additional domains. For example, in some embodiments, the fusion protein contains sequences that enhance solubility (e.g., amino acids 1-4 of SEQ ID NO: 39). Therefore, in some embodiments, the di-scFv may contain amino acids 1-519 of SEQ ID NO: 39. The tri-scFv may contain amino acids 1-786 of SEQ ID NO: 40. In some embodiments, the fusion protein contains one or more domains that enhance the purification, separation, capture, identification, isolation, etc. of the fusion protein. Exemplary domains contain, for example, a Myc tag (e.g., amino acids 520-535 of SEQ ID NO: 39) and / or a His tag (amino acids 536-541 of SEQ ID NO: 39). Therefore, in some embodiments, the di-scFv may contain the amino acid sequence of SEQ ID NO: 39. tri-scFv may contain the amino acid sequence of SEQ ID NO: 40. Other substitutable domains and additional domains have been discussed in more detail above.
[0239] The exemplary 3E10 humanized Fv sequence is discussed in WO 2016 / 033324:
[0240] DIVLTQSPASLAVSPGQRATITCRASKSVSTSSYSYMHWYQQKPGQPPKLLIYYASYLESGVPARFSGSGSGTDFTLTINPVEANDTANYYCQHSREFPWTFGQGTKVEIKGGGGSGGGGSGG GGSEVQLVESGGGLVQPGGSLRLSCSASGFTFSNYGMHWVRQAPGKGLEYVSYISSGSSTIYYADTVKGRFTISRDNSKNTLYLQMSSLRAEDTAVYYCVKRGLLLDYWGQGTLVTVSS (SEQ ID NO: 41).
[0241] Exemplary 3E10 humanized di-scFv sequences are discussed in WO 2019 / 018426 and WO / 2019 / 018428, and include:
[0242] DIQMTQSPSSLSASLGDRATITCRASKSVSTSSYSYMHWYQQKPGQPPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDAATYYCQHSREFPWTFGGGTKVEIKRADAAPGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSSASTKGPSVFPLAPLESSGSDIQMTQSPSSLSASLGDRATITCRASKSVSTSSYSYMHWYQQKPGQPPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDAATYYCQHSREFPWTFGGGTKVEIKRADAAPGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSS (Variant 2, SEQ ID NO: 61),DIQMTQSPSSLSASLGDRATITCRASKSVSTSSYSYMHWYQQKPGQPPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDAATYYCQHSREFPWTFGGGTKVEIKRADAAPGGGGSGGGGSGGGGSEVQLVESGGGVVQPGGSLRLSCAASGFTFSNYGMHWVRQAPEKGLEWVSYISSSSSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSSASTKGPSVFPLAPLESSGSDIQMTQSPSSLSASLGDRATITCRASKSVSTSSYSYMHWYQQKPGQPPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDAATYYCQHSREFPWTFGGGTKVEIKRADAAPGGGGSGGGGSGGGGSEVQLVESGGGVVQPGGSLRLSCAASGFTFSNYGMHWVRQAPEKGLEWVSYISSSSSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSS (Variant 3, SEQ ID NO: 62),DIQMTQSPSSLSASLGDRATITCRASKSVSTSSYSYMHWYQQKPGQPPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDAATYYCQHSREFPWTFGGGTKVEIKRADAAPGGGGSGGGGSGGGGSEVQLVESGGGDVKPGGSLRLSCAASGFTFSNYGMHWVRQAPEKGLEWVSYISSSSSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSSASTKGPSVFPLAPLESSGSDIQMTQSPSSLSASLGDRATITCRASKSVSTSSYSYMHWYQQKPGQPPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDAATYYCQHSREFPWTFGGGTKVEIKRADAAPGGGGSGGGGSGGGGSEVQLVESGGGDVKPGGSLRLSCAASGFTFSNYGMHWVRQAPEKGLEWVSYISSSSSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSS (variant 4, SEQ ID NO: 63),DIQMTQSPSSLSASLGDRATITCRASKSVSTSSYSYMHWYQQKPGQAPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSREFPWTFGQGTKVEIKRADAAPGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSSASTKGPSVFPLAPLESSGSDIQMTQSPSSLSASLGDRATITCRASKSVSTSSYSYMHWYQQKPGQAPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSREFPWTFGQGTKVEIKRADAAPGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSS (Variant 6, SEQ ID NO: 64),DIQMTQSPSSLSASLGDRATITCRASKSVSTSSYSYMHWYQQKPGQAPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSREFPWTFGQGTKVEIKRADAAPGGGGSGGGGSGGGGSEVQLVESGGGVVQPGGSLRLSCAASGFTFSNYGMHWVRQAPEKGLEWVSYISSSSSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSSASTKGPSVFPLAPLESSGSDIQMTQSPSSLSASLGDRATITCRASKSVSTSSYSYMHWYQQKPGQAPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSREFPWTFGQGTKVEIKRADAAPGGGGSGGGGSGGGGSEVQLVESGGGVVQPGGSLRLSCAASGFTFSNYGMHWVRQAPEKGLEWVSYISSSSSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSS (variant 7, SEQ ID NO: 65),DIQMTQSPSSLSASLGDRATITCRASKSVSTSSYSYMHWYQQKPGQAPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSREFPWTFGQGTKVEIKRADAAPGGGGSGGGGSGGGGSEVQLVESGGGDVKPGGSLRLSCAASGFTFSNYGMHWVRQAPEKGLEWVSYISSSSSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSSASTKGPSVFPLAPLESSGSDIQMTQSPSSLSASLGDRATITCRASKSVSTSSYSYMHWYQQKPGQAPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSREFPWTFGQGTKVEIKRADAAPGGGGSGGGGSGGGGSEVQLVESGGGDVKPGGSLRLSCAASGFTFSNYGMHWVRQAPEKGLEWVSYISSSSSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSS (Variant 8, SEQ ID NO: 66),DIQMTQSPSSLSASVGDRVTITCRASKSVSTSSYSYMHWYQQKPGKAPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSREFPWTFGQGTKVEIKRADAAPGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSSASTKGPSVFPLAPLESSGSDIQMTQSPSSLSASVGDRVTITCRASKSVSTSSYSYMHWYQQKPGKAPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSREFPWTFGQGTKVEIKRADAAPGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSS (Variant 10, SEQ ID NO: 67),DIQMTQSPSSLSASVGDRVTITCRASKSVSTSSYSYMHWYQQKPGKAPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSREFPWTFGQGTKVEIKRADAAPGGGGSGGGGSGGGGSEVQLVESGGGVVQPGGSLRLSCAASGFTFSNYGMHWVRQAPEKGLEWVSYISSSSSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSSASTKGPSVFPLAPLESSGSDIQMTQSPSSLSASVGDRVTITCRASKSVSTSSYSYMHWYQQKPGKAPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSREFPWTFGQGTKVEIKRADAAPGGGGSGGGGSGGGGSEVQLVESGGGVVQPGGSLRLSCAASGFTFSNYGMHWVRQAPEKGLEWVSYISSSSSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSS (Variant 11, SEQ ID NO: 68),DIQMTQSPSSLSASVGDRVTITCRASKSVSTSSYSYMHWYQQKPGKAPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSREFPWTFGQGTKVEIKRADAAPGGGGSGGGGSGGGGSEVQLVESGGGDVKPGGSLRLSCAASGFTFSNYGMHWVRQAPEKGLEWVSYISSSSSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSSASTKGPSVFPLAPLESSGSDIQMTQSPSSLSASVGDRVTITCRASKSVSTSSYSYMHWYQQKPGKAPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSREFPWTFGQGTKVEIKRADAAPGGGGSGGGGSGGGGSEVQLVESGGGDVKPGGSLRLSCAASGFTFSNYGMHWVRQAPEKGLEWVSYISSSSSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSS (Variant 12, SEQ ID NO: 69),
[0243] DIQMTQSPSSLSASLGDRATITCRASKTVSTSSYSYMHWYQQKPGQPPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDAATYYCQHSREFPWTFGGGTKVEIKRADAAPGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVSYISSGSSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSSASTKGPSVFPLAPLESSGSDIQMTQSPSSLSASLGDRATITCRASKTVSTSSYSYMHWYQQKPGQPPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDAATYYCQHSREFPWTFGGGTKVEIKRADAAPGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVSYISSGSSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSS (Variant 13, SEQ ID NO: 70),
[0244] DIQMTQSPSSLSASLGDRATITCRASKTVSTSSYSYMHWYQQKPGQPPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDAATYYCQHSREFPWTFGGGTKVEIKRADAAPGGGGSGGGGSGGGGSEVQLVESGGGVVQPGGSLRLSCAASGFTFSNYGMHWVRQAPEKGLEWVSYISSGSSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSSASTKGPSVFPLAPLESSGSDIQMTQSPSSLSASLGDRATITCRASKTVSTSSYSYMHWYQQKPGQPPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDAATYYCQHSREFPWTFGGGTKVEIKRADAAPGGGGSGGGGSGGGGSEVQLVESGGGVVQPGGSLRLSCAASGFTFSNYGMHWVRQAPEKGLEWVSYISSGSSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSS (Variant 14, SEQ ID NO: 71),DIQMTQSPSSLSASLGDRATITCRASKTVSTSSYSYMHWYQQKPGQPPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDAATYYCQHSREFPWTFGGGTKVEIKRADAAPGGGGSGGGGSGGGGSEVQLVESGGGDVKPGGSLRLSCAASGFTFSNYGMHWVRQAPEKGLEWVSYISSGSSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSSASTKGPSVFPLAPLESSGSDIQMTQSPSSLSASLGDRATITCRASKTVSTSSYSYMHWYQQKPGQPPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDAATYYCQHSREFPWTFGGGTKVEIKRADAAPGGGGSGGGGSGGGGSEVQLVESGGGDVKPGGSLRLSCAASGFTFSNYGMHWVRQAPEKGLEWVSYISSGSSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSS (Variant 15, SEQ ID NO: 72),DIQMTQSPSSLSASVGDRVTITCRASKTVSTSSYSYMHWYQQKPGKAPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSREFPWTFGQGTKVEIKRADAAPGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVSYISSGSSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSSASTKGPSVFPLAPLESSGSDIQMTQSPSSLSASVGDRVTITCRASKTVSTSSYSYMHWYQQKPGKAPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSREFPWTFGQGTKVEIKRADAAPGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVSYISSGSSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSS (Variant 16, SEQ ID NO: 73),DIQMTQSPSSLSASVGDRVTITCRASKTVSTSSYSYMHWYQQKPGKAPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSREFPWTFGQGTKVEIKRADAAPGGGGSGGGGSGGGGSEVQLVESGGGVVQPGGSLRLSCAASGFTFSNYGMHWVRQAPEKGLEWVSYISSGSSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSSASTKGPSVFPLAPLESSGSDIQMTQSPSSLSASVGDRVTITCRASKTVSTSSYSYMHWYQQKPGKAPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSREFPWTFGQGTKVEIKRADAAPGGGGSGGGGSGGGGSEVQLVESGGGVVQPGGSLRLSCAASGFTFSNYGMHWVRQAPEKGLEWVSYISSGSSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSS (Variant 17, SEQ ID NO: 74),DIQMTQSPSSLSASVGDRVTITCRASKTVSTSSYSYMHWYQQKPGKAPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSREFPWTFGQGTKVEIKRADAAPGGGGSGGGGSGGGGSEVQLVESGGGDVKPGGSLRLSCAASGFTFSNYGMHWVRQAPEKGLEWVSYISSGSSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSSASTKGPSVFPLAPLESSGSDIQMTQSPSSLSASVGDRVTITCRASKTVSTSSYSYMHWYQQKPGKAPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSREFPWTFGQGTKVEIKRADAAPGGGGSGGGGSGGGGSEVQLVESGGGDVKPGGSLRLSCAASGFTFSNYGMHWVRQAPEKGLEWVSYISSGSSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSS (Variant 18, SEQ ID NO: 75), and,
[0245] DIQMTQSPSSLSASLGDRATITCRASKTVSTSSYSYMHWYQQKPGQAPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSREFPWTFGQGTKVEIKRADAAPGGGGSGGGGSGGGG SEVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVSYISSGSSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSSASTKGPSVFPLAPL ESSGSDIQMTQSPSSLSASLGDRATITCRASKTVSTSSYSYMHWYQQKPGQAPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSREFPWTFGQGTKVEIKRADAAPGGGGSGGGG SGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVSYISSGSSTIYYADSVKGRFTISRDDNAKNSLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSS (Variant 19, SEQ ID NO: 76).
[0246] c. Other sequences
[0247] Other sequences that can be used to construct anti-DNA antigen-binding proteins, antibodies, fragments, and fusion proteins include, but are not limited to,
[0248] EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVSYISSGSSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (full-length sequence of IgG1 L234A / L235A heavy chain, SEQ ID NO: 77),
[0249] ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV (IgG1 heavy chain constant region 1, SEQ ID NO: 78),
[0250] EPKSCDKTHTCP (IgG1 hinge region, SEQ ID NO: 79),
[0251] PCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK (IgG1 L234A / L235A heavy chain constant region 2, SEQ ID NO: 80),
[0252] GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (IgG1 heavy chain constant region 3, SEQ ID NO: 81),
[0253] EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVSYISSGSSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYDSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (IgG1 N297D full-length heavy chain sequence, SEQ ID NO: 82),
[0254] PCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYDSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK (IgG1 N297D heavy chain constant region 2, SEQ ID NO: 83),
[0255] EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVSYISSGSSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYDSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (IgG1 L234A / L235A / N297D full-length heavy chain sequence, SEQ ID NO: 84),
[0256] PCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYDSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK (IgG1 L234A / L235A / N297D heavy chain constant region 2, SEQ ID NO: 85),
[0257] PCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK (SEQ ID NO: 86, unmodified heavy chain constant region 2), and
[0258] DIQMTQSPSSLSASLGDRATITCRASKTVSTSSYSYMHWYQQKPGQPPKLLIKYASYLESGVPSRFSGSGSGTDFTLTISSLQPEDAATYYCQHSREFPWTFGGGTKLEIKRTV AAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (full-length light chain sequence, SEQ ID NO: 87).
[0259] B. Goods
[0260] As used in the methods described herein, 3E10 is typically complexed with nucleic acid cargo and comes into contact with cells. The interaction between the antibody or binding protein and the nucleic acid cargo is non-covalent.
[0261] Nucleic acid cargoes can be single-stranded or double-stranded. Nucleic acid cargoes can be or include DNA, RNA, nucleic acid analogs, or combinations thereof. As discussed in more detail below, nucleic acid analogs can be modified at the base moiety, sugar moiety, or phosphate backbone. Such modifications can improve, for example, the stability, hybridization, or solubility of nucleic acids.
[0262] Nucleic acid cargoes are typically substances that are biologically active once delivered to a cell or are functional in the sense of encoding such a substance. Exemplary cargoes are discussed in more detail below, but include, for example, mRNA or DNA encoding a target polypeptide (including, for example, expression constructs and vectors), repressive nucleic acids such as siRNA, or nucleic acids encoding repressive nucleic acids (including, for example, expression constructs and vectors).
[0263] The disclosed compositions may comprise multiple single nucleic acid cargo molecules. In some embodiments, the compositions comprise multiple (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) different nucleic acid molecules.
[0264] In some implementations, the length of the cargo molecule is 0.001, 0.01, 1, tens, hundreds, thousands, tens of thousands and / or hundreds of thousands of kilobases.
[0265] In some implementations, for example, the cargo may be between 0.001 kb and 100 kb, or between 0.001 kb and 50 kb, or between 0.001 kb and 25 kb, or between 0.001 kb and 12.5 kb, or between 0.001 kb and 10 kb, or between 0.001 kb and 8 kb, or between 0.001 kb and 5 kb, or between 0.001 kb and 2.5 kb, or between 0.001 kb and 1 kb, or between 0.01 kb and 100 kb, or between 0.01 kb and 50 kb, or between 0.01 kb and 25 kb, or between 0.01 kb and 12.5 kb, or between 0.01 kb and 10 kb, or between 0.01 kb and 8 kb, or between 0.01 kb and 5 kb. Between kb, or between 0.01 kb and 2.5 kb, or between 0.01 kb and 1 kb, or between 0.1 kb and 100 kb, or between 0.1 kb and 50 kb, or between 0.1 kb and 25 kb, or between 0.1 kb and 12.5 kb, or between 0.1 kb and 10 kb, or between 0.1 kb and 8 kb, or between 0.1 kb and 5 kb, or between 0.1 kb and 2.5 kb, or between 0.1 kb and 1 kb, or between 1 kb and 100 kb, or between 1 kb and 50 kb, or between 1 kb and 25 kb, or between 1 kb and 12.5 kb, or between 1 kb and 10 kb, or between 1 kb and 8 kb, or between 1 kb and 5 kb, or between 1 kb and 2.5 kb (each inclusive).
[0266] In some implementations, for example, the cargo may be between 0.2 kb and 10 kb, or between 0.2 kb and 5 kb, or between 0.2 kb and 2.5 kb, or between 0.2 kb and 1 kb, or between 0.2 kb and 0.5 kb, or between 0.2 kb and 0.25 kb, or between 0.5 kb and 10 kb, or between 0.5 kb and 5 kb, or between 1 kb and 5 kb, or between 1 kb and 3 kb, or between 2 kb and 10 kb, or between 3 kb and 5 kb.
[0267] It will be appreciated that, for a particular application, the nucleic acid cargo can be one or more discrete lengths, for example, falling within one of the ranges (including endpoints) described above, with specific values for each explicitly disclosed. For example, the size can be as small as a single nucleotide or nucleobase. In exemplary applications, the cargo is a cyclic dinucleotide, such as cGAMP, which is a STING agonist. In other embodiments, the cargo is a short oligomer. For example, oligomers as short as 8 mers can be used for antisense or splicing conversion. Slightly longer ones (e.g., 18 to 20 mers) can be used for gene editing.
[0268] 1. Form of goods
[0269] Nucleic acid cargo is nucleic acid, and can be isolated nucleic acid compositions. As used herein, "isolated nucleic acid" refers to nucleic acid isolated from other nucleic acid molecules present in the mammalian genome, including nucleic acids that are normally located on one or both sides of the nucleic acid in the mammalian genome. As used herein, the term "isolated" with respect to nucleic acid also includes combinations with any non-naturally occurring nucleic acid sequence, such non-naturally occurring sequence does not exist in nature and has no immediately adjacent contiguous sequence in the naturally occurring genome.
[0270] Isolated nucleic acids can be, for example, DNA molecules, provided that one of the nucleic acid sequences flanking the DNA molecule, which is typically found in naturally occurring genomes, has been removed or deleted. Therefore, isolated nucleic acids include, but are not limited to, DNA molecules existing as separate molecules independent of other sequences (e.g., chemically synthesized nucleic acids, or cDNA or genomic DNA fragments produced by PCR or restriction endonuclease treatment), and recombinant DNA integrated into vectors, autonomously replicating plasmids, viruses (e.g., retroviruses, lentiviruses, adenoviruses, or herpesviruses), or prokaryotic or eukaryotic genomic DNA. Furthermore, isolated nucleic acids can include engineered nucleic acids, such as recombinant DNA molecules that are part of hybrid or fusion nucleic acids. Nucleic acids present in hundreds to millions of other nucleic acids, such as in cDNA libraries, genomic libraries, or gel sections containing restriction digested genomic DNA, should not be considered isolated nucleic acids.
[0271] The nucleic acid sequences encoding the polypeptides include genomic sequences. mRNA / cDNA sequences in which exons have been deleted are also provided. Other nucleic acid sequences encoding the polypeptides are also disclosed, such as polypeptides containing the amino acid sequences identified above, as well as their fragments and variants. The nucleic acids encoding the polypeptides can be optimized for expression in selected expression hosts. Codons can be replaced with alternative codons encoding the same amino acids to account for differences in codon usage between the organism from which the nucleic acid sequence originates and the expression host. In this way, nucleic acids can be synthesized using codons preferred by the expression host.
[0272] Nucleic acids can be sense or antisense directed, or they can be complementary to, for example, a reference sequence encoding a polypeptide.
[0273] a. Carrier
[0274] The cargo can be a vector, such as a vector encoding polypeptides and / or functional nucleic acids. Nucleic acids, as described above, can be inserted into the vector for expression in cells. As used herein, a "vector" is a replicon, such as a plasmid, bacteriophage, virus, or granule, into which another DNA segment can be inserted to induce replication of the inserted segment. A vector can be an expression vector. An "expression vector" is a vector containing one or more expression control sequences, and an "expression control sequence" is a DNA sequence that controls and regulates the transcription and / or translation of another DNA sequence.
[0275] Nucleic acids in a vector can be operatively linked to one or more expression control sequences. For example, control sequences can be introduced into a gene construct, allowing the expression control sequence to effectively control the expression of a target coding sequence. Examples of expression control sequences include promoters, enhancers, and transcription termination regions. A promoter is an expression control sequence consisting of a region of DNA molecule, typically located within 100 nucleotides upstream of the transcription start site (usually near the start site of RNA polymerase II). To place the coding sequence under the control of the promoter, the translation start site of the polypeptide translation reading frame must be located 1 to approximately 50 nucleotides downstream of the promoter. Enhancers provide expression specificity in terms of time, location, and level. Unlike promoters, enhancers can function at various distances from the transcription start site. Enhancers can also be located downstream of the transcription start site. When RNA polymerase is able to transcribe the coding sequence into mRNA, the coding sequence is operatively linked to and controlled by the expression control sequence in the cell, and the mRNA can then be translated into the protein encoded by the coding sequence.
[0276] Suitable expression vectors include, but are not limited to, plasmids, granules, and viral vectors derived from, for example, bacteriophages, baculoviruses, tobacco mosaic virus, herpesviruses, cytomegaloviruses, retroviruses, vaccinia virus, adenoviruses, and adeno-associated viruses. Many vectors and expression systems are available from companies such as Novagen (Madison, WI), Clontech (Palo Alto, CA), Stratagene (La Jolla, CA), and Invitrogen Life Technologies (Carlsbad, CA).
[0277] In some embodiments, the cargo is delivered into the cell and held outside the chromosome. In some embodiments, the cargo is introduced into a host cell and integrated into the host cell's genome. As discussed in more detail below, the composition can be used for gene therapy. Gene therapy methods may include introducing a polynucleotide that alters the cell's genotype into the cell. The introduction of the polynucleotide may involve gene recombination to correct, substitute, or otherwise alter an endogenous gene. Methods may include introducing a complete replacement copy of a defective gene, a heterologous gene, or a small nucleic acid molecule such as an oligonucleotide. For example, a corrective gene may be introduced into a non-specific location within the host genome.
[0278] In some embodiments, the cargo is a vector. Methods for constructing expression vectors containing genetic sequences and appropriate transcriptional and translational control elements are well known in the art. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo gene recombination. Expression vectors typically contain regulatory sequences and elements necessary for the translation and / or transcription of inserted coding sequences (e.g., which may be target polynucleotides). The coding sequences can be operatively linked to promoters and / or enhancers to help control the expression of the desired gene product. Promoters used in biotechnology vary depending on the intended type of gene expression control. They are generally classified as constitutive promoters, tissue-specific or developmental stage-specific promoters, inducible promoters, and synthetic promoters.
[0279] For example, in some embodiments, the target polynucleotide is operatively linked to a promoter or other regulatory element known in the art. Thus, the cargo can be a vector, such as an expression vector. The engineering of the polynucleotide for expression in prokaryotic or eukaryotic systems can be performed using techniques generally known to those skilled in recombinant expression. Expression vectors typically comprise one of disclosed compositions under the control of one or more promoters. To place the coding sequence under the “control” of a promoter, the 5’ end of the translation start site of the reading frame is typically positioned between about 1 and 50 nucleotides “downstream” (i.e., 3’) of the selected promoter. The “upstream” promoter stimulates transcription of the inserted DNA and promotes the expression of the encoded recombinant protein or functional nucleic acid. This is the meaning of “recombinant expression” in the context used herein.
[0280] Many standard techniques can be used to construct expression vectors containing appropriate nucleic acids and transcription / translation control sequences to enable protein, peptide, or functional nucleic acid expression in a variety of host expression systems.
[0281] Expression vectors used in mammalian cells typically include an origin of replication (if needed), a promoter preceding the gene to be expressed, and any necessary ribosome binding sites, RNA splicing sites, polyadenylation sites, and transcription termination sequences. The origin of replication can be provided by constructing the vector to include a foreign origin, such as from SV40 or other viruses (e.g., polyomaviruses, adenoviruses, VSVs, BPVs), or it can be provided by the host cell's chromosomal replication mechanism. If the vector integrates into the host cell's chromosome, the latter is usually sufficient.
[0282] Promoters can be derived from the genome of mammalian cells (e.g., metallothionein promoters) or from mammalian viruses (e.g., adenovirus late promoters; vaccinia virus 7.5K promoters). Furthermore, it may be possible and necessary to utilize promoters or control sequences typically associated with the desired gene sequence, provided such control sequences are compatible with the host cell system.
[0283] A variety of virus-based expression systems can be used; for example, commonly used promoters are derived from polyomaviruses, adenovirus 2, cytomegaloviruses, and simian virus 40 (SV40). Early and late promoters of SV40 virus are useful because they can be readily obtained from the virus as fragments containing the SV40 virus origin of replication. Smaller or larger SV40 fragments can also be used, provided they contain approximately 250 bp of sequence extending from the HindIII site to the BglI site located at the origin of viral replication.
[0284] When adenovirus is used as an expression vector, the coding sequence can be linked to the adenoviral transcription / translation control complex, such as the late promoter and triple leader sequence. This chimeric gene can then be inserted into the adenoviral genome via in vitro or in vivo recombination. Insertion into a non-essential region of the viral genome (e.g., the E1 or E3 region) will produce a recombinant virus that is viable and capable of expressing the protein in an infected host.
[0285] Efficient translation of the disclosed compositions may also require specific initiation signals. These signals include the ATG start codon and adjacent sequences. Exogenous translation control signals, including the ATG start codon, may also be required. Those skilled in the art will be able to readily identify this need and provide the necessary signals. It is well known that the start codon must be in-frame (or in-phase) with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translation control signals and start codons can be of various sources, including natural and synthetic. Expression efficiency can be improved by including appropriate transcriptional enhancer elements or transcription terminators.
[0286] In eukaryotic expression, if the original clone does not contain a suitable polyadenylation site, it is often desirable to introduce a suitable polyadenylation site into the transcription unit. Typically, the polyadenylation site is located approximately 30 to 2000 nucleotides "downstream" of the protein termination site, just before transcription termination.
[0287] For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines that can be engineered to stably express constructs encoding the protein can be used. Instead of using expression vectors containing viral origins of replication, host cells can be transformed with vectors controlled by appropriate expression control elements (e.g., promoters, enhancers, sequences, transcription terminators, polyadenylation sites, etc.) and selection markers. After introducing exogenous DNA, engineered cells can be allowed to grow in enrichment media for 1–2 days before being transferred to selection media. The selection markers in the recombinant plasmid confer resistance to selection and allow cells to stably integrate the plasmid into their chromosomes and grow to form colonies, which can then be cloned and expanded into cell lines.
[0288] b. mRNA
[0289] The cargo can be mRNA.
[0290] Chemical structures that promote stability and / or translation efficiency can also be used. For example, RNA can have 5' and 3' UTRs. For example, the length of the 3' UTR can exceed 100 nucleotides. In some embodiments, the 3' UTR sequence is between 100 and 5000 nucleotides. In some embodiments, the 5' UTR length is between 0 and 3000 nucleotides. The lengths of the 5' and 3' UTR sequences to be added to the coding region can be varied by various methods, including, but not limited to, primers designed to anneal to different regions of the UTR for PCR. Using this method, those skilled in the art can modify the 5' and 3' UTR lengths required to achieve optimal translation efficiency after delivery of transcribed RNA.
[0291] The 5' and 3' UTRs can be naturally occurring endogenous 5' and 3' UTRs of the target gene. Alternatively, UTR sequences that are not endogenous to the target gene can be added by integrating the UTR sequence into the forward and reverse primers or by any other modification of the template. Using UTR sequences that are not endogenous to the target gene may be useful for improving RNA stability and / or translation efficiency. For example, it is known that AU-rich elements in 3' UTR sequences can reduce mRNA stability. Therefore, 3' UTRs can be selected or designed based on the characteristics of UTRs well known in the art to increase the stability of transcribed RNA.
[0292] In some embodiments, the 5' UTR contains the Kozak sequence of the endogenous gene. Alternatively, when a 5' UTR that is not endogenous to the target gene is added by PCR as described above, the shared Kozak sequence can be redesigned by adding the 5' UTR sequence. Kozak sequences can improve the translation efficiency of some RNA transcripts, but it does not appear that they are necessary for efficient translation of all RNAs. The requirement for Kozak sequences in many mRNAs is well known in the art. In other embodiments, the 5' UTR can be derived from RNA viruses whose RNA genome is stable in cells. In other embodiments, various nucleotide analogs can be used in the 3' or 5' UTR to prevent exonuclease degradation of the mRNA.
[0293] In some implementations, the mRNA has a cap, a 3' poly(A) tail, or a combination thereof at its 5' end, which determines ribosome binding, translation initiation, and mRNA stability in the cell.
[0294] The 5' cap provides stability to the RNA molecule. The 5' cap can be, for example, m... 7 G(5')ppp(5')G、m 7 G(5')ppp(5')A, G(5')ppp(5')G, or G(5')ppp(5')A cap analogues are all commercially available. The 5' cap can also be an anti-reverse cap analogue (ARCA) (Stepinski et al., RNA , 7:1468-95 (2001)) or any other suitable analogue. A 5' cap (Cougot et al., , 7:1468-95 (2001)) can be introduced using techniques known in the art. Trends in Biochem. Sci. 29:436-444(2001); Stepinski et al., RNA , 7:1468-95 (2001); Elango et al., Biochim. Biophys. Res. Commun ., 330:958-966 (2005)).
[0295] RNA can also contain internal ribosome entry site (IRES) sequences. IRES sequences can be any viral, chromosomal, or artificially designed sequence that initiates cap-independent ribosome binding to mRNA and promotes the initiation of translation.
[0296] Typically, the length of the poly(A) tail is positively correlated with the stability of the transcribed RNA. In one embodiment, the poly(A) tail is between 100 and 5000 adenosines.
[0297] Poly(A) segments can be generated during PCR using a reverse primer containing a poly(T) tail, such as a 100T tail (size can be, for example, 50-5000T), or after PCR by any other method, including but not limited to DNA ligation or in vitro recombination. The poly(A) tail also provides stability to RNA and reduces its degradation. The poly(A) tail of RNA can be generated after in vitro transcription using poly(A) polymerases, such as... E. coli PolyA polymerase (E-PAP) is used for extension, either separately or alternatively.
[0298] Furthermore, attaching different chemical groups to the 3' end can increase mRNA stability. Such attachments can include modified / artificial nucleotides, aptamers, and other compounds. For example, ATP analogs can be introduced into the poly(A) tail using poly(A) polymerase. ATP analogs can further increase RNA stability. Suitable ATP analogs include, but are not limited to, cordycepin and 8-azaadenosine.
[0299] 2. Sequence of Goods
[0300] a. Target polypeptide
[0301] The cargo may encode one or more proteins. The cargo may be a polynucleotide that is monocistronic or polycistronic. In some embodiments, the polynucleotide is multigenic. The polynucleotide may be, for example, mRNA or an expression construct, such as a vector.
[0302] The cargo may encode one or more target peptides. The peptide can be any peptide. For example, a peptide encoded by a polynucleotide may be a peptide that provides therapeutic or preventative effects on an organism or can be used to diagnose diseases or conditions in an organism. For example, to treat cancer, autoimmune diseases, parasites, viruses, bacteria, fungi, or other infections, the polynucleotide to be expressed may encode a peptide that can act as a ligand or receptor for immune system cells, or can be used to stimulate or suppress the immune system of an organism.
[0303] In some implementations, polynucleotides supplement or replace defective polynucleotides in the organism.
[0304] In a particular embodiment, the polynucleotide encodes dystrophin, utrophin, or a combination thereof. Such compositions can be administered in effective amounts to treat subjects suffering from malnutrition (particularly muscular dystrophy, e.g., Duchenne muscular dystrophy).
[0305] In another specific embodiment, the polynucleotide encodes an antigen, for example, an antigen that can be used in vaccine formulations and related methods. In one specific embodiment, the polynucleotide encodes a viral antigen, for example, the SARS-CoV-2 antigen. Therefore, compositions and methods of use for the prevention and treatment of SARS-CoV-2 virus and viral infections and related diseases (including COVID-19) are provided.
[0306] In some implementations, the polynucleotide contains a selection marker, such as a drug resistance selection marker effective in eukaryotic cells. This selection marker gene may encode a factor essential for the survival or growth of transformed host cells grown in a selective medium. Typical selection genes encode proteins that confer resistance to antibiotics or other toxins (e.g., ampicillin, neomycin, methotrexate, kanamycin, gentamicin, bleomycin, or tetracycline), compensate for nutritional deficiencies, or provide key nutrients retained in the culture medium.
[0307] In some implementations, the polynucleotide contains a reporter gene. A reporter gene is typically a gene that is absent or not expressed in the host cell. Reporter genes typically encode proteins that provide certain phenotypic changes or enzymatic properties. Examples of such genes are provided in Weising et al. Ann. Rev. Genetics In 22, 421 (1988), preferred reporter genes included the glucuronidase (GUS) gene and the GFP gene.
[0308] b. Functional nucleic acids
[0309] Goods can be or encode functional nucleic acids. Functional nucleic acids are nucleic acid molecules with specific functions, such as binding to target molecules or catalyzing specific reactions. As discussed in more detail below, functional nucleic acid molecules can be classified into the following non-restrictive categories: antisense molecules, siRNA, miRNA, aptamers, ribozymes, RNAi and external guide sequences, and cyclic dinucleotides. Functional nucleic acid molecules can act as effectors, inhibitors, regulators, and stimulators of the specific activities possessed by target molecules, or they can have de novo activity independent of any other molecule.
[0310] Functional nucleic acid molecules can interact with any macromolecule, such as DNA, RNA, polypeptides, or carbohydrate chains. Therefore, functional nucleic acids can interact with the mRNA or genomic DNA of a target polypeptide, or they can interact with the polypeptide itself. Typically, functional nucleic acids are designed to interact with other nucleic acids based on sequence homology between the target molecule and the functional nucleic acid molecule. In other cases, specific recognition between a functional nucleic acid molecule and a target molecule is not based on sequence homology, but rather on the formation of a tertiary structure that allows specific recognition to occur.
[0311] Therefore, the composition may contain one or more functional nucleic acids designed to reduce the expression of a gene or its gene product. For example, functional nucleic acids or peptides may be designed to target and reduce or inhibit the expression or translation of mRNA; or to reduce or inhibit the expression of a protein, reduce its activity, or increase its degradation. In some embodiments, the composition contains a vector suitable for in vivo expression of the functional nucleic acid.
[0312] i. Antonyms
[0313] Functional nucleic acids can be or encode antisense molecules. Antisense molecules are designed to interact with target nucleic acid molecules via standard or non-standard base pairing. The interaction between the antisense molecule and the target molecule is designed to promote the destruction of the target molecule through RNA-DNA hybrid degradation mediated by, for example, RNase H. Alternatively, antisense molecules are designed to interrupt processing functions that normally occur on the target molecule, such as transcription or replication. Antisense molecules can be designed based on the sequence of the target molecule. There are many methods to optimize antisense efficiency by finding the regions most easily accessible to the target molecule. Exemplary methods include in vitro selection experiments and DNA modification studies using DMS and DEPC. Preferably, antisense molecules are designed with a ratio of less than or equal to 10... -6 10 -8 10 -10 Or 10 -12 dissociation constant (K) d () binds to target molecules.
[0314] ii. RNA interference
[0315] In some implementations, functional nucleic acids induce gene silencing via RNA interference. Gene expression can also be effectively silenced in a highly specific manner via RNA interference (RNAi). This silencing was initially observed upon the addition of double-stranded RNA (dsRNA) (Fire et al., (1998)). Nature 391:806-11; Napoli et al., (1990) Plant Cell 2:279-89; Hannon, (2002) Nature 418:244-51). Once dsRNA enters the cell, it is cleaved by the RNase III-like enzyme Dicer into double-stranded small interfering RNA (siRNA), which is 21-23 nucleotides in length and contains a 2-nucleotide overhang at the 3' end (Elbashir et al., (2001)). Genes Dev ., 15:188-200; Bernstein et al., (2001) Nature , 409:363-6; Hammond et al., (2000) Nature, 404:293-6). In the ATP-dependent step, siRNA becomes integrated into a multi-subunit protein complex, commonly referred to as the RNAi-induced silencing complex (RISC), which directs the siRNA to the target RNA sequence (Nykanen et al., (2001)). Cell, 107:309-21). At times, the siRNA double helix unwinds, and the antisense strand appears to remain bound to the RISC, directing the degradation of the complementary mRNA sequence via a combination of endonucleases and exonucleases (Martinez et al., (2002)). Cell (110:563-74). However, the function or use of iRNA or siRNA is not limited to any type of mechanism.
[0316] Short interfering RNA (siRNA) is a double-stranded RNA that induces sequence-specific posttranscriptional gene silencing, thereby reducing or even suppressing gene expression. In one instance, siRNA triggers the specific degradation of homologous RNA molecules (such as mRNA) within a region of sequence identity between the siRNA and the target RNA. For example, WO 02 / 44321 discloses siRNAs capable of sequence-specific degradation of target mRNAs when paired with bases at the 3' overhang, which is incorporated herein by reference for methods of preparing these siRNAs.
[0317] Sequence-specific gene silencing can be achieved in mammals using synthetic short double-stranded RNA that mimics siRNA produced by the enzyme dicer (Elbashir et al., (2001)). Nature , 411:494 498) (Ui-Tei et al., (2000) FEBS Lett 479:79-82). siRNA can be chemically synthesized or synthesized in vitro, or it can be the result of short double-stranded hairpin-like RNA (shRNA) processed into siRNA within cells. siRNA synthesis is typically designed using algorithms and conventional DNA / RNA synthesizers. Suppliers include Ambion (Austin, Texas), ChemGenes (Ashland, Massachusetts), Dharmacon (Lafayette, Colorado), Glen Research (Sterling, Virginia), MWB Biotech (Esbersberg, Germany), Proligo (Boulder, Colorado), and Qiagen (Vento, The Netherlands). Silencer, such as Ambion's, can also be used. ®Kits such as siRNA construction kits synthesize siRNA in vitro.
[0318] The generation of siRNA from vectors is more commonly accomplished through transcription by short hairpin RNase (shRNA). Kits for generating vectors with shRNA are available, such as Imgenex's GENESUPPRESSOR™ Construction Kit and Invitrogen's BLOCK-IT™ Inducible RNAi Plasmids and Lentiviral Vectors.
[0319] In some embodiments, the functional nucleic acid is siRNA, shRNA, or miRNA. In some embodiments, the composition comprises a vector expressing the functional nucleic acid.
[0320] iii. Fitts
[0321] Functional nucleic acids can be or encode aptamers. An aptamer is a molecule that interacts with a target molecule, preferably in a specific manner. Typically, aptamers are small nucleic acids ranging from 15 to 50 bases in length, folded into defined secondary and tertiary structures, such as stem-loops or G-tetramers. Aptamers can bind small molecules, such as ATP and theophylline, as well as large molecules, such as reverse transcriptase and thrombin. Aptamers can be less than 10 bases long. -12 M of K d It binds tightly to the target molecule. Preferably, the aptamer has a density of less than 10. -6 10 -8 10 -10 Or 10 -12 The aptamer binds to the target molecule via Kd. The aptamer can bind to the target molecule with very high specificity. For example, aptamers with binding affinities greater than 10,000-fold between the target molecule and another molecule that differs only at one position on the molecule have been isolated. Preferably, the aptamer binds to the target molecule via Kd. d K of molecules bound to the background d The difference should be at least 10, 100, 1000, 10,000, or 100,000 times lower. When comparing molecules such as peptides, it is preferable that the background molecules are different peptides.
[0322] iv. Ribozymes
[0323] Functional nucleic acids can be or encode ribozymes. Ribozymes are nucleic acid molecules capable of catalyzing chemical reactions intramolecularly or intermolecularly. Preferably, ribozymes catalyze intermolecular reactions. There are many different types of ribozymes that catalyze reactions of the nuclease or nucleic acid polymerase type, based on ribozymes found in natural systems, such as hammerhead ribozymes. There are also many ribozymes that do not exist in natural systems but are engineered to catalyze specific reactions de novo. Preferred ribozymes cleave RNA or DNA substrates, more preferably RNA substrates. Ribozymes typically cleave nucleic acid substrates through target substrate recognition and binding, followed by cleavage. This recognition is usually based primarily on standard or non-standard base pair interactions. This property makes ribozymes particularly good candidates for target-specific cleavage of nucleic acids because target substrate recognition is based on the target substrate sequence.
[0324] v. External guidance sequence
[0325] Functional nucleic acids can be or encode externally directed sequences (EGS). An externally directed sequence (EGS) is a molecule that binds to a target nucleic acid molecule to form a complex, which is recognized by RNase P and then cleaves the target molecule. EGS can be engineered to specifically target selected RNA molecules. RNase P facilitates the processing of transfer RNA (tRNA) within cells. By using EGS, bacterial RNase P can be recruited to cleave almost any RNA sequence, resulting in a target RNA:EGS complex that mimics the natural tRNA substrate. Similarly, eukaryotic EGS / RNase P-guided RNA cleavage can be used to cleave desired targets within eukaryotic cells. Representative examples of how EGS molecules are prepared and used to facilitate the cleavage of a variety of different target molecules are well known in the art.
[0326] Methods for preparing and using vectors for in vivo expression of functional nucleic acids such as antisense oligonucleotides, siRNA, shRNA, miRNA, EGS, ribozymes, and aptamers are well known in the art.
[0327] vi. cyclic dinucleotides
[0328] Functional nucleic acids can be or encode cyclic dinucleotides. Cyclic dinucleotides bind directly to the STING adaptor protein, leading to the production of IFN-β (Zhang et al., Mol Cell., 51(2):226-35 (2013). doi: 10.1016 / j.molcel.2013.05.022.). Several standard and non-standard dinucleotides are well known in the art, including but not limited to 2'3'-cGAMP, 2'3'-cGAMP, 3'3'-cGAMP, c-di-AMP, c-di-GMP, cAIMP (CL592), difluorocAIMP (CL614), difluorocAIM(PS)2(Rp / Sp) (CL656), 2'2'-cGAMP, 2'3'-cGAM(PS)2(Rp / Sp), fluorinated 3'3'-cGAMP, fluorinated c-di-AMP, 2'3'-c-di-AMP, 2'3'-c-di-AM(PS)2(Rp,Rp), 2'3'-c-di-AM(PS)2(Rp,Rp), fluorinated c-di-GMP, 2'3'-c-di-GMP, c-di-IMP, and DMXAA.
[0329] vii. Immunostimulatory oligonucleotides
[0330] In some implementations, the functional nucleic acid may be or encode an oligonucleotide ligand. Examples include, but are not limited to, pattern recognition receptor (PRR) ligands.
[0331] Examples of PRRs include the Toll-like signaling molecule family, which plays a role in the initiation of the innate immune response and also influences later and more antigen-specific adaptive immune responses. Therefore, oligonucleotides can serve as ligands for Toll-like family signaling molecules, such as the Toll-like receptor (TLR9).
[0332] For example, unmethylated CpG sites can be detected via TLR9 on human plasmacytoid dendritic cells and B cells (Zaida et al.). Infection and Immunity , 76(5):2123-2129, (2008)). Therefore, the sequence of an oligonucleotide may contain one or more unmethylated cytosine-guanine (CG or CpG, which are interchangeable) dinucleotide motifs. “p” refers to the phosphodiester backbone of DNA; however, in some embodiments, the oligonucleotide containing CG may have a modified backbone, such as a phosphate thioester (PS) backbone.
[0333] In some embodiments, the oligonucleotide may contain more than one CG dinucleotide, which are arranged sequentially or separated by inserted nucleotides. The CpG motif may be internal to the oligonucleotide sequence. Many nucleotide sequences stimulate TLR9 by variations in the number and position of CG dinucleotides and the precise base sequence flanking the CG dimer.
[0334] CG ODNs are typically classified based on their sequence, secondary structure, and effects on human peripheral blood mononuclear cells (PBMCs). The five categories are: A (type D), B (type K), C, P, and S (Vollmer, J&Krieg, AM). Advanced drug delivery reviews 61(3): 195–204 (2009), incorporated herein by reference. CG ODNs can stimulate the production of type I interferons (e.g., IFNα) and induce the maturation of dendritic cells (DCs). Some types of ODNs are also potent activators of natural killer (NK) cells transduced via indirect cytokine signaling. Some types are potent stimulators of the maturation of human B cells and monocytes (Weiner, GL, PNAS USA 94(20): 10833-7 (1997); Dalpke, AH, Immunology 106(1):102-12 (2002);Hartmann, G, J of Immun . 164(3):1617-2 (2000), each of which is incorporated herein by reference.
[0335] Other PRR Toll-like receptors include TLR3 and TLR7, which can recognize double-stranded RNA, single-stranded RNA, and short double-stranded RNA, respectively, as well as retinoic acid-induced gene I (RIG-I)-like receptors, namely RIG-I and melanoma differentiation-associated gene 5 (MDA5). The most well-known of these is the RNA-sensing receptor in the cytosol.
[0336] RIG-I (retinoic acid-inducible protein 1, also known as Ddx58) and MDA-5 (melanoma differentiation-associated gene 5, also known as Ifih1 or Helicard) are cytoplasmic RNA helicases belonging to the RIG-I-like receptor (RLR) family, which are crucial for the host's antiviral response.
[0337] RIG-I and MDA-5 sense double-stranded RNA (dsRNA), a replication intermediate of RNA viruses, and signal through the mitochondrial antiviral signal transduction protein MAVS (also known as IPS-1, VISA, or Cardif) to produce type I interferons (IFN-α and IFN-β).
[0338] RIG-I assays reveal viral RNA with uncapped 5'-bis / triphosphate ends and short blunt-ended double-stranded portions, two key features that help distinguish it from its own RNA. The physiological ligands of MDA-5 have not been fully characterized. However, it is well known that RIG-I and MDA-5 exhibit different length dependencies on dsRNA: RIG-I selectively binds to short dsRNAs, while MDA-5 selectively binds to long dsRNAs. Consistent with this, RIG-I and MDA-5 bind to Poly(I:C), a synthetic dsRNA analog, with different length preferences.
[0339] In some cases, RIG-I can also indirectly sense dsDNA. Viral dsDNA can be transcribed into dsRNA with a 5'-triphosphate moiety by RNA polymerase III. Therefore, Poly(dA:dT), a synthetic analog of type B DNA, constitutes another RIG-I ligand.
[0340] Exemplary RIG-I ligands include, but are not limited to, 5'ppp-dsRNA, a specific agonist of RIG-I; 3p-hpRNA, a specific agonist of RIG-I; a Poly(I:C) / LyoVec complex recognized by RIG-I and / or MDA-5 according to the poly(I:C) size; and a Poly(dA:dT) / LyoVec complex indirectly recognized by RIG-I.
[0341] In some embodiments, the oligonucleotide contains a functional ligand targeting TLR3, TLR7, TLR8, TLR9, or RIG-I-like receptors or combinations thereof.
[0342] Examples of immunostimulatory oligonucleotides and methods for their preparation are well known in the art and are commercially available; see, for example, Bodera, P. Recent Pat Inflamm Allergy Drug Discov . 5(1):87-93 (2011), incorporated herein by reference.
[0343] 3. Composition of Goods
[0344] The disclosed nucleic acid cargo may be or contains DNA or RNA nucleotides, which typically contain a heterocyclic base (nucleic acid base), a sugar moiety linked to the heterocyclic base, and a phosphate moiety of the hydroxyl functional group of the esterified sugar moiety. Major naturally occurring nucleotides include uracil, thymine, cytosine, adenine, and guanine as heterocyclic bases, and ribose or deoxyribose linked by phosphodiester bonds.
[0345] In some embodiments, the cargo comprises or is composed of nucleotide analogs that are chemically modified to improve the stability, half-life, specificity, or affinity of the target receptor relative to its DNA or RNA counterpart. Chemical modifications include modifications to nucleobases, sugar moieties, nucleotide bonds, or combinations thereof. As used herein, “modified nucleotide” or “chemically modified nucleotide” defines a nucleotide having one or more of the following components: a heterocyclic base, a sugar moiety, or a phosphate ester moiety. In some embodiments, the modified nucleotide has a reduced charge compared to DNA or RNA having the same nucleobase sequence. For example, oligonucleotides may have a low negative charge, no charge, or a positive charge.
[0346] Typically, nucleoside analogs support bases capable of forming hydrogen bonds with standard polynucleotide bases via Watson-Crick base pairing, wherein the analog backbone presents the bases in a manner that allows such hydrogen bonding between bases in the oligonucleotide analog molecule and the standard polynucleotide (e.g., single-stranded RNA or single-stranded DNA) in a sequence-specific manner. In some embodiments, the analog has a substantially uncharged phosphorus-containing backbone.
[0347] a. Heterocyclic bases
[0348] The main naturally occurring nucleotides include uracil, thymine, cytosine, adenine, and guanine as heterocyclic bases. Goods may include chemical modifications to their nucleobase components. Chemical modifications to heterocyclic bases or heterocyclic base analogs can effectively increase binding affinity or stability to target sequences. Chemically modified heterocyclic bases include, but are not limited to, inosine, 5-(1-propynyl)uracil (pU), 5-(1-propynyl)cytosine (pC), 5-methylcytosine, 8-oxoadenine, pseudocytosine, pseudoisocytosine, 5- and 2-amino-5-(2'-deoxy-β-D-furanoribosyl)pyridine (2-aminopyridine), and various pyrrolo and pyrazolopyrimidine derivatives.
[0349] b. Sugar modification
[0350] The cargo may also contain nucleotides with modified sugar moieties or sugar moieties analogues. Sugar moieties include, but are not limited to, 2'-O-aminoethoxy, 2'-O-aminoethyl (2'-OAE), 2'-O-methoxy, 2'-O-methyl, 2-guanidinoethyl (2'-OGE), 2'-O,4'-C-methylene (LNA), 2'-O-(methoxyethyl) (2'-OME), and 2'-O-(N-(methyl)acetamido) (2'-OMA). 2'-O-aminoethyl sugar moieties are particularly preferred because they are protonated at neutral pH and thus suppress charge repulsion between the TFO and the target duplex. This modification stabilizes the C3'-inner conformation of ribose or dextrorotatory ribose and also forms a bridge with the i-1 phosphate in the purine chain of the duplex.
[0351] In some embodiments, the nucleic acid is a morpholine oligonucleotide. A morpholine oligonucleotide typically consists of two additional morpholine monomers containing purine or pyrimidine base-pairing moieties, which are efficiently bound to bases in the polynucleotide via base-specific hydrogen bonds. These moieties are linked together by a phosphorus-containing bond of one to three atoms in length, attaching the morpholine nitrogen of one monomer to the 5' exocyclic carbon of the adjacent monomer. The purine or pyrimidine base-pairing moieties are typically adenine, cytosine, guanine, uracil, or thymine. The synthesis, structure, and binding characteristics of morpholine oligomers are detailed in U.S. Patent Nos. 5,698,685, 5,217,866, 5,142,047, 5,034,506, 5,166,315, 5,521,063, and 5,506,337.
[0352] Key properties of morpholine-based subunits typically include: the ability to link in oligomeric form via stable, uncharged skeletal bonds; and the ability to support nucleotide bases (e.g., adenine, cytosine, guanine, thymine, uracil, or inosine), allowing the resulting polymers to bind with high To groups. m Hybridization with complementary base target nucleic acids (including target RNA), and even with oligomers as short as 10-14 bases; the ability of oligomers to be actively transported into mammalian cells; and the ability of oligomers: RNA heteroduplexes to resist RNase degradation.
[0353] In some implementations, as described above, oligonucleotides use morpholino-based subunits with base-pairing moieties linked by uncharged bonds.
[0354] c. Nucleotide linkages
[0355] Oligonucleotides are linked by internucleotide bonds, which are chemical linkages between two nucleoside moieties. Modifications to the phosphate backbone of DNA or RNA oligonucleotides can increase their binding affinity or stability, or decrease their sensitivity to nuclease digestion. Cationic modifications, including but not limited to diethyl-ethylenediamine (DEED) or dimethyl-aminopropylamine (DMAP), can be particularly useful due to reduced electrostatic repulsion between the oligonucleotide and its target. Modifications to the phosphate backbone can also involve the substitution of one of the non-bridging oxygen atoms in the phosphodiester bond with a sulfur atom. This substitution produces a thiophosphate internucleotide bond that replaces the phosphodiester bond. Oligonucleotides containing thiophosphate internucleotide bonds have been shown to be more stable in vivo.
[0356] Examples of modified nucleotides that reduce charge include modified internucleotide bonds, such as phosphate analogs with achiral and uncharged subunit bonds (e.g., Sterchak, EP, etc.). Organic. Chem ., 52:4202, (1987)), and uncharged morpholino polymers with non-chiral subunit bonds (see, for example, U.S. Patent No. 5,034,506), as discussed above. Some nucleotide bond analogues include morpholidate, acetal, and polyamide-linked heterocycles.
[0357] In another embodiment, the cargo is composed of locked nucleic acids. Locked nucleic acids (LNAs) are modified RNA nucleotides (see, for example, Braasch et al.). Chem. Biol ., 8(1):1-7 (2001)). LNA forms a hybrid with DNA, which is more stable than a DNA / DNA hybrid, a property similar to that of a peptide nucleic acid (PNA) / DNA hybrid. Therefore, LNA can be used like a PNA molecule. In some embodiments, the binding efficiency of LNA can be improved by adding a positive charge to it. Commercially available nucleic acid synthesizers and standard phosphoramide chemistry are used to prepare LNA.
[0358] In some embodiments, the cargo is composed of peptide nucleic acids. Peptide nucleic acids (PNAs) are synthetic DNA mimics in which the phosphate backbone of an oligonucleotide is completely replaced by repeating N-(2-aminoethyl)-glycine units, and the phosphodiester bonds are typically replaced by peptide bonds. Various heterocyclic bases are linked to the backbone via methylene carbonyl bonds. PNAs maintain the spacing of the heterocyclic bases, similar to conventional DNA oligonucleotides, but they are achiral and neutrally charged molecules. Peptide nucleic acids are composed of peptide nucleic acid monomers.
[0359] Other skeletal modifications include peptide and amino acid variations and modifications. Therefore, the skeletal components of oligonucleotides such as PNA can be peptide-linked, or they can be non-peptide-linked. Examples include acetyl caps, amino spacers such as 8-amino-3,6-dioxanoic acid (referred to herein as O-connectors), amino acids such as lysine which are particularly useful when a positive charge is required in PNA, and so on. Chemical assembly methods for PNA are well known. See, for example, U.S. Patent Nos. 5,539,082, 5,527,675, 5,623,049, 5,714,331, 5,736,336, 5,773,571, and 5,786,571.
[0360] The cargo optionally contains one or more terminal residues, or modifications at either or both ends, to increase the stability and / or affinity of the oligonucleotide to its target site. Commonly used positively charged moieties include the amino acids lysine and arginine, although other positively charged moieties may also be useful. The cargo can be further modified with a propylamine group to cap it and prevent degradation. The steps for using 3' or 5' capped oligonucleotides are well known in the art.
[0361] In some implementations, nucleic acids can be single-stranded or double-stranded.
[0362] C. Pharmaceutical Composition
[0363] The composition can be combined with a pharmaceutically acceptable carrier for therapeutic purposes.
[0364] Compositions containing nucleic acid cargo conjugated with a 3E10 antibody are preferably combined with a suitable pharmaceutical carrier for therapeutic use. Such compositions comprise an effective amount of the composition and a pharmaceutically acceptable carrier or excipient.
[0365] The composition can be a formulation for topically, locally, or systemically administered in a suitable drug carrier. Typical carriers and preparation methods are disclosed in EW Martin's Remington's Pharmaceutical Sciences, 15th edition (Mark Publishing Company, 1975). The complex can also be encapsulated in suitable biocompatible particles formed from biodegradable or non-biodegradable polymers, proteins, or liposomes to target cells. Such systems are well known to those skilled in the art. In some embodiments, the complex is encapsulated in nanoparticles.
[0366] Injectable formulations may be available in unit dosage forms, such as in ampoules or multi-dose containers, optionally with added preservatives. Compositions may be in the form of sterile aqueous or non-aqueous solutions, suspensions, and emulsions, and in some embodiments, these compositions may be isotonic with the blood of the subject. Examples of non-aqueous solvents are polypropylene glycol; polyethylene glycol; vegetable oils such as olive oil, sesame oil, coconut oil, peanut oil, mineral oil; injectable organic esters such as ethyl oleate; or non-volatile oils containing synthetic monoglycerides or diglycerides. Aqueous carriers include water, alcoholic / aqueous solutions, emulsions, or suspensions containing saline and buffer media. Parenteral mediators include sodium chloride solution, 1,3-butanediol, Ringer's dextran, dextran and sodium chloride, lactated Ringer's oil, or non-volatile oils. Intravenous mediators include fluids and nutritional supplements, as well as electrolyte supplements, such as those based on Ringer's dextran. These materials can be in solutions, emulsions, or suspensions (e.g., incorporated into particles, liposomes, or cells). Typically, an appropriate amount of pharmaceutically acceptable salt is used in the formulation to make it isotonic. Typically, 1-5% trehalose can be added to the pharmaceutical composition. The pH of the solution is preferably from about 5 to about 8, and more preferably from about 7 to about 7.5.
[0367] Pharmaceutical compositions may include carriers, thickeners, diluents, buffers, preservatives, and surfactants. Carrier formulations can be found at Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa. Those skilled in the art can readily determine the various parameters used to prepare and formulate the compositions without excessive experimentation.
[0368] Compositions, alone or in combination with other suitable components, can also be formulated as aerosol formulations (i.e., these compositions can be “nebulized”) for administration by inhalation. Aerosol formulations can be placed in a pressurized, acceptable propellant, such as dichlorodifluoromethane, propane, nitrogen, and air. For administration by inhalation, the compound is delivered as an aerosol spray from a pressurized pack or nebulizer using a suitable propellant.
[0369] In some embodiments, a pharmaceutically acceptable carrier is included, which contains formulation components such as salts, carriers, buffers, emulsifiers, diluents, excipients, chelating agents, preservatives, solubilizers, or stabilizers.
[0370] Nucleic acids can conjugate with lipophilic groups possessing the C32 functional group (such as cholesterol and lauric acid and lithocholic acid derivatives) to improve cellular uptake. For example, cholesterol has been shown to improve uptake in vitro (Lorenz et al., Bioorg. Med. Chem. Lett., 14(19):4975-4977 (2004)) and in vivo (Soutschek et al., Nature , 432(7014):173-178(2004)) enhance siRNA uptake and serum stability. Furthermore, it has been shown that steroid-conjugated oligonucleotides bind to different lipoproteins (such as LDL) in the bloodstream, protecting integrity and promoting biodistribution (Rump et al., 432(7014):173-178(2004)). Biochem. Pharmacol .,59(11):1407-1416 (2000)). Other groups that can be linked or conjugated to the above compounds to increase cellular uptake include: acridine derivatives; cross-linking agents, such as psoralen derivatives, azidobenzoylmethyl, proflavin, and azidoproflavin; artificial endonucleases; metal complexes, such as EDTA-Fe(II) and porphyrin-Fe(II); alkylation moieties; nucleases, such as alkaline phosphatases; terminal transferases; antibody enzymes; cholesterol moieties; lipophilic carriers; peptide conjugates; long-chain alcohols; phosphate esters; radiolabels; non-radiolabels; carbohydrates; and polylysine or other polyamines. U.S. Patent No. 6,919,208 to Levy et al. also describes methods for enhanced delivery. These pharmaceutical formulations can be prepared in ways known per se, such as by means of conventional mixing, dissolving, granulating, grinding, emulsifying, encapsulating, embedding, or lyophilizing methods.
[0371] Other carriers include sustained-release formulations, such as semi-permeable matrices containing solid hydrophobic polymers of complexes, which are in the form of shaped particles, such as membranes, liposomes, or microparticles. Implantation includes inserting implantable drug delivery systems, such as microspheres, hydrogels, polymer reservoirs, cholesterol matrices, polymer systems, such as matrix erosion and / or diffusion systems, and non-polymer systems. Inhalation involves administering the composition alone or together with an aerosol attached to an absorbable carrier in an inhaler. For systemic administration, encapsulation of the composition in liposomes is preferred.
[0372] The composition can be delivered using invasive devices (such as vascular catheters or urinary catheters) and interventional devices (such as stents with drug delivery capabilities and configured as dilatation devices or stent grafts) to achieve tissue-specific drug uptake and / or nucleotide delivery systems.
[0373] The formulation can be delivered using biodegradable implants via diffusion or degradation of the polymer matrix. In some embodiments, the administration of the formulation can be programmed to sequentially expose the composition over a period of time (e.g., hours, days, weeks, months, or years). This can be accomplished, for example, by repeated administration of the formulation or by a continuous or controlled release delivery system in which the composition is delivered over an extended period of time without repeated administration.
[0374] Other suitable delivery systems include timed-release, delayed-release, sustained-release, or controlled-release delivery systems. In many cases, such systems can avoid repeated administration, thereby increasing convenience for both the subject and the physician. Many types of release delivery systems are available and known to those skilled in the art. These systems include, for example, polymer-based systems such as polylactic acid and / or polyglycolic acid, polyanhydride, polycaprolactone, copolyoxalic acid, polyesteramide, polyorthoester, polyhydroxybutyrate, and / or combinations thereof. Microcapsules of the aforementioned nucleic acid-containing polymers are described, for example, in U.S. Patent No. 5,075,109. Other examples include: lipid-based non-polymer systems containing sterols (such as cholesterol, cholesterol esters, and fatty acids) or neutral fats (such as monoglycerides, diglycerides, and triglycerides); hydrogel release systems; liposome-based systems; phospholipid-based systems; silicone rubber systems; peptide-based systems; wax-coated systems; compressed tablets using conventional adhesives and excipients; or partially fused implants. Formulations can be, for example, microspheres, hydrogels, polymer reservoirs, cholesterol matrices, or polymer systems. In some implementations, the system can allow for sustained or controlled release of the composition, for example, by controlling the diffusion or erosion / degradation rate of the formulation containing the complex.
[0375] Complexes comprising nucleic acid cargoes and antibodies, or combinations thereof, can be formulated for application to the lungs or mucous membranes. Application may involve delivering the composition to the mucous membranes of the lungs, nose, mouth (sublingual, buccal), vagina, or rectum. As used herein, the term "aerosol" refers to any formulation of a fine spray of particles, which may be in the form of a solution or suspension, whether or not it is generated using a propellant. Aerosols can be generated using standard techniques such as ultrasonication or high-pressure processing.
[0376] For administration via the upper respiratory tract, the preparation can be formulated as a solution (e.g., water or isotonic saline), buffered or unbuffered, or as a suspension for intranasal administration in the form of drops or sprays. Preferably, such solutions or suspensions are isotonic relative to nasal secretions and have substantially the same pH, for example, in the range of about pH 4.0 to about pH 7.4 or pH 6.0 to pH 7.0. The buffer should be physiologically compatible and, by way of example only, contains phosphate buffer.
[0377] The complex can be delivered to target cells using particulate delivery mediators. Nanoparticles are generally defined as particles ranging from 500 nm to less than 0.5 nm in diameter, preferably between 50 and 500 nm, and more preferably between 50 and 300 nm. The internalization of polymer particles within cells is highly dependent on their size, with nanoparticle polymer particles being internalized much more efficiently than microparticle polymer particles. For example, Desai et al. demonstrated that cultured Caco-2 cells took up approximately 2.5 times more 100 nm diameter nanoparticles than 1 μM diameter microparticles (Desai et al.). Pharm. Res., 14:1568-73 (1997). Nanoparticles also have a greater ability to diffuse deeper into tissues in vivo.
[0378] In some implementations, the delivery medium is a dendritic polymer.
[0379] Examples of preferred biodegradable polymers include synthetic polymers that degrade via hydrolysis (such as polymers and copolymers of poly(hydroxy acids), such as lactic acid and glycolic acid), other biodegradable polyesters, polyanhydrides, poly(ortho-esters), polyesters, polyurethanes, poly(butyric acid), poly(valeric acid), poly(caprolactone), poly(hydroxyalkanoates), poly(lactide-co-caprolactone), and poly(amine-co-ester) polymers, such as those by Zhou et al. Nature Materials Those described in , 11:82-90 (2012) and WO 2013 / 082529, U.S. Public Application No. 2014 / 0342003 and PCT / US2015 / 061375.
[0380] In some implementations, particularly those intended for targeting T cells in vivo, such as those for generating CAR-T cells, immune cells, or T cell markers like CD3, CD7, or CD8, or markers for target tissues like the liver, targeting can be achieved. For example, anti-CD8 antibodies and anti-CD3 Fab fragments have both been used to target T cells in vivo (Pfeiffer et al.). EMBO Mol Med., 10(11) (2018). pii: e9158. doi: 10.15252 / emmm.201809158., Smith et al. Nat Nanotechnol., 12(8):813-820 (2017). doi: 10.1038 / nnano.2017.57). Therefore, in some embodiments, the particles or other delivery media include a targeting portion that is specific to a marker of CD3, CD7, CD8 or another immune cell (e.g., T cell) or a marker of a specific tissue such as the thymus, spleen, or liver. The binding portion may be, for example, an antibody or an antigen-binding fragment thereof.
[0381] The targeting portion can associate, connect, conjugate, or otherwise attach directly or indirectly to nanoparticles or other delivery agents. The targeting molecule can be a protein, peptide, nucleic acid molecule, sugar, or polysaccharide that binds to receptors or other molecules on the surface of the target cell. The specificity and affinity of the graft can be modulated by selecting the targeting molecule.
[0382] Examples of such components include, for example, targeting portions that provide delivery of molecules to specific cells, such as hematopoietic stem cells or CD34. + Antibodies targeting hematopoietic stem cells, T cells, or any other preferred cell type, and receptors and ligands expressed on the preferred cell type. Preferably, these portions target hematopoietic stem cells. Examples of molecules targeting the extracellular matrix (“ECM”) include glycosaminoglycans (“GAG”) and collagen. In one embodiment, the outer surface of the polymer particles can be modified to enhance the particles’ ability to interact with selected cells or tissues. The method described above is preferred, wherein a connecting element conjugated to the targeting molecule is inserted into the particles. However, in another embodiment, the outer surface of polymer microparticles or nanoparticles having carboxyl-terminated ends can be linked to a targeting molecule having free amine-terminated ends.
[0383] Other useful ligands attached to polymeric microparticles and nanoparticles include pathogen-associated molecular patterns (PAMPs). PAMPs target Toll-like receptors (TLRs) on the surface of cells or tissues, or signal cells or tissues internally, thereby potentially increasing uptake. PAMPs conjugated to or co-encapsulated on the particle surface can include: unmethylated CpG DNA (bacteria), double-stranded RNA (viruses), lipopolysaccharide (bacteria), peptidoglycan (bacteria), lipoarabinomannan (bacteria), yeast polysaccharide (yeast), mycoplasmal lipoproteins such as MALP-2 (bacteria), flagellin (bacteria), poly(inosine-cytidine) acid (bacteria), lipoteichoic acid (bacteria), or imidazoquinone (synthetic).
[0384] In another embodiment, the outer surface of the particles may be treated with mannosamine, thereby mannosylating the outer surface of the particles. This treatment may enable the particles to bind to target cells or tissues at mannose receptors on the surface of antigen-presenting cells. Alternatively, surface conjugation to immunoglobulin molecules containing an Fc moiety (targeting Fc receptor), a heat shock protein moiety (HSP receptor), phosphatidylserine (scavenger receptor), and lipopolysaccharide (LPS) represents another receptor target on cells or tissues.
[0385] lectins can be covalently attached to microparticles and nanoparticles to make them target-specific to mucins and mucosal cell layers.
[0386] The choice of targeting portion will depend on the method of application of the nanoparticle composition and the cells or tissues to be targeted. Targeting molecules can typically increase the binding affinity of the particles to cells or tissues, or can target the nanoparticles to specific tissues within an organ or specific cell types within a tissue. In some embodiments, the targeting portion targets the thymus, spleen, or cancer cells.
[0387] Covalent attachment of any natural component of the mucin to particles in pure or partially purified form reduces the surface tension at the bead-gut interface and increases the solubility of beads in the mucin layer. Attachment of polyamino acids containing additional side carboxylic acid groups (e.g., polyaspartic acid and polyglutamic acid) increases bioadhesion. Using polyamino acids with molecular weights ranging from 15,000 to 50,000 kDa generates chains of 120 to 425 amino acid residues attached to the particle surface. The polyamino chains enhance bioadhesion through chain entanglement within the mucin chains and the increased carboxyl charge.
[0388] III. How to Use
[0389] Methods for using 3E10 to enhance nucleic acid construct delivery are provided. Typically, an effective amount of 3E10 antibody is first contacted with the nucleic acid cargo to be delivered to cells. For example, the nucleic acid cargo and antibody may be mixed in solution for a sufficient time to allow the nucleic acid cargo and antibody to form a complex. Next, the mixture is contacted with cells. In other embodiments, the cargo and antibody are added to a solution containing or additionally soaking cells, and a complex is formed in the presence of the cells. The complex may contact cells in vitro, ex vivo, or in vivo. Thus, in some embodiments, the complex solution is added to cultured cells or injected into an animal to be treated.
[0390] Antibodies are believed to facilitate the delivery of nucleic acids into the cell nucleus, thereby altering the function of the RAD51 pathway, which can promote gene editing of donor DNA. This method has no sequence restrictions on the design of the nucleic acid cargo. For example, treatment can be administered to subjects in need via a simple IV infusion, delivering a mixture of antibody and nucleic acid cargo.
[0391] The compositions and methods may include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more different nucleic acid constructs formed from RNA, DNA, PNA or other modified nucleic acids or combinations thereof.
[0392] An effective or therapeutically effective amount of the composition may be a dose sufficient to treat, inhibit or alleviate one or more symptoms of a disease or condition or otherwise provide the desired pharmacological and / or physiological effects, such as reducing, inhibiting or reversing one or more pathophysiological mechanisms that are the cause of a disease or condition.
[0393] An effective amount can also be the amount that effectively increases the delivery rate, quantity, and / or quality of nucleic acid cargo relative to the administration of the cargo in the absence of antibodies. The composition is formulated to suit the administration modality. A pharmaceutically acceptable carrier is determined in part by the specific composition being administered and by the specific method used to administer the composition. Therefore, there are various suitable formulations of pharmaceutical compositions containing complexes. The precise dosage will vary depending on various factors, such as subject-related variables (e.g., age, immune system health status, clinical symptoms, etc.).
[0394] The composition may be applied or otherwise brought into contact with target cells once, twice, or three times daily; once, twice, three, four, five, six, or seven times weekly; or once, twice, three, four, five, six, seven, or eight times monthly. For example, in some embodiments, the composition is applied every two or three days or an average of about two to about four times per week. Thus, in some embodiments, the composition is administered as part of a dosage regimen comprising two or more individual treatments.
[0395] Dosing regimens include maintenance regimens, in which the dose remains the same between two or more administrations; escalation regimens, in which the dose is increased between two or more administrations; decrement regimens, in which the dose is decreased between two or more administrations; or combinations thereof.
[0396] In some embodiments, the first dose may be a low dose. The dose may be gradually increased until a satisfactory biochemical or clinical response is achieved. The clinical response will depend on the disease or condition being treated and / or the desired outcome. In some embodiments, the dose may be increased until a therapeutic effect is identified, preferably without causing undesirable toxicity or an acceptable high level thereof. The dose may then be maintained or steadily reduced until a maintenance dose is reached. These methods can be used to standardize, optimize, or customize the dose level, frequency, or duration of treatment.
[0397] Typically, before administration, especially for in vivo administration, the antibody and nucleic acid are mixed at room temperature for a period of time. In some embodiments, the complexation time ranges from, for example, 1 minute to 30 minutes, or 10 minutes to 20 minutes, including all endpoints, with a preferred complexation time of about 15 minutes. The antibody dose can range from 0.0001 mg to 1 mg, including all endpoints, with a preferred dose of about 0.1 mg. The nucleic acid dose can range from about 0.001 µg to 100 µg, including all endpoints, with a preferred dose of 10 µg. The following in vivo data (e.g., Figure 6 B) was produced by using 0.1 mg 3E10, 10 µg mRNA, and compounding for 15 minutes.
[0398] The following examples may suggest that DNA cargo can be delivered more generally to multiple tissues, not just tumors, while RNA delivery may be more selective to tumor tissues. Therefore, in some embodiments, RNA cargo (e.g., alone) can be selectively delivered to cancer cells or other tumor tissues. In some embodiments, when a wider distribution of RNA cargo is required, RNA can be mixed with DNA (e.g., vector DNA) to facilitate delivery to non-cancer / tumor tissues. Vector DNA can be, for example, plasmid DNA or low molecular weight DNA derived from, for example, salmon sperm. In some embodiments, vector DNA is non-coding DNA. Vector DNA can be single-stranded or double-stranded, or a combination thereof. In some embodiments, vector DNA consists of nucleic acids of lengths of 1-10, 1-100, 1-1,000, or 1-10,000 nucleotides, or any subrange or integer thereof, or combinations thereof. Typically, vector DNA is not conjugated to or otherwise covalently attached to antibodies. Typically, vector DNA is co-incubated with cargo nucleic acids (e.g., RNA) and antibodies, and delivered as a complex. In some embodiments, vector DNA is non-coding DNA.
[0399] A. In vitro and ex vivo methods
[0400] For in vitro and ex vivo methods, cells are typically contacted with the composition during culture. For ex vivo methods, cells can be isolated from the subject and in vitro contacted with the composition to produce cells containing cargo nucleic acids. In a preferred embodiment, the cells are isolated from the subject to be treated or from a syngeneic host. Target cells can be removed from the subject before contact with the composition.
[0401] B. In vivo methods
[0402] In some embodiments, nucleic acid cargoes are delivered in vivo to cells for gene editing and / or treatment of a subject's disease or condition. Compositions typically containing antibody-nucleic acid cargoes can be administered directly to a subject for in vivo therapy.
[0403] Methods of administering compounds (including antibodies, oligonucleotides, and related molecules) are generally well known in the art. In particular, administration routes already used for nucleic acid therapy and currently used formulations provide preferred administration routes and formulations for the aforementioned donor oligonucleotides. Preferably, the composition is injected or infused into animals.
[0404] The composition can be administered via a variety of routes, including but not limited to intravenous, intraperitoneal, intraamniotic, intramuscular, subcutaneous, or local (sublingual, rectal, intranasal, pulmonary, rectal mucosa, and vaginal) and oral (sublingual, oral).
[0405] In some embodiments, the composition is formulated for pulmonary delivery, such as intranasal administration or oral inhalation. Administration of the formulation can be accomplished by any acceptable method that allows the complex to reach its target site. Depending on the condition being treated, administration can be local (i.e., applied to a specific area, physiological system, tissue, organ, or cell type) or systemic. Compositions and methods for in vivo delivery are also discussed in WO 2017 / 143042.
[0406] C. Application
[0407] The 3E10 antibody can be used to deliver nucleic acid cargo (e.g., mRNA, functional nucleic acid, DNA expression construct, vector, etc.) encoding a target polypeptide or functional nucleic acid into cells to express or inhibit the polypeptide in the cells. The compositions and methods can be used for a range of different applications. Non-limiting examples include CRISPR and gRNA expression vectors for + / - editing DNA, delivery of large DNA (plasmids and expression vectors), gene substitution and gene therapy, delivery of DNA and / or RNA, for example, to generate CAR-T cells in vivo or in vitro and to simplify the generation of CAR-T cells in vivo or in vitro, delivery of siRNA, delivery of mRNA, etc. Exemplary applications related to gene therapy / gene editing and immunomodulation, particularly the generation of chimeric antigen receptor T cells, are discussed below.
[0408] 1. Gene therapy and gene editing
[0409] In some embodiments, the composition is used for gene editing.
[0410] For example, this method can be particularly applicable to treating genetic defects, symptoms, and diseases caused by single-gene mutations, such as correcting genetic defects, symptoms, and diseases caused by point mutations. If the target gene contains mutations that cause genetic disorders, this method can be used for mutagenesis repair, which can restore the DNA sequence of the target gene to normal. The target sequence can be within the coding DNA sequence of the gene or within introns. The target sequence can also be within the DNA sequence that regulates the expression of the target gene, including promoter or enhancer sequences.
[0411] In the method described herein, cells that have been contacted with the complex may be administered to a subject. The subject may suffer from a disease or condition such as hemophilia, muscular dystrophy, globulinosis, cystic fibrosis, xeroderma pigmentosum, or lysosomal storage disease. In such embodiments, gene modification, gene substitution, gene addition, or a combination thereof may occur in an effective amount to alleviate one or more symptoms of the subject's disease or condition.
[0412] In some embodiments, the DNA cargo includes nucleic acids encoding nucleases, donor oligonucleotides, or nucleic acids encoding donor oligonucleotides, or combinations thereof.
[0413] a. Gene-editing nucleases
[0414] Nucleic acid cargoes include those encoding one or more elements that induce single- or double-strand breaks in the target cell genome, and optionally, but preferably, in combination with other elements such as donor oligonucleotides and / or, particularly in the case of CRISPR / Cas, other elements of the system, such as gRNA. The composition can be used, for example, to reduce or otherwise alter the expression of the target gene.
[0415] i. Chain breakage inducing element CRISPR / Cas
[0416] In some embodiments, the nucleic acid cargo includes one or more elements of a CRISPR / Cas-mediated genome editing composition, nucleic acids encoding one or more elements of a CRISPR / Cas-mediated genome editing composition, or combinations thereof. As used herein, a CRISPR / Cas-mediated genome editing composition refers to an element of the CRISPR system required for CRISPR / Cas-mediated genome editing in a mammalian subject. As discussed in more detail below, a CRISPR / Cas-mediated genome editing composition typically comprises one or more nucleic acids encoding crRNA, tracrRNA (or a chimera thereof, also known as guide RNA or single guide RNA), and a Cas enzyme (such as Cas9). The CRISPR / Cas-mediated genome editing composition may optionally contain a donor polynucleotide that can be recombined into the genome of a target cell at or near a target site (e.g., a site of a Cas9-induced single-strand break or double-strand break).
[0417] The CRISPR / Cas system has been adapted for use in eukaryotes for gene editing (silencing, enhancing, or altering specific genes) (see, for example, Cong). Science 15:339(6121):819–823 (2013) and Jinek et al., Science,337(6096):816-21 (2012)). By transfecting cells with desired elements including the cas gene and specially designed CRISPR, the genome of an organism can be cut and modified at any desired location. Methods for preparing compositions for genome editing using the CRISPR / Cas system are described in detail in WO 2013 / 176772 and WO 2014 / 018423, the entire contents of which are incorporated herein by reference.
[0418] The delivery method disclosed in this paper is applicable to various variants of the CRISPR / Cas system.
[0419] Generally, the term "CRISPR system" refers to transcripts and other elements involved in expressing or directing the activity of CRISPR-related ("Cas") genes, including sequences encoding Cas genes, tracr (trans-activating CRISPR) sequences (e.g., tracrRNA or active tracrRNA), tracr-mate sequences (included in "direct repeats" and tracrRNA-processed partial direct repeats in the context of an endogenous CRISPR system), directing sequences (also known as "spacer regions" in the context of an endogenous CRISPR system), or other sequences and transcripts derived from CRISPR loci. One or more tracr-mate sequences operatively linked to the directing sequence (e.g., direct repeat-spacer-direct repeat) may also be referred to as pre-crRNA (pre-CRISPRRNA) (before processing) or crRNA (after processing by nucleases).
[0420] As discussed in more detail below, in some embodiments, tracrRNA and crRNA are linked to form a chimeric crRNA-tracrRNA hybrid, wherein the mature crRNA is fused with a portion of the tracrRNA via a synthetic stem-loop to mimic the natural crRNA:tracrRNA duplex, as in Cong, Science , 15:339(6121):819–823 (2013) and Jinek et al., Science As described in , 337(6096):816-21 (2012). The single fusion crRNA-tracrRNA construct is also referred to herein as a guide RNA or gRNA (or a single guide RNA (sgRNA)). In sgRNA, the crRNA portion can be recognized as the “target sequence,” while tracrRNA is often referred to as the “scaffold.”
[0421] In some embodiments, one or more elements of the CRISPR system are derived from a type I, type II, or type III CRISPR system. In some embodiments, one or more elements of the CRISPR system are derived from a specific organism, including endogenous CRISPR systems, such as Streptococcus pyogenes (Streptococcus pyogenes). Streptococcus pyogenes ).
[0422] Generally, a CRISPR system is characterized by elements that promote the formation of a CRISPR complex at a target sequence site (also known as the prespacer region in the context of endogenous CRISPR systems). In the context of CRISPR complex formation, a "target sequence" refers to a sequence designed to be complementary to the guide sequence, wherein hybridization between the target and guide sequences promotes the formation of the CRISPR complex. The target sequence can be any polynucleotide, such as a DNA or RNA polynucleotide. In some implementations, the target sequence is located in the cell nucleus or cytoplasm.
[0423] In the target nucleic acid, each prespacer region is associated with a prespacer adjacent motif (PAM), and its recognition is specific to a single CRISPR system. In the *Streptococcus pyogenes* CRISPR / Cas system, the PAM is the nucleotide sequence NGG. In the *Streptococcus thermophilus* CRISPR / Cas system, the PAM is the nucleotide sequence NNAGAAW. The tracrRNA duplex directs Cas to the DNA target composed of the prespacer region and the essential PAM through heteroduplex formation between the crRNA's spacer region and the prespacer region DNA.
[0424] Typically, in the context of an endogenous CRISPR system, the formation of a CRISPR complex (including a guide sequence that hybridizes to the target sequence and is complexed with one or more Cas proteins) results in the cleavage of one or both strands in or near the target sequence (e.g., within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50 or more base pairs from the target sequence). All or part of the Tracr sequence can also form a portion of the CRISPR complex, such as by hybridizing with all or part of a Tracr mate sequence operatively linked to the guide sequence.
[0425] Once the desired DNA target sequence has been identified, numerous resources are available to help operators determine suitable target sites. For example, many public resources (including a bioinformatics-generated list of approximately 190,000 potential sgRNAs targeting over 40% of human exons) are available to assist operators in selecting target sites and designing relevant sgRNAs that influence nicks or double-strand breaks at that site. See also crripr.u-psud.fr / , a tool designed to help scientists find CRISPR target sites and generate appropriate crRNA sequences across a wide range of species.
[0426] In some embodiments, one or more vectors driving the expression of one or more elements of the CRISPR system are introduced into target cells, such that the expression of the CRISPR system elements guides the formation of a CRISPR complex at one or more target sites. For example, the Cas enzyme, the guide sequence linked to the tracr-mate sequence, and the tracr sequence can each be operatively linked to a separate regulatory element on a separate vector. Alternatively, two or more elements expressed from the same or different regulatory elements can be combined in a single vector, wherein one or more additional vectors provide any components of the CRISPR system not included in the first vector. The CRISPR system elements combined in a single vector can be aligned in any suitable orientation, such as one element being located at the 5' ("upstream") or 3' ("downstream") relative to the second element. The coding sequence of one element can be located on the same or opposite strand of the coding sequence of the second element and oriented in the same or opposite directions. In some embodiments, a single promoter drives the expression of a transcript encoding a CRISPR enzyme and a guide sequence, a tracr mate sequence (optionally operably ligated to the guide sequence), and one or more tracr sequences embedded in one or more intron sequences (e.g., each in different introns, two or more in at least one intron, or all in a single promoter). In some embodiments, the CRISPR enzyme, guide sequence, tracr mate sequence, and tracr sequence are operably ligated to and expressed from the same promoter.
[0427] In some embodiments, the vector contains one or more insertion sites, such as restriction endonuclease recognition sequences (also known as “cloning sites”). In some embodiments, one or more insertion sites (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more insertion sites) are located upstream and / or downstream of one or more sequence elements of one or more vectors. In some embodiments, the vector contains insertion sites upstream of a tracermate sequence and optionally downstream of a regulatory element operatively linked to the tracermate sequence, such that, after the guide sequence is inserted into the insertion site and after expression, the guide sequence guides the CRISPR complex to sequence-specific binding to a target sequence in eukaryotic cells. In some embodiments, the vector contains two or more insertion sites, each located between two tracermate sequences, to allow the insertion of a guide sequence at each site. In such arrangements, the two or more guide sequences may comprise two or more copies of a single guide sequence, two or more different guide sequences, or a combination thereof. When using multiple different guide sequences, a single expression construct can be used to target CRISPR activity to multiple different corresponding target sequences within cells. For example, a single vector may contain approximately or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20 guide sequences. In some embodiments, approximately or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 such vectors containing guide sequences may be provided and optionally delivered to cells.
[0428] In some embodiments, the vector contains a regulatory element operatively linked to an enzyme-coding sequence that encodes a CRISPR enzyme, such as the Cas protein. Non-limiting examples of Cas proteins include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csnl and Csxl2), Cas1O, Csyl, Csy2, Csy3, Csel, Cse2, Cscl, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Csbl, Csb2, Csb3, Csxl7, Csxl4, CsxlO, Csxl6, CsaX, Csx3, Csxl, Csxl5, Csfl, Csf2, Csf3, Csf4, their homologs, or their modified forms. In some embodiments, the unmodified CRISPR enzyme has DNA cleaving activity, such as Cas9. In some embodiments, the CRISPR enzyme directs the cleavage of one or two strands at a location on the target sequence, for example, within the target sequence and / or within the complementary sequence of the target sequence. In some embodiments, the CRISPR enzyme directs the cleavage of one or two strands from the first or last nucleotide of the target sequence within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 100, 200, 500 or more base pairs.
[0429] In some embodiments, the vector encodes a CRISPR enzyme mutated relative to the corresponding wild-type enzyme, such that the mutated CRISPR enzyme lacks the ability to cleave one or both strands of a target polynucleotide containing the target sequence. For example, an aspartic-to-alanine substitution (D10A) in the RuvC I catalytic domain of Cas9 from Streptococcus pyogenes transforms Cas9 from a two-strand cleaving nuclease into a nicking enzyme (cleaving a single strand). Other examples of mutations that make Cas9 a nicking enzyme include, but are not limited to, H840A, N854A, and N863A. As another example, two or more catalytic domains of Cas9 (RuvC I, RuvC II, and RuvC III) can be mutated to produce a mutant Cas9 that substantially lacks all DNA cleaving activity. In some embodiments, the D10A mutation is combined with one or more of the H840A, N854A, or N863A mutations to produce a Cas9 enzyme that substantially lacks all DNA cleaving activity. In some implementations, when the DNA cleavage activity of the mutant enzyme is less than about 25%, 10%, 5%, 1%, 0.1%, 0.01% or lower relative to its non-mutant form, the CRISPR enzyme is considered to be substantially lacking all DNA cleavage activity.
[0430] In some implementations, the enzyme-coding sequence encoding a CRISPR enzyme is codon-optimized for expression in specific cells, such as eukaryotic cells. Eukaryotic cells can be those belonging to or derived from a specific organism, such as mammals, including but not limited to humans, mice, rats, rabbits, dogs, or non-human primates. Generally, codon optimization refers to the process of modifying nucleic acid sequences to enhance expression in target host cells by replacing at least one codon of the natural sequence with a codon that is more frequently or most frequently used in the host cell gene while maintaining the natural amino acid sequence (e.g., approximately or more than about 1, 2, 3, 4, 5, 10, 15, 20, 25, 50, or more codons). Various species exhibit specific preferences for certain codons of specific amino acids. Codon bias (differences in codon use between organisms) is generally associated with the translation efficiency of messenger RNA (mRNA), which is considered to be particularly dependent on the characteristics of the codons being translated and the availability of specific transfer RNA (tRNA) molecules.
[0431] The dominance of the selected tRNA in a cell typically reflects the most frequently used codons in peptide synthesis. Therefore, genes can be tailored based on codon optimization to achieve optimal gene expression in a given organism. Codon usage tables are readily available, for example, in codon usage databases, and these tables can be modified in various ways. See Nakamura, Y. et al. Nucl. Acids Res ., 28:292 (2000). Computer algorithms for codon optimization of specific sequences for expression in specific host cells, such as Gene Forge (Aptagen; Jacobus, PA), are also available. In some implementations, one or more codons (e.g., 1, 2, 3, 4, 5, 10, 15, 20, 25, 50 or more or all of the codons) in the sequence encoding the CRISPR enzyme correspond to the most frequently used codon for a specific amino acid.
[0432] In some embodiments, the vector encodes a CRISPR enzyme containing one or more nuclear localization sequences (NLS). When more than one NLS is present, each NLS can be selected independently of the others, such that a single NLS can exist in more than one copy and / or be combined with one or more other NLS present in one or more copies. In some embodiments, an NLS is considered to be close to the N-terminus or C-terminus when the nearest amino acid of the NLS is within approximately 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50 or more amino groups along the polypeptide chain from the N-terminus or C-terminus.
[0433] Generally, one or more NLSs have sufficient strength to drive detectable amounts of CRISPR enzyme accumulation in the nucleus of eukaryotic cells. The strength of nuclear localization activity can generally be derived from the number of NLSs in the CRISPR enzyme, the specific NLS used, or a combination of these factors.
[0434] Accumulation in the nucleus can be detected using any suitable technique. For example, detectable markers can be fused with CRISPR enzymes to visualize the intracellular location, such as in conjunction with methods for detecting the location of the cell nucleus (e.g., nucleus-specific staining, such as DAPI). The nucleus can also be isolated from the cell and its contents analyzed using any suitable protein detection method, such as immunohistochemistry, Western blotting, or enzyme activity assays. Accumulation in the nucleus can also be determined indirectly, for example, by measuring the effect on CRISPR complex formation (e.g., assays of DNA cleavage or mutation at target sequences, or assays of altered gene expression activity affected by CRISPR complex formation and / or CRISPR enzyme activity).
[0435] In some implementations, one or more elements of the CRISPR system are under the control of an inducible promoter, which may include an inducible Cas, such as Cas9.
[0436] Cong, Science, 15:339(6121):819–823 (2013) reported that heterologous expression of Cas9, tracrRNA, pre-crRNA (or Cas9 and sgRNA) can achieve targeted cleavage of mammalian chromosomes. Therefore, the CRISPR system used in the methods disclosed herein, and consequently the cargo nucleic acid, is a vector system that may contain one or more vectors encoding CRISPR system elements, said elements may contain a first regulatory element operatively linked to a CRISPR / Cas system chimeric RNA (chiRNA) polynucleotide sequence, said nucleotide sequence comprising (a) a guide sequence capable of hybridizing to a target sequence in eukaryotic cells, (b) a tracr mate sequence and (c) a tracr sequence; and a second regulatory element operatively linked to an enzyme-coding sequence encoding a CRISPR enzyme, said CRISPR enzyme may optionally contain at least one or more nuclear localization sequences. Elements (a), (b), and (c) may be arranged in a 5' to 3' orientation, wherein components I and II are located on the same or different vectors of the system, wherein during transcription, the tracr mate sequence hybridizes with the tracr sequence, and the guide sequence guides the CRISPR complex to sequence-specific binding to the target sequence, and wherein the CRISPR complex may contain a CRISPR enzyme complexed with (1) the guide sequence hybridizing with the target sequence and (2) the tracr mate sequence hybridizing with the tracr sequence, wherein the enzyme-coding sequence encoding the CRISPR enzyme further encodes a heterologous functional domain. In some embodiments, one or more vectors also encode a suitable Cas enzyme, for example, Cas9. Different gene elements may be controlled by the same or different promoters.
[0437] While the details may vary in different engineered CRISPR systems, the overall approach is similar. Operators interested in targeting DNA sequences using CRISPR technology (identified using one of the many available online tools) can insert a short DNA fragment containing the target sequence into a guide RNA expression plasmid. The sgRNA expression plasmid contains the target sequence (approximately 20 nucleotides), the tracr sequence (scaffold) form, and suitable promoters and elements required for proper processing in eukaryotic cells. Such vectors are commercially available (see, for example, Addgene). Many systems rely on custom-made complementary oligonucleotides, which are annealed to form double-stranded DNA and then cloned into the sgRNA expression plasmid. In transfected cells, co-expression of the sgRNA from the same or separate plasmids and the appropriate Cas enzyme results in single- or double-strand breaks at the desired target site (depending on the activity of the Cas enzyme).
[0438] ii. Zinc finger nucleases
[0439] In some implementations, the element that induces single-strand or double-strand breaks in the target cell genome is a nucleotide construct or a construct encoding a zinc finger nuclease (ZFN). Therefore, the nucleic acid cargo can encode a ZFN.
[0440] ZFNs are typically fusion proteins containing a DNA-binding domain derived from a zinc finger protein linked to a cleavage domain. The most common cleavage domain is the IIS-type enzyme Fok1. Fok1 catalyzes double-strand cleavage of DNA at a distance of 9 nucleotides from its recognition site on one strand and 13 nucleotides from its recognition site on the other strand. See, for example, U.S. Patent Nos. 5,356,802; 5,436,150 and 5,487,994; and Li et al. Proc., Natl. Acad. Sci. USA 89 (1992):4275-4279; Li et al., Proc. Natl. Acad. Sci. USA , 90:2764-2768 (1993); Kim et al., Proc. Natl. Acad. Sci. USA 91:883-887 (1994a); Kim et al. J. Biol. Chem 269:31, 978-31,982(1994b). One or more of these enzymes (or their enzymatically functional fragments) can be used as a source of cleavage domains.
[0441] In principle, a DNA-binding domain designed to target any genomic location can be a tandem array of Cys2His2 zinc fingers, where each zinc finger typically recognizes three to four nucleotides in the target DNA sequence. The Cys2His2 domain has a general structure: Phe (sometimes Tyr)-Cys (2 to 4 amino acids)-Cys- (3 amino acids)-Phe (sometimes Tyr)- (5 amino acids)-Leu- (2 amino acids)-His- (3 amino acids)-His. By using multiple fingers (the number varies: in published studies, three to six fingers are used per monomer), ZFN pairs can be designed to bind to genomic sequences 18–36 nucleotides long.
[0442] Engineering methods include, but are not limited to, rational design and various types of empirical selection methods. Rational design includes, for example, using a database containing triplet (or tetrad) nucleotide sequences and individual zinc finger amino acid sequences, wherein each triplet or tetrad nucleotide sequence is associated with one or more amino acid sequences of a zinc finger that binds to a specific triplet or tetrad sequence. See, for example, U.S. Patent Nos. 6,140,081; 6,453,242; 6,534,261; 6,610,512; 6,746,838; 6,866,997; 7,067,617; U.S. Publication Nos. 2002 / 0165356; 2004 / 0197892; 2007 / 0154989; 2007 / 0213269; and International Patent Application Publication Nos. WO 98 / 53059 and WO 2003 / 016496.
[0443] iii. Transcription activator-like effector nucleases
[0444] In some implementations, the element that induces single-strand or double-strand breaks in the target cell genome is a nucleic acid construct or a construct encoding a transcription activator-like effector nuclease (TALEN). Therefore, the nucleic acid cargo can encode a TALEN.
[0445] TALENs have an overall architecture similar to ZFNs, the main difference being that their DNA-binding domains originate from TAL effector proteins, i.e., transcription factors from plant pathogens. The DNA-binding domain of TALENs is a tandem array of amino acid repeat sequences, each approximately 34 residues long. The repeat sequences are very similar to each other; typically, they differ primarily at two positions (amino acids 12 and 13, called repeat variable diresidues, or RVDs). Each RVD specifies the preferential binding of one of four possible nucleotides, meaning each TALEN repeat binds a single base pair, although NN RVDs are known to bind adenine in addition to guanine. The mechanism of TAL effector DNA binding is not as well understood as that of zinc finger proteins, but its seemingly simpler coding may prove highly beneficial for the design of engineered nucleases. TALENs also cleave into dimers with relatively long target sequences (the shortest reported to date binds 13 nucleotides per monomer) and appear to have less stringent requirements on the length of the spacers between binding sites than ZFNs. Monomeric and dimer TALENs can contain more than 10, 14, 20, or 24 repeats.
[0446] In Cermak, etc. Nucl. Acids Res Methods for engineering TAL to bind specific nucleic acids are described in .1-11 (2011). U.S. Patent Application No. 2011 / 0145940 discloses TAL effectors and methods for modifying DNA using them. Miller et al. Nature Biotechnol 29:143 (2011) reported the preparation of TALENs for site-specific nuclease structures by linking truncated TAL variants to the catalytic domain of FokI nucleases. The resulting TALENs were demonstrated to induce gene modification in immortalized human cells. General design principles for TALEN binding domains can be found, for example, WO 2011 / 072246.
[0447] b. Donor polynucleotide
[0448] The genome editing system described in this article uses nuclease activity to cleave target DNA to create single-strand or double-strand breaks. Cells can repair double-strand breaks in one of two ways: non-homologous end joining (NHEJ) and homologous directed repair (HDR). In NHEJ, double-strand breaks are repaired by directly joining the broken ends together. No new nucleic acid material is inserted into the site, although some nucleic acid material may be lost, resulting in deletion. In HDR, a donor polynucleotide homologous to the cleaved target DNA sequence is used as a template for repairing the cleaved target DNA sequence, causing genetic information to be transferred from the donor polynucleotide to the target DNA. This allows new nucleic acid material to be inserted / replicated into the site.
[0449] Therefore, in some embodiments, the nucleic acid cargo is or contains donor polynucleotides. Modifications to target DNA resulting from NHEJ and / or homology-directed repair can be used to induce gene correction, gene substitution, gene markers, transgene insertion, nucleotide deletion, gene disruption, gene mutation, etc.
[0450] Therefore, the DNA cleavage of the genome editing composition can be used to remove nucleic acid material from the target DNA sequence by cutting the target DNA sequence and allowing the cell to repair the sequence in the absence of exogenously provided donor polynucleotides. Alternatively, if the genome editing composition contains a donor polynucleotide sequence that contains at least a fragment homologous to the target DNA sequence, the method can be used to add (i.e., insert or replace) nucleic acid material (e.g., “knock-in” nucleic acids encoding proteins, siRNA, miRNA, etc.) to the target DNA sequence, add tags (e.g., 6xHis, fluorescent proteins (e.g., green fluorescent protein; yellow fluorescent protein, etc.), hemagglutinin (HA), FLAG, etc.), add regulatory sequences to genes (e.g., promoters, polyadenylation signals, internal ribosome entry sequences (IRES), 2A peptides, start codons, stop codons, splicing signals, localization signals, etc.), modify nucleic acid sequences (e.g., introduce mutations), and so on. In this way, the composition can be used to modify DNA in a site-specific (i.e., “targeted” manner, such as gene knockout, gene knock-in, gene editing, gene tagging, etc., for example, for gene therapy.
[0451] In applications requiring the insertion of a polynucleotide sequence into a target DNA sequence, the cell is also supplied with a polynucleotide containing the donor sequence to be inserted. A “donor sequence,” “donor polynucleotide,” or “donor oligonucleotide” refers to the nucleic acid sequence to which the cleavage site is to be inserted. The donor polynucleotide typically contains sufficient homology to the genomic sequence at the cleavage site—for example, 70%, 80%, 85%, 90%, 95%, or 100% homology to nucleotide sequences flanking the cleavage site—for example, within approximately 50 bases, such as approximately 30 bases, approximately 15 bases, approximately 10 bases, approximately 5 bases, or immediately adjacent to the cleavage site—to support homology-directed repair with its homologous genomic sequence. The donor sequence is typically not identical to the genomic sequence it replaces. Instead, the donor sequence may contain at least one or more single-base alterations, insertions, deletions, inversions, or rearrangements relative to the genomic sequence, provided sufficient homology exists to support homology-directed repair. In some implementations, the donor sequence includes non-homologous sequences flanking two homologous regions, such that homologous directed repair between the target DNA region and the two flanking sequences results in the insertion of the non-homologous sequence at the target region.
[0452] 2. Immune regulation
[0453] a. CAR T cells
[0454] The disclosed compositions and methods are particularly suitable for preparing lymphocytes expressing immune receptors, especially chimeric immune receptors (CIRs), such as chimeric antigen receptors (CARs). Artificial immune receptors (also referred to herein as chimeric T-cell receptors, chimeric immune receptors, chimeric antigen receptors (CARs), and chimeric immune receptors (CIRs)) are engineered receptors that have selected specificities transplanted onto cells. As discussed in more detail below, cells modified according to the methods discussed can be used in a variety of immunotherapies for treating cancer, infections, inflammation, and autoimmune diseases.
[0455] In a particularly preferred embodiment, mRNA or DNA encoding a chimeric antigen receptor cargo is delivered to immune cells, such as lymphocytes.
[0456] The cargo can be delivered to immune cells in vivo, ex vivo, or in vitro. In a preferred embodiment, the cargo is mRNA, which may allow for one or more of the following: reduced cost, ease of manufacture, and reduced side effects (e.g., cytokine storm, neurotoxicity, graft-versus-host disease, etc.). In a particular embodiment, immune cells (e.g., T cells) are harvested from a subject requiring CAR T-cell therapy, the compositions and methods disclosed herein are used to deliver mRNA encoding one or more CAR T-cell constructs into the harvested cells, and the cells are returned to the subject. In some embodiments, the process from initially harvesting cells to returning them to the subject takes one week or less, e.g., 1, 2, 3, 4, 5, 6, or 7 days. In a particular embodiment, the process from initially harvesting cells to returning them to the subject is completed in one or two days, or in less than one day, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 hours.
[0457] A review of chimeric antigen receptor design and development strategies was published in Dotti et al. Immunol Rev. January 2014; 257(1):. doi:10.1111 / imr.12131 (35 pages), the entire contents of which are incorporated herein by reference, and Dotti, Molecular Therapy , 22(5):899-890 (2014), Karlsson et al., Cancer Gene Therapy , 20:386-93 (2013), Charo et al., Cancer Res ., 65(5):2001-8 (2005), Jensen et al. Immunol Rev .,257(1): 127–144 (2014), Eaton et al., Gene Therapy , 9:527-35 (2002), Barrett et al., Annu Rev Med ., 65: 333–347 (2014), Cartellieri et al., Journal of Biomedicine and Biotechnology Volume 2010, Article No. 956304, 13 pages doi:10.1155 / 2010 / 956304; and U.S. Publication Application Nos. 2015 / 0017120, 2015 / 0283178, 2015 / 0290244, 2014 / 0050709 and 2013 / 0071414.
[0458] CAR combines the antigen-binding properties of monoclonal antibodies with the lytic and self-renewal capabilities of T cells, and offers several advantages over traditional T cells (Ramos and Dotti, ...). Expert Opin Biol Ther ., 11:855–873 (2011), Curran et al., J Gene Med ., 14:405–415 (2012), Maher, ISRN Oncol 2012:278093(2012)). CAR-T cells recognize and kill cancer cells independently of the major histocompatibility complex (MHC). Therefore, target cell recognition is not affected by certain mechanisms by which tumors evade MHC-restricted T cell recognition, such as downregulation of human leukocyte antigen (HLA) class I molecules and defective antigen processing.
[0459] Chimeric immune receptors were initially developed in the 1980s and initially included the variable (antigen-binding) region of a monoclonal antibody and the constant regions of the α and β chains of the T-cell receptor (TCR) (Kuwana et al.). Biochem Biophys Res Commun .,149:960–968 (1987)). In 1993, this design was revised to include an extracellular domain, a single-chain variable fragment (scFv) from the antigen-binding region of the heavy and light chains of the monoclonal antibody, a transmembrane domain, and an intracellular domain with a signal transduction domain from CD3-ζ. Subsequent CARs generally follow a similar structural design with a co-stimulatory signal transduction intracellular domain. Therefore, the CAR construct used in the method described herein can include an antigen-binding domain or an extracellular domain, a hinge domain, a transmembrane domain, an intracellular domain, or a combination thereof.
[0460] In some implementations, the intracellular domain is scFv. The affinity of scFv predicts CAR function (Hudecek et al., Clin Cancer Res ., 19(12):3153-64 (2013), Chmielewski et al., J Immunol ., 173:7647–7653(2004)). Antigen binding and subsequent activation can also be modified by adding a flexible adapter sequence to the CAR, which allows expression of two distinct scFvs that recognize two different antigens (Grada et al., 173:7647–7653(2004)). Mol Ther Nucleic Acids , 2:e105 (2013) (called tandem CAR (TanCAR)). Tandem CARs can more effectively kill cancers that express low levels of each antigen alone, and can also reduce the risk of tumor immune escape caused by single antigen loss variants. Other extracellular domains include IL13Rα2 (Kahlon et al., 2:e105 (2013)) (called tandem CAR (TanCAR)). Cancer Res ., 64:9160–9166 (2004), Brown et al., Clin Cancer Res .,18(8):2199-209 (2012), Kong et al., Clin Cancer Res ., 18:5949–5960 (2012)), NKG2D ligands and CD70 receptors, peptide ligands (e.g., T1E peptide ligands) and so-called “universal extracellular domains” (e.g., avidin extracellular domains designed to recognize targets already contacted with biotinylated monoclonal antibodies, or FITC-specific scFvs designed to recognize targets already contacted with FITC-labeled monoclonal antibodies) (Zhang et al., 18:5949–5960 (2012)), NKG2D ligands and CD70 receptors, peptide ligands (e.g., T1E peptide ligands) and so-called “universal extracellular domains” (e.g., avidin extracellular domains designed to recognize targets already contacted with FITC-labeled monoclonal antibodies, or FITC-specific scFvs designed to recognize targets already contacted with FITC-labeled monoclonal antibodies) (Zhang et al., 18:5949–5960 (2012)). Blood , 106:1544–1551 (2005), Barber et al., Exp Hematol ., 36:1318–1328 (2008), Shaffer et al., Blood , 117:4304–4314(2011), Davies et al. Mol Med ., 18:565–576 (2012), Urbanska et al., Cancer Res ., 72:1844–1852 (2012), Tamada et al., Clin Cancer Res .,18:6436–6445 (2012)).
[0461] In some implementations, the CAR includes a hinge region. While the extracellular domain is important for CAR specificity, the sequence that connects the extracellular domain to the transmembrane structural domain (the hinge region) can also influence CAR-T cell function by generating differences in CAR length and flexibility. The hinge may include, for example, a CH2CH3 hinge derived from immunoglobulins such as IgG1 or a fragment thereof. For example, Hudecek et al., (Hudecek et al., Clin Cancer Res A study comparing the effects of the CH2-CH3 hinge [229 amino acids (AA)], the CH3 hinge (119 AA), and the short hinge (12 AA) on the effector function of T cells expressing third-generation ROR1-specific CARs found that T cells expressing the “short hinge” CAR exhibited superior antitumor activity. Other researchers have found that the CH2-CH3 hinge impairs epitope recognition of first-generation CD30-specific CARs (Hombach et al., 19(12):3153-64 (2013)). Gene Ther ., 7:1067–1075 (2000)).
[0462] A transmembrane domain typically exists between the hinge (or extracellular domain if there is no hinge domain) and the intracellular domain for signal transduction, most commonly derived from CD3-ζ, CD4, CD8, or CD28 molecules. Like the hinge, the transmembrane domain can also influence the function of CAR-T cell effectors.
[0463] Following antigen recognition, the intracellular domain of the CAR is activated and transmits co-stimulatory signals to T cells. T cell activation depends on the phosphorylation of the immune receptor tyrosine-based activation motif (ITAM) in the cytoplasmic domain into the cytoplasmic CD3-ζ domain of the TCR complex (Irving et al.). Cell , 64:891–901 (1991)). Although most CAR intracellular domains contain an activation domain derived from CD3-ζ, others may contain domains containing ITAM, such as Fc receptors targeting the IgE-γ domain (Haynes et al., 64:891–901 (1991)). J Immunol ., 166:182–187 (2001)).
[0464] The target specificity of CAR-expressing cells is determined by the antigen recognized by the antibody / extracellular domain. The disclosed compositions and methods can be used to generate constructs targeting any antigen and cells expressing said constructs. In the context of immunotherapy, particularly cancer immunotherapy, many antigens and suitable extracellular domains for targeting them are well known. Unlike natural TCRs, most scFv-based CARs recognize target antigens expressed on the cell surface, rather than internal antigens processed and presented by the cell's MHC. However, CARs have the advantage of recognizing structures other than protein epitopes, including carbohydrates and glycolipids, dotti, etc. Immunol Rev January 2014; 257(1):. doi:10.1111 / imr.12131 (35 pages), thus increasing the potential target antigen library. Preferred targets include antigens expressed only on cancer cells or the surrounding matrix (Cheever et al., Clin Cancer Res .,15:5323–5337 (2009)), such as splice variants of EGFR (EGFRvIII), which are specific for glioma cells (Sampson et al., 15:5323–5337 (2009)). Semin Immunol ., 20(5):267-75(2008)). However, human antigens meet this requirement, and most target antigens are expressed at low levels on normal cells (e.g., GD2, CAIX, HER2) and / or in a lineage-restricted manner (e.g., CD19, CD20).
[0465] Preferred targets and CARs targeting them are well known in the art (see, for example, Dotti et al.). Immunol Rev . 2014 Jan 257(1): . doi:10.1111 / imr.12131 (35 pages)). For example, CAR targets for hematologic malignancies include, but are not limited to, CD19 (e.g., B cells) (Savoldo et al., J Clin Invest ., 121:1822-1826 (2011), Cooper et al., Blood , 105:1622-1631 (2005); Jensen et al., Biol Blood Marrow Transplant (2010), Kochenderfer et al. Blood , 119:2709-2720 (2012), Brentjens et al., Molecular Therapy , 17:S157 (2009), Brentjens et al., Nat Med. , 9:279-286 (2003), Brentjens et al., Blood , 118:4817-4828 (2011), Porter et al. N Engl J Med ., 365:725-733(2011), Kalos et al., Sci Transl Med ., 3:95ra73 (2011), Brentjens et al., Sci Transl Med .,5:177ra38 (2013), Grupp et al., N Engl J Med (2013)); CD20 (e.g., B cells) (Jensen et al., Biol Blood Marrow Transplant (2010), Till et al. Blood , 112:2261-2271 (2008), Wang et al. Hum Gene Ther ., 18:712-725 (2007), Wang et al. Mol Ther., 9:577-586 (2004), Jensen et al. Biol Blood Marrow Transplant , 4:75-83 (1998)); CD22 (e.g., B cells) (Haso et al., ... Blood, 121:1165-1174 (2013)); CD30 (e.g., B cells) (Di Stasi et al., Blood , 113:6392-6402 (2009), Savoldo et al., Blood , 110:2620-2630 (2007), Hombach et al., Cancer Res ., 58:1116-1119(1998)); CD33 (e.g., myeloid) (Finney et al ... J Immunol ., 161:2791-2797 (1998)); CD70 (e.g., B cells / T cells) (Shaffer et al ... Blood , 117:4304-4314 (2011)); CD123 (e.g., myeloid) (Tettamanti et al., Br J Haematol ., 161:389-401 (2013)); Kappa (e.g., B cells) (Vera et al ... Blood , 108:3890-3897 (2006)); Lewis Y (e.g., myeloid) (Peinert et al., Gene Ther ., 17:678-686 (2010), Ritchie et al. Mol Ther (2013)); NKG2D ligands (e.g., myeloid) (Barber et al., Exp Hematol ., 36:1318-1328 (2008), Lehner et al., PLoS One ., 7:e31210 (2012), Song et al. Hum Gene Ther ., 24:295-305 (2013), Spear et al. J Immunol 188:6389-6398 (2012)); ROR1 (e.g., B cells) (Hudecek et al., Clin Cancer Res (2013)).
[0466] CAR targets for solid tumors include, but are not limited to, B7H3 (e.g., sarcoma, glioma) (Cheung et al.). Hybrid Hybridomics , 22:209–218 (2003)); CAIX (e.g., kidney) (Lamers et al., 22:209–218 (2003)); J Clin Oncol ., 24:e20–e22. (2006), Weijtens et al., Int J Cancer , 77:181–187 (1998)); CD44 v6 / v7 (e.g., cervix) (Hekele et al. ... Int J Cancer , 68:232-238 (1996), Dall et al. Cancer Immunol Immunother ,54:51-60 (2005)); CD171 (e.g., neuroblastoma) (Park et al., Mol Ther ., 15:825-833(2007)); CEA (e.g., colon) (Nolan et al., 15:825-833(2007)); Clin Cancer Res ., 5:3928-3941 (1999)); EGFRvIII (e.g., glioma) (Bullain et al ... J Neurooncol (2009), Morgan et al. Hum Gene Ther., 23:1043-1053 (2012)); EGP2 (e.g., cancer) (Meier et al., Magn Reson Med ., 65:756-763 (2011), Ren-Heidenreich et al., Cancer Immunol Immunother ., 51:417-423 (2002)); EGP40 (e.g., colon) (Daly et al ... Cancer Gene Ther., 7:284-291 (2000); EphA2 (e.g., glioma, lung) (Chow et al., Mol Ther ., 21:629-637 (2013)); ErbB2 (HER2) (e.g., breast, lung, prostate, glioma) (Zhao et al ... J Immunol., 183:5563-5574 (2009), Morgan et al. Mol Ther ., 18:843-851 (2010), Pinthus et al., 114:1774-1781 (2004), Teng et al., Hum Gene Ther ., 15:699-708 (2004), Stancovski et al., J Immunol., 151:6577-6582 (1993), Ahmed et al. Mol Ther., 17:1779-1787 (2009), Ahmed et al. Clin Cancer Res ., 16:474-485 (2010), Moritz et al., Proc Natl Acad Sci USA ., 91:4318-4322 (1994)); ErbB receptor family (e.g., breast, lung, prostate, glioma) (Davies et al ... Mol Med ., 18:565-576 (2012)); ErbB3 / 4 (e.g., breast, ovary) (Muniappan et al., Cancer Gene Ther ., 7:128-134 (2000), Altenschmidt et al., Clin Cancer Res ., 2:1001-1008(1996)); HLA-A1 / MAGE1 (e.g., melanoma) (Willemsen et al ... Gene Ther ., 8:1601-1608 (2001), Willemsen et al., J Immunol ., 174:7853-7858 (2005)); HLA-A2 / NY-ESO-1 (e.g., sarcoma, melanoma) (Schuberth et al ... Gene Ther ., 20:386-395 (2013)); FR-α (e.g., ovary) (Hwu et al ... J Exp Med., 178:361-366 (1993), Kershaw et al. Nat Biotechnol ., 20:1221-1227 (2002), Kershaw et al. Clin Cancer Res ., 12:6106-6115 (2006), Hwu et al., Cancer Res ., 55:3369-3373 (1995)); FAP (e.g., cancers associated with fibroblasts) (Kakarla et al ... Mol Ther (2013)); FAR (e.g., rhabdomyosarcoma) (Gattenlohner et al., Cancer Res ., 66:24-28 (2006)); GD2 (e.g., neuroblastoma, sarcoma, melanoma) (Pule et al., Nat Med., 14:1264-1270 (2008), Louis et al. Blood , 118:6050-6056 (2011), Rossig et al., Int J Cancer ., 94:228-236 (2001)); GD3 (e.g., melanoma, lung cancer) (Yun et al ... Neoplasia. , 2:449-459 (2000)); HMW-MAA (e.g., melanoma) (Burns et al. ... Cancer Res., 70:3027-3033 (2010)); IL11RA (e.g., osteosarcoma) (Huang et al., Cancer Res ., 72:271-281 (2012)); IL13RA2 (e.g., glioma) (Kahlon et al ... Cancer Res .,64:9160-9166 (2004), Brown et al., Clin Cancer Res (2012), Kong et al. Clin Cancer Res .,18:5949-5960 (2012), Yaghoubi et al., Nat Clin Pract Oncol ., 6:53-58 (2009)); Lewis Y (e.g., breast / ovary / pancreas) (Peinert et al., Gene Ther., 17:678-686 (2010), Westwood et al. Proc Natl Acad Sci USA, 102:19051-19056 (2005), Mezzanzanica et al. Cancer Gene Ther., 5:401-407 (1998)); mesothelin (e.g., mesothelioma, breast, pancreas) (Lanitis, etc.) Mol Ther ., 20:633-643 (2012), Moon et al., Clin Cancer Res., 17:4719-4730 (2011)); Mue1 (e.g., ovaries, breasts, prostate) (Wilkie et al., J Immunol ., 180:4901-4909 (2008)); NCAM (e.g., neuroblastoma, colorectal cancer) (Gilham et al ... J Immunother ., 25:139-151 (2002)); NKG2D ligands (e.g., ovaries, sarcomas) (Barber et al ... Exp Hematol ., 36:1318-1328 (2008), Lehner et al., PLoS One , 7:e31210(2012), Song et al., Gene Ther., 24:295-305 (2013), Spear et al. J Immunol ., 188:6389-6398(2012)); PSCA (e.g., prostate, pancreas) (Morgenroth et al ... Prostate, 67:1121-1131 (2007), Katari et al., HPB , 13:643-650 (2011)); PSMA (e.g., prostate) (Maher et al, , 13:643-650 (2011)); Nat Biotechnol .,20:70-75 (2002), Gong et al. Neoplasia. 1:123-127 (1999)); TAG72 (e.g., colon) (Hombach et al., Gastroenterology , 113:1163-1170 (1997), McGuinness et al., Hum Gene Ther ., 10:165-173 (1999)); VEGFR-2 (e.g., tumor vascular system) ( J Clin Invest ., 120:3953-3968(2010), Niederman et al., Proc Natl Acad Sci USA ., 99:7009-7014 (2002)).
[0467] b. Metabolic stability
[0468] In some embodiments, the metabolic stability of cells (e.g., CAR cells) is improved by conferring upon them the ability to produce specific growth factors that are limiting in vivo. In some embodiments, nucleic acid cargo encoding anti-apoptotic factors such as BCL-XL is transiently delivered to the cells. B-cell lymphoma-extra-large (Bcl-XL, or BCL2-like 1 subtype 1) is a transmembrane protein in mitochondria. It is a member of the Bcl-2 protein family and acts as a pro-survival protein in the intrinsic apoptotic pathway by preventing the release of mitochondrial contents such as cytochrome c (which leads to caspase activation). The amino acid and nucleotide sequences encoding BCL-XL are well known in the art and include, for example, UniProtKB-Q07817 (B2CL1_HUMAN), subtype Bcl-X(L) (identifier: Q07817-1) (amino acid sequence); ENA|U72398|U72398.1 Bcl-xβ (bcl-x) gene, complete CDS (Genomic nucleic acid sequence); ENA|Z23115|Z23115.1 Human bcl-XL mRNA (mRNA / cDNA nucleic acid sequence).
[0469] In some embodiments, the nucleic acid cargo encodes a proliferation-inducing factor, such as IL-2. The amino acid and nucleic acid sequences encoding IL-2 are well known in the art and include, for example, UniProtKB-P60568 (IL2_HUMAN) (amino acid sequence); ENA|X00695|X00695.1 human interleukin-2 (IL-2) gene and... 5'-wing flank (Gene nucleic acid sequence); and ENA|V00564|V00564.1 encoding Human mRNA of interleukin-2 (IL-2) (mRNA / cDNA nucleic acid sequence).
[0470] However, the production of secreted IL-2 may also have adverse side effects such as stimulating the proliferation of lymphoma and Treg cells and impairing the formation of memory T cells (Zhang et al., Nature Medicine , 11:1238-1243 (2005)). Furthermore, the use of IL-2 in patients receiving tumor-infiltrating lymphocyte (TIL) therapy led to increased toxicity (Heemskerk et al., 11:1238-1243 (2005)). Human Gene Therapy , 19:496-510 (2008)). To avoid this possibility, in addition to or as a substitute for IL-2, nucleic acid cargoes can encode chimeric γc cytokine receptors (CγCRs), such as one composed of interleukin-7 (IL-7) tethered to IL-7Rα / CD127, which provides cell-intrinsic, STAT5 cytokine signaling independent of exogenous cytokines (Hunter et al., 19:496-510 (2008)). Molecular Immunology, 56:1-11 (2013)). The design is modular because the IL-2Rβ / CD122 cytoplasmic chain can be exchanged for the IL-7Rα / CD127 chain to enhance Shc activity. This construct mimics wild-type IL-2 signaling in human CD8+ T cells (Hunter et al., , 56:1-11 (2013)). Molecular Immunology , 56:1-11 (2013)), and therefore should work similarly to IL-2 mRNA without producing unwanted side effects.
[0471] Alternatively or concurrently, other anti-apoptotic molecules and cytokines can be used to maintain cell viability in the native state. Exemplary factors include, but are not limited to:
[0472] Myeloid leukemia 1 (MCL-1) (e.g., UniProtKB-Q07820 (MCL1_HUMAN) (amino acid sequence); ENA|AF147742|AF147742.1) Human myeloid cell differentiation protein (MCL1) gene, promoter and intact CDS (Genomic nucleic acid sequence); ENA|AF118124|AF118124.1 Human myeloid leukemia sequence 1 (MCL1) mRNA, complete cds (mRNA / cDNA nucleic acid sequence)), which is an anti-apoptotic factor;
[0473] IL-7 (e.g., UniProtKB-P13232 (IL7_HUMAN) (amino acid sequence); ENA|EF064721|EF064721.1) Human interleukin-7 (IL7) gene, complete CDS (Genomic nucleic acid sequence); ENA|J04156|J04156.1 White Interleukin-7 (IL-7) mRNA, intact CDS (mRNA / cDNA nucleic acid sequence), which is important for T cell survival and development, and
[0474] IL-15 (e.g., UniProtKB-P40933 (IL15_HUMAN) (amino acid sequence); ENA|X91233|X91233.1) Human IL15 gene (Genomic nucleic acid sequence); ENA|U14407|U14407.1 Human interleukin-15 (IL15) mRNA, complete whole CDS (mRNA / cDNA nucleic acid sequence)), which promotes the survival of T cells and NK cells (Opferman et al., Nature , 426:671-676 (2003); Meazza et al., Journal of Biomedicine&Biotechnology , 861920, doi:10.1155 / 2011 / 861920 (2011); Michaud et al., Journal of Immunotherapy, 33:382-390 (2010)). These cytokine mRNAs can be used alone or in combination with BCL-XL, IL-2 and / or CγCR mRNAs. Therefore, in some embodiments, mRNAs encoding MCL-1, IL-7, IL-15 or combinations thereof are delivered to cells.
[0475] c. Inhibitory CAR (iCAR)
[0476] In some embodiments, T-cell therapy is delivered to CAR cells that have shown long-term efficacy and curative potential in treating some cancers; however, its use is limited by damage to non-cancerous tissues, reminiscent of graft-versus-host disease following donor lymphocyte infusion. Any disclosed composition and method can be combined with nonspecific immunosuppression (e.g., high-dose corticosteroid therapy, which exerts cytosolic or cytotoxic effects on T cells to suppress the immune response), irreversible T-cell elimination (e.g., so-called suicide genetic engineering strategies), or combinations thereof. However, in some preferred embodiments, off-target effects are reduced by introducing a construct encoding a repressive chimeric antigen receptor (iCAR) into CAR cells. T cells specific to tumors and off-target tissues can be limited to tumors simply by using antigen-specific iCARs introduced into T cells to protect off-target tissues (Fedorov et al.). Science Translational Medicine , 5:215ra172(2013)). iCARs can contain a combination of surface antigen recognition domains and potent acute inhibitory signaling domains to limit T cell reactivity, even though activating receptors (e.g., CARs) are also involved. In a preferred embodiment, the iCAR contains a single-chain variable fragment (scFv) specific to the inhibitory antigen, which is fused via a transmembrane region to the signaling domain of an immunosuppressive receptor (e.g., CTLA-4, PD-1, LAG-3, 2B4 (CD244), BTLA (CD272), KIR, TIM-3, TGFβ receptor dominant-negative analogues, etc.), the transmembrane region specifically inhibiting T cell function after antigen recognition. Once CAR cells encounter cells that do not express inhibitory antigens (e.g., cancer cells), iCAR-transduced T cells can produce a CAR-induced response to the CAR's target antigen. In Fedorov et al., Science Translational Medicine DNA iCARs using PSMA-specific scFvs with CTLA-4 or PD-1 inhibitory signal transduction domains were discussed in , 5:215ra172 (2013).
[0477] Design considerations included the observation that PD-1 is a stronger inhibitor than CTLA-4, and that CTLA-4 exhibits cytoplasmic localization unless the Y165G mutant is used, and that iCAR expression levels are important.
[0478] iCARs can be designed to target cell type-specific surface molecules. In some implementations, iCARs are designed to prevent the reactivity of T cells, NK cells, or other immune cells to certain tissues or cell types.
[0479] d. Reduce endogenous inhibitory signal transduction
[0480] In some embodiments, cells are brought into contact with nucleic acid cargo that prevents the expression of one or more antigens. For example, in some embodiments, the nucleic acid cargo is or encodes interfering RNA that blocks the expression of mRNA encoding antigens such as CTLA-4 or PD-1. This method can be used to prepare universal donor cells. The RNA used to alter the expression of allogeneic antigens can be used alone or in combination with RNA that causes dedifferentiation of target cells.
[0481] While the foregoing sections provide compositions and methods utilizing inhibitory signaling domains (e.g., CTLA-4 or PD-1 from artificial iCARs) to limit on-target / detumescent cytotoxicity, alternatively or otherwise, the overall efficiency of CAR cells against tumor effectors can be improved by reducing the expression of endogenous inhibitory signaling in CAR cells, thereby enabling CAR cells to develop resistance to inhibitory signals from the hostile tumor microenvironment.
[0482] CTLA-4 and PD-1 suppress T cells at different stages of activation and function. CTLA-4 regulates the T cell response to self-antigens, as knockout mice spontaneously develop organ damage in the absence of specific antigen exposure due to highly active tissue-infiltrating T cells (Tivol et al.). Immunity , 3:541-547 (1995); Waterhouse et al., Science Interestingly, conditional knockout of CTLA-4 in Treg cells reenacted global knockout, suggesting that it typically functions within Treg cells (Wing et al., 270:985-988 (1995)). Science , 322:271-275 (2008)). In contrast, PD-L1 knockout mice exhibit an autoimmune predisposition but do not spontaneously produce large amounts of inflammatory cell infiltration in normal organs, suggesting that their primary physiological function is to mediate negative feedback control of ongoing tissue inflammation in an inducible manner (Dong et al., 322:271-275 (2008)). Immunity , 20:327-336 (2004)). In fact, according to the "adaptive resistance" hypothesis, most tumors respond to IFNγ upregulation of PD-L1; which is a key cytokine released by effector T cells (including CART cells) (Greenwald et al., 20:327-336 (2004)). Annu Rev Immunol ,23:515-548 (2005); Carreno et al.,Annu Rev Immunol , 20:29-53 (2002); Chen et al., The Journal of Clinical Investigation , 125:3384-3391 (2015); Keir et al., Annu Rev Immunol , 26:677-704 (2008); Pentcheva-Hoang et al., Immunological Reviews , 229:67-87(2009)). Then, PD-L1 delivers inhibitory signals to T cells to reduce their proliferation, as well as the production of cytokines and perforin (Butte et al., 229:67-87(2009)). Immunity , 27:111-122 (2007); Chen et al., Immunology , 4:336-347 (2004); Park et al., Blood , 116:1291-1298 (2010); Wherry et al., Nat Immunol, 12:492-499 (2011); Zou et al., Immunology , 8:467-477 (2008)). Furthermore, T cells induce anti-apoptotic activity through reverse signaling of B7-H1 on cancer cells, which counteracts Fas-L signaling (Azuma et al., 8:467-477 (2008)). Blood , 111:3635-3643 (2008)).
[0483] Given the upregulation of B7-H1 in cancer cells and its association with cancer progression and poor clinical outcomes (Flies et al., Journal of Immunotherapy , 30:251-260 (2007); Nishimura et al., Immunity , 11:141-151 (1999); Wang et al., Curr Top Microbiol Immunol Antibodies antagonizing the PD-1 and CTLA-4 pathways have shown significant efficacy in solid tumors, particularly melanoma, with combinations exhibiting even higher activity. The anti-CTLA-4 antibody ipilimumab primarily improves overall survival in metastatic melanoma by inhibiting Treg cells, utilizing increased T cell infiltration into the tumor, and an increased intratumoral CD8+:Treg ratio (Hamid et al., 344:245-267 (2011)). J Transl Med , 9:204 (2011); Ribas et al., Clinical Cancer Research: An Official Journal of the American Association for Cancer Research , 15:6267-6276 (2009); Twyman-Saint et al., Nature, 520:373-377 (2015)). The overall response rate of the anti-PD-1 antibody nivolumab in metastatic melanoma is 30-40% (Robert et al., 520:373-377 (2015)). The New England Journal of Medicine , 372:320-330 (2015); Topalian et al., J Clin Oncol, 32:1020-1030 (2014)), similar findings have been observed in early clinical trials of other solid tumors (including metastatic renal cell carcinoma, non-small cell lung cancer, and relapsed Hodgkin's lymphoma) (Ansell et al., 372:320-330 (2015); Topalian et al., J Clin Oncol, 32:1020-1030 (2014)), and similar findings have been observed in early clinical trials of other solid tumors (including metastatic renal cell carcinoma, non-small cell lung cancer, and relapsed Hodgkin's lymphoma) (Ansell et al., 372:320-330 (2015)). The New England Journal of Medicine , 372:311-319 (2015); Brahmer et al., J Clin Oncol, 28:3167-3175 (2010); Topalian et al., The New England Journal of Medicine , 366:2443-2454 (2012)). Since resistance to anti-CTLA-4 antibodies in mouse melanoma models is due to the upregulation of PD-L181, the combination of ipilimumab and nivolumab has shown further efficacy in both mouse models and human patients (Larkin et al., 366:2443-2454 (2012)). The New England Journal of Medicine , 373:23-34 (2015); Spranger et al., J Immunother Cancer , 2, 3, doi:10.1186 / 2051-1426-2-3 (2014); Yu et al., Clinical Cancer Research: An Official Journal of the American Association for Cancer Research , 16:6019-6028 (2010)). Given the importance of the checkpoint inhibition pathway, it is believed that PD-1 / CTLA-4 inhibition will release the brakes, while chimeric antigen receptors will drive the accelerator pedal. Importantly, transient delivery can be used to release the brakes only transiently, so that these cells do not lead to future autoimmune diseases.
[0484] i. CRISPRi
[0485] To avoid permanent genomic modifications and the inactivation of repressive signals such as PD-1 and CTLA-4, the dCAS9 CRISPRi system (Larson et al.) can be used. Nat Protoc, 8:2180-2196 (2013)). Nucleic acids encoding the enzymatically inactivating dCAS9-KRAB repressive domain, fusion proteins, and sgRNAs targeting inhibitory signal transduction proteins (e.g., CTLA-4, PD-1, LAG-3, 2B4 (CD244), BTLA (CD272), KIR, TIM-3, TGFβ receptor dominant-negative analogues, etc.) can be co-delivered to CAR cells. One or more sgRNAs can be used. sgRNAs can be engineered to target both the proximal promoter region and the coding region (non-template strand). An alternative approach utilizes the single-component Cpf1 CRISPR system, which consists of smaller RNAs used for electroporation and expression (Zetsche et al., 8:2180-2196 (2013)). Cell, doi:10.1016 / j.cell.2015.09.038 (2015)). Any of the aforementioned RNA components can also be encoded by DNA expression constructs, such as vectors, for example, plasmids. Therefore, RNA, DNA, or combinations thereof can be used as nucleic acid cargo.
[0486] Although extensive suppression of CTLA-4 with ipilimumab can lead to autoimmune sequelae, these side effects are believed to be mitigated by limiting the loss to CAR cells and the transient nature of mRNA delivery. Suppressive function will recover in time.
[0487] ii. Repressive RNA
[0488] Deliverable nucleic acid cargo to cells may be or encode functional nucleic acids or peptides designed to target and reduce or inhibit the expression or translation of inhibitory signaling molecule mRNAs; or to reduce or inhibit the expression, activity, or degradation of inhibitory signaling molecule proteins. Suitable techniques include, but are not limited to, antisense molecules, siRNAs, miRNAs, aptamers, ribozymes, triplet-forming molecules, RNAi, etc. In some embodiments, the mRNA encodes an antagonistic peptide that reduces inhibitory signaling.
[0489] In some implementations, cargoes of functional RNA that are or encode the expression of CTLA-4, PD-1, LAG-3, 2B4 (CD244), BTLA (CD272), KIR, TIM-3, TGFβ receptor dominant-negative analogues, etc., can be delivered to cells alone or in combination.
[0490] In some embodiments, the cargo is RNA or DNA encoding a polypeptide that reduces bioavailability, or acts as an antagonist or other negative regulator or inhibitor of another protein in a dominant-negative analogue of CTLA-4, PD-1, LAG-3, 2B4 (CD244), BTLA (CD272), KIR, TIM-3, TGFβ receptor, or an immunosuppressive pathway. The protein can be paracrine, endocrine, or autocrine. It can regulate cells within the cell. It can be secreted and regulate expressing cells and / or other (e.g., adjacent) cells. It can be a transmembrane protein that regulates expressing cells and / or other cells. The protein can be a fusion protein, such as an Ig fusion protein.
[0491] e. Apoptosis-promoting factors
[0492] Compositions and methods for activating and reactivating apoptotic pathways are also provided. In some embodiments, the nucleic acid is or encodes a factor or agent that activates, reactivates, or otherwise enhances or increases the intrinsic apoptotic pathway. Preferably, the factor activates, reactivates, or otherwise enhances the intrinsic apoptotic pathway in cancer (e.g., tumor) cells, and more preferably is specific to or targets cancer cells.
[0493] In some implementations, after delivery of anti-apoptotic or pro-proliferative factors (such as those discussed above or known in the art), cells are more resistant to or less sensitive to induced apoptosis than untreated cells. Pro-apoptotic factors can, for example, induce or increase apoptosis in untreated cells relative to treated T cells, and are preferably selective for cancer cells. This approach results in a two-pronged attack on cancer cells, one cellular and one molecular.
[0494] Targeting members of the BCL-2 family can activate, reactivate, or otherwise enhance intrinsic apoptotic pathways. BCL-2 family members are divided into three subgroups based on function and Bcl-2 homology (BH) domains: multi-domain anti-apoptotic (e.g., BCL-2 or BCL-XL), multi-domain pro-apoptotic (e.g., BAX and BAK), and BH3-only pro-apoptotic (e.g., BIM) proteins. Members of the BH3-only subgroup, such as BIM, act as death sentinels throughout the cell, preparing to transmit various physiological and pathological signals of cellular damage to the core apoptotic mechanisms located in the mitochondria (Danial et al.). Cell , 116:205-219 (2004)).
[0495] In some implementations, the pro-apoptotic factor is a pro-apoptotic BH3 mimic. Various pro-apoptotic BH3 mimics can mimic the natural pro-apoptotic activity of BIM and provide the ability to manipulate multiple points in the apoptosis pathway. For example, BIM SAHB (a stabilized α-helix of the BCL-2 domain), ABT-737, and ABT-199 are pro-apoptotic BH3 mimics designed through structural studies of the interaction between the pro-apoptotic BH3 helical domain and the hydrophobic groove formed by the convergence of the BH1, BH2, and BH3 domains of anti-apoptotic proteins (Oltersdorf et al.). Nature , 435:677-681 (2005)).
[0496] D. Target cells
[0497] In some embodiments, one or more specific cell types or tissues are targets of the disclosed complex. Target cells can be in vitro, ex vivo, or in a subject (i.e., in vivo). The applications discussed herein can be performed in vitro, ex vivo, or in vivo. For ex vivo applications, cells can be collected or isolated and processed in culture. Ex vivo-processed cells can be administered in therapeutically effective amounts to subjects in need. For in vivo applications, the cargo can be passively delivered to target cells, e.g., based on composition circulation, local delivery, etc., or can be actively targeted, e.g., using additional cell, tissue, or organ-specific targeting portions. Thus, in some embodiments, the cargo is delivered to target cells to exclude other cells. In some embodiments, the cargo is delivered to both target and non-target cells.
[0498] Operators can select target cells based on the desired treatment and therapy, as well as the expected effects of the nucleic acid cargo. For example, when the nucleic acid cargo is designed to induce cell death, the target cells could be cancer cells; when the nucleic acid cargo is designed to induce genomic alterations, the target cells could be stem cells; and when the nucleic acid cargo encodes a chimeric antigen receptor, the target cells could be immune cells.
[0499] 3E10 scFv has previously been shown to penetrate into the nucleus in an ENT2-dependent manner, with significantly impaired nuclear uptake efficiency in ENT2-deficient cells (Hansen et al.). J Biol Chem 282, 20790-20793 (2007)). ENT2 (SLC29A2) is a sodium-independent transporter involved in the transport of purine and pyrimidine nucleosides and nucleobases, and is less sensitive to nitrobenzylthiopurine riboside (NBMPR) than ENT1.
[0500] In some implementations, target cells express ENT2 on their plasma membrane, nuclear membrane, or both. ENT2 expression is relatively widespread, but its abundance varies across tissue and cell types. It has been demonstrated in the brain, heart, placenta, thymus, pancreas, prostate, and kidney (Griffiths et al., Biochem J , 1997. 328 (Pt 3): p. 739-43, Crawford et al., J Biol Chem , 1998. 273(9): p. 5288-93). ENT2 has one of the highest mRNA expression levels in skeletal muscle compared to other transport proteins (Baldwin et al., 1998. 273(9): p. 5288-93). Pflugers Arch, 2004. 447(5): p. 735-43, Govindarajan et al., Am J Physiol Regul Integr Comp Physiol , 2007. 293(5): p.R1809-22). Therefore, in some embodiments, the target cells are the brain, heart, placenta, thymus, pancreas, prostate, kidney, or skeletal muscle. Due to the high expression of ENT2 in skeletal muscle, the disclosed compositions and methods may be particularly effective for delivering nucleic acid cargo to these cells, and / or can deliver higher levels of cargo to these cells compared to other cells expressing lower levels of ENT2.
[0501] Other, non-limiting exemplary target cells are discussed below.
[0502] 1. Progenitor cells and stem cells
[0503] The cells can be hematopoietic progenitor cells or stem cells. In some implementations, particularly those related to gene editing and gene therapy, the target cell is CD34. + Hematopoietic stem cells. Hematopoietic stem cells (HSCs), such as CD34... + The cell is a pluripotent stem cell, which produces all types of blood cells, including red blood cells.
[0504] Stem cells can be isolated and enriched by those skilled in the art. For CD34 + Methods for the isolation and enrichment of cells in this manner are well known in the art and disclosed, for example, in U.S. Patent Nos. 4,965,204; 4,714,680; 5,061,620; 5,643,741; 5,677,136; 5,716,827; 5,750,397 and 5,759,793. As used herein in the context of compositions rich in hematopoietic progenitor cells and stem cells, “enrichment” means that the proportion of the desired element (e.g., hematopoietic progenitor cells and stem cells) is higher than that found in the natural source of the cells. The cell composition can be enriched by at least one order of magnitude, preferably two or three orders of magnitude, more preferably 10, 100, 200 or 1000 orders of magnitude compared to the natural source of the cells.
[0505] In humans, CD34 + Bone marrow cells can be obtained from umbilical cord blood, bone marrow, or recovered from the blood after subcutaneous or intravenous injection of hematopoietic growth factors such as granulocyte colony-stimulating factor (G-CSF), granulocyte-monocyte colony-stimulating factor (GM-CSF), and stem cell factor (SCF) in an amount sufficient to induce hematopoietic stem cells to enter the peripheral circulation from the bone marrow cavity. Initially, bone marrow cells can be obtained from any suitable bone marrow source, such as the tibia, femur, spine, and other bone cavities. To isolate the bone marrow, the bone can be flushed with a suitable solution, which is a balanced salt solution conveniently supplemented with fetal bovine serum or other naturally occurring factors, bound to a low concentration (typically about 5 to 25 mM) of a recombinant buffer. Common buffers include Hepes, phosphate buffer, lactate buffer, etc.
[0506] Cells can be selected using both positive and negative selection techniques. Commercially available antibodies that bind to hematopoietic progenitor or stem cell surface antigens (e.g., CD34) can be used, employing methods known to those skilled in the art to select cells. For example, antibodies can be conjugated to magnetic beads, and immunogenic procedures can be used to recover the desired cell type. Other techniques involve the use of fluorescence-activated cell sorting (FACS). The CD34 antigen, present on progenitor cells within the hematopoietic system of non-leukemic individuals, is expressed on cell populations recognized by the monoclonal antibody My-10 (i.e., expressing the CD34 antigen) and can be used to isolate stem cells for bone marrow transplantation. My-10 is deposited as HB-8483 at the American Center for Type Culture Collection (Rockville, Md.) and is commercially available as anti-HPCA 1. Furthermore, negative selection can be used with differentiated and “dedicated” cells derived from human bone marrow to select for virtually any desired cell marker. For example, progenitor cells or stem cells (preferably CD34) can be selected. + Cellular) characterized as CD3 - CD7 - CD8 - CD10 - CD14 - CD15 - CD19 - CD20 - CD33 - Class II HLA + and Thy-1 + Any one of them.
[0507] Once progenitor cells or stem cells are isolated, they can be propagated by growth in any suitable culture medium. For example, progenitor cells or stem cells can be grown in conditioned media derived from stromal cells, such as those obtained from bone marrow or liver associated with secretory factors, or in a medium containing cell surface factors that support stem cell proliferation. Stromal cells can be used to remove hematopoietic cells using appropriate monoclonal antibodies to eliminate unwanted cells.
[0508] Isolated cells are contacted in vitro with antibody and nucleic acid cargo complexes. Cells to which cargoes have been delivered can be referred to as modified cells. The complex solution can be simply added to the cultured cells. Synchronization of cells in S phase may be desired. Methods for synchronizing cell culture, such as thymidine blockade, are well known in the art (Zielke et al., Methods Cell Biol ., 8:107-121 (1974)).
[0509] Before administration to a subject, modified cells can be maintained or expanded in a culture. Depending on the cell type, culture conditions are generally well-known in the art. This is especially true for maintaining CD34 cells. + The conditions for this process have been thoroughly studied, and several suitable methods are available. A common method for expanding pluripotent hematopoietic cells in vitro is to culture purified progenitor cells or stem cells in the presence of early-acting cytokines such as interleukin-3. It has also been shown that a combination of thrombopoietin (TPO), stem cell factor (SCF), and flt3 ligand (Flt-3L; i.e., the ligand of the flt3 gene product) in the nutrient medium used to maintain hematopoietic progenitor cells in vitro can be used to expand primitive (i.e., relatively undifferentiated) human hematopoietic progenitor cells in vitro, and these cells can be transplanted into SCID-hu mice (Luens et al., 1998). Blood 91:1206-1215). In other known methods, cells can be maintained in vitro (e.g., for minutes, hours, or 3, 6, 9, 13 or more days) in a nutrient medium containing mouse prolactin-like protein E (mPLP-E) or mouse prolactin-like protein F (mPIP-F; collectively referred to as mPLP-E / IF) (US Patent No. 6,261,841). It will be appreciated that other suitable cell culture and expansion methods can also be used. Cells can also be grown in serum-free media, as described in US Patent No. 5,945,337.
[0510] In another embodiment, prior to administration to a subject using methods well-known in the art, modified hematopoietic stem cells are differentiated in vitro into CD4 cells using a specific combination of interleukins and growth factors. +Cell cultures. Compared to the isolated primitive population of hematopoietic stem cells, the cells can be expanded in large quantities in vitro, preferably at least 5 times, more preferably at least 10 times, and even more preferably at least 20 times.
[0511] In another implementation, the cells can be dedifferentiated somatic cells. These somatic cells can be reprogrammed into pluripotent stem cell-like cells, which can then be induced to become hematopoietic progenitor cells. Then, as described above regarding CD34... + The composition described in the cell therapy treats hematopoietic progenitor cells. Representative reprogrammable somatic cells include, but are not limited to, fibroblasts, adipocytes, and muscle cells. Hematopoietic progenitor cells derived from induced stem cell-like cells have been successfully developed in mice (Hanna, J. et al.). Science, 318:1920-1923 (2007)).
[0512] To generate hematopoietic progenitor cells from induced stem cell-like cells, somatic cells are harvested from the host. In a preferred embodiment, the somatic cells are autologous fibroblasts. The cells are cultured and transduced using vectors encoding transcription factors Oct4, Sox2, Klf4, and c-Myc. The transduced cells are cultured and screened for embryonic stem cell (ES) morphology and ES cell markers, including but not limited to AP, SSEA1, and Nanog. The transduced ES cells are cultured and induced to produce induced stem cell-like cells. The cells are then screened for CD41 and c-kit markers (markers of early hematopoietic progenitor cells) as well as markers of bone marrow and erythrocyte differentiation.
[0513] The modified hematopoietic stem cells or modified cells (including, for example, induced hematopoietic progenitor cells) are then introduced into the subject. Various methods can be used to influence cell delivery, and most preferably include intravenous administration by infusion and direct injection from a reservoir into the periosteum, bone marrow, and / or subcutaneous sites.
[0514] Subjects receiving modified cells may undergo bone marrow conditioning therapy to enhance cell transplantation. Radiation or chemotherapy may be used to treat the recipient before cell administration to enhance engraftment. After administration, cells typically require some time to engraft. Significant engraftment of hematopoietic stem cells or progenitor cells usually takes weeks to months.
[0515] A high percentage of modified hematopoietic stem cell implantation may not be necessary to achieve significant preventative or therapeutic effects. It is believed that cells proliferate over time after implantation to increase the percentage of modified cells. It is also believed that in some cases, only a small percentage or even a small amount of modified hematopoietic stem cells may be needed to provide preventative or therapeutic effects.
[0516] In a preferred embodiment, the cells to be administered to the subject are autologous (e.g., derived from the subject) or genetically identical.
[0517] 2. Embryo
[0518] Contact can be achieved by adding the composition to a liquid culture medium in which the embryos are immersed. For example, the composition can be pipetted directly into the embryo culture medium, where it is then absorbed by the embryos.
[0519] 3. Immune cells
[0520] In some implementations, the target cells are one or more types of immune cells. For example, different types of cells or other targeting methods may be used for immunomodulation and CAR-based therapies. Preferred targeting / engineered T cells may vary depending on the tumor and adoptive therapy objectives. Effector T cells are generally preferred because they secrete high levels of effector cytokines and are effective killers of tumor targets in vitro (Barrett et al.). Annu Rev Med ., 65: 333–347 (2014)). Two complementary lymphocyte populations with robust CAR-mediated cytotoxicity are CD3-CD56+ NK cells and CD3+CD8+ T cells. Using CD8+ T cells in conjunction with CD4+ helper T cells leads to an increase in the presence of suppressor T-reg cells and suppresses the cytotoxicity of CD8+ T cells. Since the reprogrammed CD8+ T cells are pre-activated, allowing them to act directly on tumor cells without requiring activation in lymph nodes, support from CD4+ T cells is not essential.
[0521] Furthermore, there is evidence that naive T cells (Rosenberg et al.) Adv. Cancer Res., 25:323–388 (1977)), central memory T cells (TCM cells) (Berger, et al.), J. Clin. Invest ., 118:294–305(2008)), Th17 cells (Paulos et al., Sci. Transl. Med ., 2:55–78 (2010)) and T memory stem cells (Gattinoni et al., Nat. Med., Infusion of cells (17:1290–1297 (2012)) may have certain advantages in some applications, for example, due to their high replication capacity. Tumor-infiltrating lymphocytes (TILs) also have certain advantages due to their antigen specificity and can be used in the delivery strategies disclosed herein.
[0522] Although sometimes referred to as CAR cells, CAR immune cells, and CAR T cells (or CAR T cells), it will be appreciated that the CAR and other delivery strategies disclosed herein can also be performed in other cell types, particularly different types of immune cells, including those discussed herein (e.g., lymphocytes, natural killer cells, dendritic cells, B cells, antigen-presenting cells, macrophages, etc.) and described elsewhere (see, e.g., Barrett et al.). Annu Rev Med ., 65: 333–347(2014)).
[0523] 4. Cancer cells and tumors
[0524] In some implementations, the target cells are cancer cells. In such implementations, therapeutic methods that may be useful in the context of cancer are provided, including oncology therapies. The examples below may suggest that DNA cargo can be delivered more generally to multiple tissues, not just tumors, while RNA delivery may be more selective for tumor tissue. Therefore, in some implementations, when cancer cells are the target cells, the cargo may consist of RNA (e.g., RNA alone).
[0525] Goods that can be delivered to cancer cells include, but are not limited to, constructs for expressing one or more pro-apoptotic factors, immunogenic factors, or tumor suppressor factors; gene editing compositions; repressive nucleic acids that target oncogenes; and other strategies discussed herein and elsewhere. In some embodiments, the goods are mRNAs encoding pro-apoptotic factors or immunogenic factors that increase the immune response to cells. In other embodiments, the goods are siRNAs that reduce the expression of oncogenes or other oncogenic transcripts.
[0526] In mature animals, a balance is normally maintained between cell renewal and cell death in most organs and tissues. Various types of mature cells in the body have a given lifespan; as these cells die, new cells are generated through the proliferation and differentiation of various types of stem cells. Under normal circumstances, the production of new cells is so regulated that the number of any particular type of cell remains constant. However, occasionally, cells emerge that no longer respond to normal growth control mechanisms. The production of these cells can expand into a fairly large cell clone, thus creating a tumor or vegetation. Tumors that do not grow indefinitely and do not extensively invade healthy surrounding tissues are benign. Tumors that continue to grow and gradually invade are malignant. The term cancer specifically refers to a malignant tumor. In addition to uncontrolled growth, malignant tumors also exhibit metastasis. In this process, small clusters of cancer cells detach from the tumor, invade blood vessels or lymphatic vessels, and are carried to other tissues, where they continue to proliferate. In this way, a primary tumor in one site can generate a secondary tumor in another site.
[0527] The compositions and methods described herein can be used to treat subjects with benign or malignant tumors by delaying or inhibiting tumor growth in subjects, reducing tumor growth or size, inhibiting or reducing tumor metastasis, and / or inhibiting or alleviating symptoms associated with tumor development or growth.
[0528] Treatable malignant tumors are classified in this paper according to their embryonic origin from the tissue from which they originate. Carcinomas are tumors originating from endoderm or ectoderm tissues, such as the epithelial lining of the skin or internal organs and glands. The disclosed compositions are particularly effective in treating carcinomas. Less common sarcomas originate from mesodermal connective tissues, such as bone, fat, and cartilage. Leukemia and lymphoma are malignant tumors of hematopoietic cells in the bone marrow. Leukemia occurs as a single-cell proliferation, while lymphoma tends to grow as a tumor mass. Malignant tumors can occur in many organs or tissues of the body, thus forming cancer.
[0529] The types of cancers that can be treated with the provided compositions and methods include, but are not limited to, cancers such as angiomyolipoma, multiple myeloma, adenocarcinoma, and sarcoma, including bone cancer, bladder cancer, brain cancer, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, kidney cancer, liver cancer, lung cancer, nasopharyngeal carcinoma, pancreatic cancer, prostate cancer, skin cancer, stomach cancer, and uterine cancer. In some embodiments, the disclosed compositions are used to treat multiple cancer types simultaneously. The compositions can also be used to treat metastases or tumors in multiple sites.
[0530] The disclosed compositions and methods can be further understood through the following numbered paragraphs.
[0531] 1. A composition comprising or consisting of the following:
[0532] (a) 3E10 monoclonal antibody, its cell-penetrating fragment; monovalent, bivalent or multivalent single-chain variable fragment (scFv); or biclonal antibody; or humanized form or variant thereof, and
[0533] (b) Nucleic acid cargo, comprising nucleic acids encoding polypeptides, functional nucleic acids, nucleic acids encoding functional nucleic acids, or combinations thereof.
[0534] 2. The composition according to paragraph 1, wherein (a) comprises:
[0535] (i) A combination of a CDR of any one of SEQ ID NO: 1-6, 12, 13, 46-48 or 50-52 and a CDR of any one of SEQ ID NO: 7-11, 14 or 53-58;
[0536] (ii) A combination of any first, second, and third heavy chain CDR selected from SEQ ID NO: 15-23, 42, or 43 and any first, second, and third light chain CDR selected from SEQ ID NO: 24-30, 44, or 45;
[0537] (iii) (i) or (ii) humanized forms;
[0538] (iv) A combination of a heavy chain comprising an amino acid sequence containing at least 85% sequence identity with any one of SEQ ID NO: 1 or 2 and a light chain comprising an amino acid sequence containing at least 85% sequence identity with SEQ ID NO: 7 or 8;
[0539] (v) (iv) humanization forms; or
[0540] (vi) includes a heavy chain comprising an amino acid sequence containing at least 85% sequence identity with any one of SEQ ID NO: 3-6, 46-48 or 50-52 and a light chain comprising an amino acid sequence containing at least 85% sequence identity with any one of SEQ ID NO: 9-11 or 53-58.
[0541] 3. The composition according to paragraph 1 or paragraph 2, wherein (a) comprises the same or different epitope specificity as the monoclonal antibody 3E10 generated from the hybridoma of ATCC accession number PTA 2439.
[0542] 4. The composition according to any one of paragraphs 1-3, wherein (a) is a recombinant antibody having a complementary site of monoclonal antibody 3E10.
[0543] 5. A composition comprising
[0544] (a) Binding proteins, which include
[0545] (i) A combination of a CDR of any one of SEQ ID NO: 1-6, 12, 13, 46-48 or 50-52 and a CDR of any one of SEQ ID NO: 7-11, 14 or 53-58;
[0546] (ii) A combination of the first, second, and third heavy chain CDRs selected from SEQ ID NO: 15-23, 42, or 43 and the first, second, and third light chain CDRs selected from SEQ ID NO: 24-30, 44, or 45;
[0547] (iii) (i) or (ii) humanized forms;
[0548] (iv) A combination of a heavy chain comprising an amino acid sequence containing at least 85% sequence identity with any one of SEQ ID NO: 1 or 2 and a light chain comprising an amino acid sequence containing at least 85% sequence identity with any one of SEQ ID NO: 7 or 8;
[0549] (v) (iv) humanization forms; or
[0550] (vi) comprises a heavy chain containing at least 85% sequence identity of an amino acid sequence of any one of SEQ ID NO: 3-6, 46-48, or 50-52, and a light chain containing at least 85% sequence identity of an amino acid sequence of any one of SEQ ID NO: 9-11 or 53-58, and
[0551] (b) Nucleic acid cargo, comprising nucleic acids encoding polypeptides, functional nucleic acids, nucleic acids encoding functional nucleic acids, or combinations thereof.
[0552] 6. The composition according to any one of paragraphs 1-5, wherein (a) is bispecific.
[0553] 7. The composition according to paragraph 6, wherein (a) targets a specific cell type.
[0554] 8. The composition according to any one of paragraphs 1-7, wherein (a) and (b) are non-covalently linked.
[0555] 9. The composition according to any one of paragraphs 1-8, wherein (a) and (b) are in the complex.
[0556] 10. The composition according to any one of paragraphs 1-9, wherein (b) comprises DNA, RNA, PNA or other modified nucleic acid, or nucleic acid analogue, or a combination thereof.
[0557] 11. The composition according to any one of paragraphs 1-10, wherein (b) comprises mRNA.
[0558] 12. The composition according to any one of paragraphs 1-11, wherein (b) comprises a carrier.
[0559] 13. The composition according to paragraph 12, wherein the vector comprises a nucleic acid sequence encoding a target polypeptide operatively linked to an expression control sequence.
[0560] 14. The composition according to paragraph 13, wherein the carrier is a plasmid.
[0561] 15. The composition according to any one of paragraphs 1-14, wherein (b) comprises a nucleic acid encoding a Cas endonuclease, gRNA, or a combination thereof.
[0562] 16. The composition according to any one of paragraphs 1-15, wherein (b) comprises a nucleic acid encoding a chimeric antigen receptor polypeptide.
[0563] 17. The composition according to any one of paragraphs 1-16, wherein (b) comprises a functional nucleic acid.
[0564] 18. The composition according to any one of paragraphs 1-17, wherein (b) comprises a nucleic acid encoding a functional nucleic acid.
[0565] 19. The composition according to paragraph 17 or paragraph 18, wherein the functional nucleic acid is an antisense molecule, siRNA, miRNA, aptamer, ribozyme, RNAi, or external guide sequence.
[0566] 20. The composition according to any one of paragraphs 1-19, wherein (b) comprises a plurality of single nucleic acid molecules.
[0567] 21. The composition according to any one of paragraphs 1-19, wherein (b) comprises a plurality of 2, 3, 4, 5, 6, 7, 8, 9, 10 or more different nucleic acid molecules.
[0568] 22. The composition according to any one of paragraphs 1-21, wherein (b) comprises or consists of a nucleic acid molecule having a length of about 1 to 25,000 nucleobases.
[0569] 23. The composition according to any one of paragraphs 1-22, wherein (b) comprises or consists of a single-stranded nucleic acid, a double-stranded nucleic acid, or a combination thereof.
[0570] 24. The composition according to any one of paragraphs 1-23 further comprises vector DNA.
[0571] 25. The composition according to paragraph 24, wherein the vector DNA is non-coding DNA.
[0572] 26. The composition according to paragraph 24 or paragraph 25, wherein (b) is composed of RNA.
[0573] 27. A pharmaceutical composition comprising the composition described in any one of paragraphs 1-26 and a pharmaceutically acceptable excipient.
[0574] 28. The composition according to paragraph 27 further comprises polymer nanoparticles encapsulating the composite of (a) and (b).
[0575] 29. The composition according to paragraph 28, wherein the targeting portion, cell-penetrating peptide, or combination thereof is bound, connected, conjugated, or otherwise directly or indirectly attached to the nanoparticles.
[0576] 30. A method for delivering nucleic acid cargo to cells, comprising contacting the cells with an effective amount of the composition described in any one of paragraphs 1-29.
[0577] 31. The method according to paragraph 30, wherein the contact separation occurs.
[0578] 32. The method described in paragraph 31, wherein the cell is a hematopoietic stem cell or a T cell.
[0579] 33. The method according to any one of paragraphs 30-32, further comprising administering the cells to a subject in need.
[0580] 34. The method according to paragraph 33, wherein the cells are administered to the subject in an effective amount to treat one or more symptoms of a disease or condition.
[0581] 35. The method according to paragraph 30, wherein the contact occurs in vivo after administration to a subject in need.
[0582] 36. The method according to any one of paragraphs 33-35, wherein the subject suffers from a disease or condition.
[0583] 37. The disease or condition described in paragraph 36 is a genetic condition, cancer, or an infection or infectious disease.
[0584] 38. The method according to paragraph 36 or paragraph 37, wherein (b) is delivered to the subject's cells in an effective amount to reduce one or more symptoms of the subject's disease or condition.
[0585] 39. A method for preparing the composition described in any one of paragraphs 1-29, comprising incubating (a) and (b) at a suitable temperature and / or mixing effective amounts for a period of time prior to contact with cells to form a complex of (a) and (b).
[0586] 40. A method for preparing the composition of any one of paragraphs 1-29, comprising incubating and / or mixing (a) and (b) for about 1 min to about 30 min, about 10 min to about 20 min, or about 15 min, optionally at room temperature or 37 degrees Celsius.
[0587] 41. The composition or method of any one of paragraphs 1-40, wherein the 3E10 monoclonal antibody, its cell-penetrating fragment; a monovalent, bivalent or multivalent single-chain variable fragment (scFv); or a biclonal antibody; or a humanized form or variant thereof comprising the nucleic acid binding pocket of SEQ ID NO: 92 or 93, or a variant thereof having the same or enhanced nucleic acid binding capacity.
[0588] 42. The composition or method of any one of paragraphs 1-41, wherein the amino acid residues corresponding to the D31 or N31 of the heavy chain amino acid sequence or its CDR are substituted with R.
[0589] 43. The composition or method of any one of paragraphs 1-42, wherein the amino acid residues corresponding to D31 or N31 of the heavy chain amino acid sequence or its CDR are substituted with L.
[0590] 44. A binding protein comprising
[0591] (i) A combination of a variant of any one of the CDRs of SEQ ID NO: 1-6, 12, 13, 46-48 or 50-52 with any one of the CDRs of SEQ ID NO: 7-11, 14 or 53-58;
[0592] (ii) A combination of a variant of the first heavy chain CDR with a second and third heavy chain CDR selected from SEQ ID NO: 15-23, 42 or 43 and a combination of a first, second and third light chain CDR selected from SEQ ID NO: 24-30, 44 or 45;
[0593] (iii) (i) or (ii) humanized forms;
[0594] (iv) A combination of a heavy chain comprising an amino acid sequence containing at least 85% sequence identity with any one of SEQ ID NO: 1 or 2 and a light chain comprising an amino acid sequence containing at least 85% sequence identity with any one of SEQ ID NO: 7 or 8;
[0595] (v) (iv) humanization forms; or
[0596] (vi) A combination of a heavy chain comprising an amino acid sequence containing at least 85% sequence identity with any one of SEQ ID NO: 3-6, 46-48 or 50-52 and a light chain comprising an amino acid sequence containing at least 85% sequence identity with any one of SEQ ID NO: 9-11 or 53-58.
[0597] The amino acid residues corresponding to D31 or N31 are replaced by R or L.
[0598] 45. The binding protein according to paragraph 44, comprising a nucleic acid binding pocket of SEQ ID NO: 92 or 93, or a variant thereof having the same or enhanced nucleic acid binding capacity.
[0599] Examples
[0600] For the following experiments, the standard 3E10 sequence was used except where the D31N variant is noted (e.g., Example 4). Both the standard 3E10 and the D31N variant were used as full-length antibodies.
[0601] Example 1: 3E10 increases PNA uptake by cells after 1 hour
[0602] Materials and methods
[0603] At room temperature, PNA alone (1 nmole) (MW = 9984.39; 29 nucleotides in length) or PNA compounded with 3E10 (0.75 mg) was mixed for 5 min. Then, 200,000 K562 cells were added to a suspension of 3E10 or PNA alone in serum-free medium. Additional serum-free medium was added to a final volume of 500 μL. After incubating the cells at 37°C for 1 hr, the cells were centrifuged and washed three times with PBS, followed by flow cytometry analysis. PNA was labeled by ligation with the fluorescent dye tetramethylrhodamine (TAMRA).
[0604] result
[0605] The results are shown in the flow cytometry dot plot ( Figures 1A-1C The intake percentage was quantified. Figure 1D ).
[0606] The results showed that PNA uptake increased when mixed with 3E10.
[0607] Example 2: 3E10 increases PNA uptake by cells after 24 hours
[0608] Materials and methods
[0609] At room temperature, mix PNA alone (1 nmole) (MW=9984.39; 29 nucleotides in length) or PNA compounded with 3E10 (0.75 mg) for 5 minutes. Then, add 200,000 K562 cells to a suspension of 3E10 or PNA alone in serum-free medium. Add additional serum-free medium to a final volume of 500 μL. After incubating the cells at 37°C for 24 hours, centrifuge and wash three times with PBS, followed by flow cytometry analysis.
[0610] 20,000 U2OS cells were seeded on 8-well slides and allowed to adhere for 24 hours. Cells were then treated with PNA alone (1 nmole) or PNA mixed with 3E10 (10 μM). After incubation at 37°C for 24 hours, cells were washed with PBS with either PNA or PNA mixed with 3E10, then fixed and stained nuclearly. PNA uptake was subsequently quantified by flow cytometry and imaged using fluorescence microscopy. PNA was labeled by ligation with the fluorescent dye tetramethylrhodamine (TAMRA).
[0611] result
[0612] The results are shown in the flow cytometry dot plot ( Figures 2A-2C The intake percentage was quantified. Figure 2D ).
[0613] The results showed that PNA uptake increased when mixed with 3E10.
[0614] Fluorescence microscopy revealed the colocalization of nuclear DNA (blue DAPI) and PNA (red Tamra), evidenced by the distinct pink hue produced.
[0615] Example 3: 3E10 increases cellular uptake of siRNA after 24 hours
[0616] Materials and methods
[0617] At room temperature, labeled siRNA (by attachment to fluorescent imide, FAM) (1 nmole) or siRNA complexed with 3E10 (0.75 mg) was mixed for 5 minutes. Then, 200,000 K562 cells were added to a suspension of 3E10 or siRNA alone in serum-free medium. Additional serum-free medium was added to a final volume of 500 μL. After incubating the cells at 37°C for 24 hours, the cells were centrifuged and washed three times with PBS, followed by flow cytometry analysis.
[0618] result
[0619] The results are shown in the flow cytometry dot plot ( Figures 3A-3C The intake percentage was quantified. Figure 3D ).
[0620] The results showed that cellular uptake of siRNA increased when mixed with 3E10.
[0621] Example 4: 3E10 increases cellular mRNA uptake after 24 hours
[0622] Materials and methods
[0623] At room temperature, mix individual labeled mRNA (via attachment to cyanine 5, Cy5) (2 μg) or labeled mRNA complexed with 3E10 (2.5, 5, and 10 μM) for 5 minutes. Add the suspension of 3E10 plus mRNA or individual mRNA to 200,000 K562 cells in serum-free medium. Add additional serum-free medium to a final volume of 500 μL. After incubating the cells at 37°C for 24 hours, centrifuge and wash three times with PBS, followed by flow cytometry analysis.
[0624] result
[0625] The results are shown in the flow cytometry dot plot ( Figures 4A-4H The intake percentage was quantified. Figure 4I ).
[0626] The results showed that cellular uptake of mRNA increased when mixed with 3E10.
[0627] It is worth noting that mRNA delivery via the D31N variant of 3E10 resulted in the highest levels of mRNA cellular uptake.
[0628] Fluorescence microscopy revealed the expression of functional GFP in U2OS cells following translation of the same Cy5-labeled mRNA, which encodes a green fluorescent protein (GFP) reporter.
[0629] Example 5: 3E10 increases cellular mRNA uptake after 1 hour
[0630] Materials and methods
[0631] At room temperature, mix labeled mRNA (Cy5) (2 μg) or labeled mRNA complexed with the D31N variant of 3E10 (0.1–10 μM) for 5 minutes. Add the suspension of 3E10 plus mRNA or mRNA alone to 200,000 K562 cells in serum-free medium. Add additional serum-free medium to a final volume of 500 μL. After incubating the cells at 37°C for 1 hour, centrifuge and wash three times with PBS, followed by flow cytometry analysis.
[0632] result
[0633] The results are shown in the flow cytometry dot plot ( Figures 5A-5H The intake percentage was quantified. Figure 5I ).
[0634] Example 6: 3E10 increases cellular uptake of plasmid DNA
[0635] Materials and methods
[0636] At room temperature, GFP reporter plasmid DNA (250 μg) was infused with 3E10 (10 μM) for 5 minutes. A suspension of 3E10 with plasmid DNA or plasmid DNA alone was added to 200,000 K562 cells in serum-free medium. Additional serum-free medium was added to a final volume of 500 μL. After incubating the cells at 37°C for 24 hours, the cells were centrifuged and washed three times with PBS. 72 hours after initial treatment, the cells were imaged and GFP expression was analyzed.
[0637] result
[0638] The results showed that when 3E10 was combined with plasmid DNA, the GFP plasmid was strongly taken up by cells, as measured by green fluorescence, indicating the uptake and functional expression of the GFP construct. No uptake or green fluorescence was observed when using plasmid DNA alone. Figure 6 ).
[0639] Example 7: 3E10 mediates mRNA delivery in vivo
[0640] Materials and methods
[0641] 10 μg of GFP-encoding mRNA was mixed with 0.1 mg of 3E10 for 15 minutes at room temperature. The 3E10-encoded mRNA was then systemically injected into BALB / c mice carrying a 100 mm HbA1c protein. 3 EMT6 flank tumor. Twenty hours after treatment, the tumor was harvested and mRNA expression (GFP) was analyzed using IVIS imaging.
[0642] result
[0643] Compared to free-injected mRNA, 3E10-mediated mRNA delivery resulted in a significant increase in GFP expression levels in tumors, while free-injected mRNA did not produce any GFP expression in tumors. No detectable GFP expression was found in any normal tissues examined using any treatment, including the liver, spleen, heart, and kidneys. These results indicate that the mRNA is stably delivered to tumors and functionally translated and expressed.
[0644] Example 8: 3E10-mediated siRNA delivery in vivo
[0645] Materials and methods
[0646] 40 μg of fluorescently labeled siRNA was mixed with increasing doses of 3E10 (0.25, 0.5, and 1 mg) for 15 minutes at room temperature. The siRNA conjugated with 3E10 was then systemically injected into BALB / c mice carrying a 100 mm... 3EMT6 rib-abdominal tumor. Twenty hours post-treatment, the tumor was harvested and siRNA delivery was analyzed using IVIS imaging.
[0647] 40 μg of fluorescently labeled siRNA was mixed with 1 mg of 3E10 or 0.1 mg of the D31N variant of 3E10 for 15 minutes at room temperature. The siRNA complexed with 3E10 was then systemically injected into BALB / c mice carrying a 100 mm... 3 EMT6 rib-abdominal tumor. Twenty hours post-treatment, the tumor was harvested and siRNA delivery was analyzed using IVIS imaging.
[0648] result
[0649] like Figure 7A As shown, increasing the dose of 3E10 leads to higher accumulation of siRNA in tumors.
[0650] like Figure 7B As shown, a 10-fold lower dose of D31N 3E10 resulted in siRNA delivery at a similar level to that of 3E10.
[0651] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the disclosed invention pertains. Publications cited herein and the material cited herein are specifically incorporated by reference.
[0652] Example 9: Vector DNA Enhancement to mRNA in Non-tumor Tissues
[0653] Materials and methods
[0654] At room temperature, 2 μg of fluorescently labeled mRNA was mixed with 20 μg of 3E10-D31N (with or without vector DNA) for 15 minutes. The mRNA complexed with 3E10 was injected into the fetus at E15.5. 24–48 hours after treatment, the fetus was harvested and the mRNA delivery was analyzed using IVIS imaging.
[0655] result
[0656] In the absence of vector DNA, 3E10-D31N complexed with mRNA is rapidly cleared from the fetus within 24 hours. However, the addition of vector DNA results in detectable mRNA signaling in multiple fetal tissues within 48 hours.
[0657] The above examples may suggest that DNA cargo delivery may be more generally applicable to a variety of tissues, not just tumors, while RNA delivery may be more selective for tumor tissues.
[0658] Example 10: 3E10 (D31N) complexed with mRNA and vector DNA leads to sustained levels of protein expression.
[0659] Materials and methods
[0660] At room temperature, 10 μg of luciferase mRNA and 10 μg of single-stranded vector DNA (60 nts) were mixed with 100 μg of 3E10 (WT) or 3E10 (D31N) for 15 minutes. The mRNA complexed with 3E10 was injected intramuscularly (IM) into the right quadriceps femoris muscle of each mouse. Luciferase expression was monitored over 6 days.
[0661] result
[0662] like Figure 8 As shown, administration of 3E10 (D31N) complexed with mRNA and vector DNA resulted in sustained levels of luciferase expression, while 3E10 (WT) complexed with mRNA and vector DNA failed to produce any significant signal above the background.
[0663] Example 11: In vivo distribution of 3E10 injected intravenously
[0664] The distribution of IV-injected 3E10 into muscle was investigated. Mice were intravenously injected with 200 µg of 3E10 (WT or D31N) labeled with VivoTag680 (Perkin Elmer). Four hours post-injection, muscle was harvested and imaged via IVIS (Perkin Elmer). Figure 9A and Figure 9B Quantification of IVIS images indicates that 3E10-D31N has a higher distribution into muscles compared to 3E10-WT. Figure 9C ).
[0665] The dose-dependent biodistribution of 3E10-D31N in tissues was investigated. Mice were intravenously injected with 100 µg or 200 µg of 3E10-D31N labeled with VivoTag680 (Perkin Elmer). Twenty-four hours post-injection, tissues were harvested and imaged via IVIS (Perkin Elmer). Quantification of tissue distribution showed a dose-dependent two-fold increase in muscle accumulation, while no proportional increase was observed in several tissues, including the liver. Figure 10 ).
[0666] Distribution of 3E10 to tumors. Mice carrying syngeneic colon tumors (CT26) in the costal abdomen were intravenously injected with 200 µg of 3E10 (WT or D31N) labeled with VivoTag680 (Perkin Elmer). Tumors were harvested 24 hours post-injection and imaged using IVIS (Perkin Elmer). Figures 11A-11BQuantitative analysis of tumor distribution showed that 3E10-D31N had a higher accumulation rate in tumors compared to 3E10-WT. Figure 11C ).
[0667] The distribution of ssDNA non-covalently bound to 3E10 was investigated. 200 μg of 3E10 (WT or D31N) (mixed with 40 μg of labeled ssDNA (IR680)) was intravenously injected into mice carrying syngeneic rib and abdominal colon tumors (CT26). Twenty-four hours post-injection, tumors were harvested and imaged using IVIS (Perkin Elmer). Figures 12A-12B Quantification of tissue distribution showed that delivery of ssDNA via 3E10-D31N resulted in higher tumor accumulation compared to 3E10-WT. Figure 12D ).
[0668] Example 12: 3E10-mediated delivery of RIG-I ligands and stimulation of RIG-I activity
[0669] Materials and methods
[0670] RIG-I reporter cells (HEK-Lucia RIG-I, Invivogen) were seeded at 50,000 cells per well and treated with either RIG-I ligand (1 μg) or a ligand complexed with 3E10-D31N (20 μg). The assay used a cell line with a luciferase reporter gene that is activated upon interferon induction.
[0671] result
[0672] In all cases, the RIG-I ligand alone did not stimulate IFN-γ secretion. However, delivery of the RIG ligand with 3E10-D31N stimulated higher levels of IFN-γ secretion than the control, with the highest levels observed for both low and high molecular weight (LMW and HMW) poly(I:C).
[0673] Example 13: Molecular modeling of 3E10 and its engineered variants
[0674] WT heavy chain scFv sequence
[0675] E VQ LVESGGG L VKPGGS RKLSC AASGFTFSD Y GMHWVRQ AP E KG L E WVAYISSGSSTI YYADTVKGRFT I S RDNAKNT LFL QMTSLRSEDT AM YYCARRG L LL DYWGQGTT LTVS (SEQ ID NO:92)
[0676] Light chain scFv sequence
[0677] DIVLT QSPASL AVSLGQRATI SC RASKSVS T SSY SYMH W Y Q QKPGQPPKL LI K YASYLESGVPARFSGSGSGTDFTLNIHPVEEEDA ATYYCQHSR EFPW TFGGG TKLEIK RADAAPGGGG SGGGGSGGGGS(SEQ ID NO:93)
[0678] Molecular modeling of 3E10 (Pymol) revealed the putative nucleic acid binding pocket (NAB1). Figures 14A-14B The mutation of aspartic acid at residue 31 of CDR1 to asparagine increases the cationic charge of the residue and enhances nucleic acid binding and delivery in vivo (3E10-D31N).
[0679] The mutation of aspartic acid to arginine at residue 31 of CDR1 (3E10-D31R) further expands the cationic charge, while the mutation to lysine (3E10-D31K) changes the charge direction. Figure 14A ).
[0680] The NAB1 amino acids predicted from molecular modeling are underlined in the heavy and light chain sequences above. Figure 14B This is a diagram showing the molecular modeling (Pymol) of 3E10-scFv with NAB1 amino acid residues, where the NAB1 amino acid residues are shown as dots.
[0681] Those skilled in the art will recognize or be able to determine many equivalents of the specific embodiments of the invention described herein using only conventional experiments. Such equivalents are intended to be covered by the following claims.
Claims
1. A composition comprising or consisting of a non-covalent complex, the non-covalent complex comprising: (a) An antibody or its antigen-binding fragment, or a humanized antibody or its antigen-binding fragment, including The heavy chain variable region (VH) comprises a complementarity-determining region (CDR) 1 consisting of an amino acid sequence as shown in SEQ ID NO: 15 or 16; a CDR2 consisting of an amino acid sequence as shown in SEQ ID NO: 17; a CDR3 consisting of an amino acid sequence as shown in SEQ ID NO: 18; and The light chain variable region (VL) comprises CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 24, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 25, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 26; and (b) Nucleic acid cargo containing nucleic acids encoding polypeptides.
2. The composition according to claim 1, wherein (a) is bispecific.
3. The composition according to claim 2, wherein (a) targets a specific cell type.
4. The composition according to claim 1, wherein (b) comprises DNA, RNA, PNA, or a combination thereof.
5. The composition according to claim 1, wherein (b) comprises mRNA.
6. The composition according to claim 1, wherein (b) comprises a carrier.
7. The composition of claim 6, wherein the vector comprises a nucleic acid sequence encoding a target polypeptide operatively linked to an expression control sequence.
8. The composition according to claim 7, wherein the carrier is a plasmid.
9. The composition according to claim 1, wherein (b) comprises a nucleic acid encoding a Cas endonuclease, gRNA, or a combination thereof.
10. The composition of claim 1, wherein (b) comprises a nucleic acid encoding a chimeric antigen receptor polypeptide.
11. The composition according to claim 1, wherein (b) comprises a plurality of the nucleic acid molecules.
12. The composition according to claim 1, wherein (b) comprises 2, 3, 4, 5, 6, 7, 8, 9, 10 or more different nucleic acid molecules.
13. The composition according to claim 1, wherein (b) comprises or consists of a nucleic acid molecule having a length of 1 to 25,000 nucleobases.
14. The composition according to claim 1, wherein (b) comprises or consists of a single-stranded nucleic acid, a double-stranded nucleic acid, or a combination thereof.
15. The composition according to claim 1, further comprising vector DNA.
16. The composition of claim 15, wherein the vector DNA is non-coding DNA.
17. The composition according to claim 15 or claim 16, wherein (b) is composed of RNA.
18. A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable excipient.
19. The composition according to claim 18, further comprising polymer nanoparticles encapsulating the composite of (a) and (b).
20. The composition of claim 19, wherein the targeting portion, cell-penetrating peptide, or combination thereof is bound, connected, conjugated, or otherwise directly or indirectly attached to the nanoparticles.
21. A method for delivering nucleic acid cargo to cells, comprising contacting the cells in vitro with an effective amount of the composition of claim 1.
22. The method of claim 21, wherein the cell is a hematopoietic stem cell or a T cell.
23. A method for preparing the composition of claim 1, comprising incubating (a) and (b) at a suitable temperature and / or mixing effective amounts of (a) and (b) for a period of time prior to contact with cells to form a complex of (a) and (b).
24. A method for preparing the composition of claim 1, comprising incubating and / or mixing (a) and (b) for 1 min to 30 min, optionally at room temperature or 37 degrees Celsius.
25. The composition of claim 1, wherein the antibody or its antigen-binding fragment, or the humanized antibody or its antigen-binding fragment, comprises a nucleic acid binding pocket as shown in SEQ ID NO: 92 or 93.
Citation Information
Patent Citations
Wirebound box machine
CA197574A
Determination device, sealing system, estimation model, generation device, determination method, sealing method, and generation method
US11631170B2
Information processing apparatus
US12211227B2
Zinc finger binding domains for nucleotide sequence ANN
US20020165356A1
Composition binding polypeptides
US20040197892A1
